We harness the powers of **State Of The Art Technologies** for ultimate accuracy and the best resolution
Content

Committees ...........................................4
Welcome address ...............................5
Foreword ...........................................7
Conference Programme
at a Glance ........................................8
Conference Programme ......................17
General Information ...........................27
Social Programme ...............................33
Awards ................................................36
Associated meetings ............................37
Plenary sessions .................................38
Poster sessions .................................43
Industry Sponsored Satellite Symposia .....44
General Assembly ..............................46
Detailed Scientific Programme .............47
Poster presentations ...........................61
Exhibition Plan and Listing .................102
Exhibitor Information .........................107
Author index .....................................121
Stockholm map .................................147
Venue map ........................................148

Platinum sponsors

Silver sponsors

Bronze sponsors

Exhibitors

Beckman Coulter AB
Copan Flock Technologies
DNA Genotek
ROSE GenTec. Ltd
SystemLink, Inc.
Committees

Organising Committee

Co-chairs
Mats Bengtsson  
_(Uppsala)_
Marie Schaffer  
_(Stockholm)_
Ann-Charlotte Wikström  
_(Stockholm)_

Members
Josefina Dykes  
_(Lund)_
Dan Hauzenberger  
_(Stockholm)_
Jan Holgersson  
_(Gothenburg)_
Ann-Sofie Liedberg  
_(Lund)_
Bo Nilsson  
_(Uppsala)_

EFI Executive Committee
Gottfried Fischer  
_(Austria)_ – President
Ann-Margaret Little  
_(UK)_ – Secretary
Mats Bengtsson  
_(Sweden)_ – Deputy Secretary
Valerie Dubois  
_(France)_ – Treasurer
Gwendaline Guidicelli  
_(France)_ – Deputy Treasurer

EFI Councillors
Carlo Carcassi  
_(Italy)_
Peter Horn  
_(Germany)_
Martin Petrek  
_(Czech Republic)_
Michel Toungouz  
_(Belgium)_
Blanca Vidan-Jeras  
_(Slovenia)_
Carlos Vilches  
_(Spain)_

EFI Scientific Committee and reviewers
Katharina Fleischhauer  
_(Germany)_, Chair
Rainer Blaszyk  
_(Germany)_
Ronald Bontrop  
_(The Netherlands)_
Frits Koning  
_(The Netherlands)_
Ludvig Sollid  
_(Norway)_
Jean-Marie Tiercy  
_(Switzerland)_
John Trowsdale  
_(UK)_
Mats Bengtsson  
_(Sweden)_ – LOC  
_(ex-officio)_

Conference Secretariat
MCI Stockholm  
Email: confirmation@mci-group.com 
Tel: + 46 8 5465 1500
Welcome address

On behalf of the Local Organizing Committee, we are happy to welcome you to Stockholm for the 28th European Immunogenetics and Histocompatibility Conference.

The theme for this year’s conference “From Genes to Therapy” highlights all the various aspects of science and clinical practice that our Society represents. The conference will address issues from basic science of gene regulation and identification of polymorphisms to highly sophisticated investigations of transplant recipients and donors, to state-of-the-art clinical therapies.

We hope that you will enjoy the long bright nights in Stockholm and that you will spend some time exploring our city built on water and its beautiful surroundings. We have chosen to have the conference somewhat later in the year than usual, just after midsummer, to give you all the possibility to enjoy the unique Nordic light. We hope that you will enjoy the social programme with music, dining and dancing, all taking place on the brink of Lake Mälaren.

Hereby we would like to express our gratitude to the EFI Executive Committee, the EFI Scientific Committee, the EFI Education Committee and Members of the Organizing Committee. They have all provided us with invaluable help and support in preparation of the Scientific Programme, teaching sessions, evaluation of all the abstracts and preparation of the Conference app. We are also very grateful to all the plenary speakers, leading experts in their fields, for sharing their work and knowledge.

A conference of this size is not possible to arrange without support from a number of commercial sponsors and a professional conference organization. We sincerely thank all our sponsors for their contributions, interest and hard work with the 28th European Immunogenetics and Histocompatibility Conference.

We welcome you all to Stockholm in June, to participate in what we hope will be an inspiring meeting both scientifically and socially!

Mats Bengtsson, Marie Schaffer and Ann-Charlotte Wikström
Chairmen 28th EFI Conference
Innovation and New Horizons

Increasing scientific knowledge combined with innovative technologies give rise to innovative products that lead to significant advances in healthcare. In transplantation this is especially the case.

Since the introduction of the first commercially available HLA sequence-based typing products, Abbott has led the way in introducing class-leading innovative genetic testing products for the routine laboratory.

Abbott Molecular continues to lead the way.

- **AlleleSEQR HLA Sequencing-based typing**
  - HLA typing for transplantation

- **HLA-SSP Go**
  - Low resolution HLA typing
  - Disease association and pharmacogenetics

- **AlleleSEQR Chimerism Assay**
  - Chimerism testing
  - Research use only
Foreword

Welcome to the 28th EFI European Immunogenetics and Histocompatibility Conference in Stockholm!

Stockholm and the topos of Histocompatibility and Immunogenetics: firstly, there is the connotation with a place where founders and pioneers of the field that we all are working in have been highly honoured; “for their discoveries concerning genetically determined structures on the cell surface that regulate immunological reactions”, “for their discoveries concerning the specificity of the cell mediated immune defence”, to cite two exemplary statements of the Nobel Assembly at the Karolinska Institute.

Secondly, on a more ‘applied’ aspect, Stockholm is one of the places where a highly useful and widely used HLA-typing technique has been developed very early on.

These are two of many reasons that make it seem only logical that the EFI community should gather exactly here. However, until such an event is going to happen there are quite some things to arrange. Thank worthily, the local organising committee together with the

EFI Scientific and Education Committee took the effort, organised the facilities and prepared the programme for our meeting from June 25-28, 2014.

The Ceppellini lecture, traditionally the first lecture of the conference, will this year be delivered by Marco Colonna from the Washington University School of Medicine in St. Louis. After this and until the closing ceremony there is space for celebrating other awardees, most notably the Julia Bodmer Award for young scientists, and vast opportunities to make scientific, educational and social interactions.

The motto of the conference ‘From Genes to Therapy’ reflects nicely the flow from basic research to clinical service, the ‘translational’ aspect that is so characteristic for the continuous development of the stunning field called Histocompatibility and Immunogenetics.

Let’s enjoy the flow.

Gottfried Fischer
 EFI President
## Conference Programme at a Glance

**Conference Programme at a Glance**

- General sessions
- Registration and Workshop sessions
- Refreshments/Lunch/Posters/Exhibition
- Symposia
- Social programme
- EFI matters

## Wednesday 25 June

<table>
<thead>
<tr>
<th>Time</th>
<th>Event</th>
<th>Location</th>
</tr>
</thead>
<tbody>
<tr>
<td>08.00–18.30</td>
<td><strong>Registration</strong></td>
<td></td>
</tr>
<tr>
<td>14.00–15.30</td>
<td><strong>Open meeting: EFI population genetics working group</strong></td>
<td>Room 35/36 Level 3</td>
</tr>
<tr>
<td></td>
<td>Chair: A. Sanchez-Mazas</td>
<td></td>
</tr>
<tr>
<td>16.00–18.00</td>
<td><strong>Welcome and Opening Ceremony</strong></td>
<td>Room A1 Level 4</td>
</tr>
<tr>
<td></td>
<td>Chairs: G. Fischer, M. Bengtsson, M. Schaffer, A.-C. Wikström</td>
<td></td>
</tr>
<tr>
<td>16.10–16.15</td>
<td><strong>Welcome address</strong></td>
<td>Room A1 Level 4</td>
</tr>
<tr>
<td></td>
<td>Dean of Research, Professor Hans-Gustaf Ljunggren, Karolinska Institutet, Stockholm, Sweden</td>
<td></td>
</tr>
<tr>
<td>16.15–16.45</td>
<td><strong>Julia Bodmer Award Lecture</strong></td>
<td>Room A1 Level 4</td>
</tr>
<tr>
<td></td>
<td>Chair: K. Fleischhauer</td>
<td></td>
</tr>
<tr>
<td>16.45–17.30</td>
<td><strong>Ceppellini Lecture</strong></td>
<td>Room A1 Level 4</td>
</tr>
<tr>
<td></td>
<td>Chair: G. Fischer</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Professor Marco Colonna, Dept of Pathology &amp; Immunology, Washington University Medical School, St Louis, MA, USA</td>
<td>Room A1 Level 4</td>
</tr>
<tr>
<td>17.30–18.00</td>
<td><strong>Music with “Little Green”</strong></td>
<td>Room A1 Level 4</td>
</tr>
<tr>
<td>19.00–21.00</td>
<td><strong>Welcome Reception at Stockholm City Hall</strong></td>
<td>Stockholm City Hall</td>
</tr>
<tr>
<td>22.00</td>
<td><strong>Run for Fun</strong></td>
<td></td>
</tr>
</tbody>
</table>
### Thursday 26 June

<table>
<thead>
<tr>
<th>Time</th>
<th>Event</th>
<th>Location</th>
</tr>
</thead>
<tbody>
<tr>
<td>07.30 - 18.00</td>
<td>Registration</td>
<td></td>
</tr>
<tr>
<td>08.00 - 09.30</td>
<td><strong>Plenary session 1: New concepts in cell therapies</strong></td>
<td>Room A1 Level 4</td>
</tr>
<tr>
<td></td>
<td>Chairs: M.Tilanus, A.-C. Wikström</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Prof Kathryn Wood, University of Oxford, UK</td>
<td></td>
</tr>
<tr>
<td></td>
<td><em>Regulatory T cells – from mechanisms to medicine</em></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Prof Fabio Ciceri, San Raffaele Scientific Institute, Milan, Italy</td>
<td></td>
</tr>
<tr>
<td></td>
<td><em>Haploidentical Stem Cell Transplantation in acute leukemias</em></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Prof Dolores Schendel, Helmholtz Zentrum, Munich, Germany</td>
<td></td>
</tr>
<tr>
<td></td>
<td>*Adoptive T cell therapy with high-affinity TCRs for hematopoietic</td>
<td></td>
</tr>
<tr>
<td></td>
<td>malignancies*</td>
<td></td>
</tr>
<tr>
<td>09.30 - 10.00</td>
<td>Refreshment break</td>
<td>Hall M1 Level 4</td>
</tr>
<tr>
<td>10.00 - 11.30</td>
<td><strong>PARALLEL SESSIONS:</strong> Meet the Speakers/Abstract/Educational</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Room A1 Level 4</td>
<td></td>
</tr>
<tr>
<td></td>
<td>10.00–11.30</td>
<td></td>
</tr>
<tr>
<td></td>
<td><strong>Educational session 1: NK cells and their receptors</strong></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Prof Steven Marsh, Anthony Nolan Research Institute, London, UK</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Prof Karl-Johan Malmberg, University of Oslo, Norway</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Abstract session 1: Immunogenetics O10-17</td>
<td>Room A2 Level 6</td>
</tr>
<tr>
<td></td>
<td>Chairs: P. Horn, M.-L Lokki</td>
<td>10.00–11.30</td>
</tr>
<tr>
<td></td>
<td>Abstract session 2: Bioinformatics O18-25</td>
<td>Room C1/C2 Level 2</td>
</tr>
<tr>
<td></td>
<td>Chairs: C. Carcassi, W. Helmberg</td>
<td>10.00–11.30</td>
</tr>
<tr>
<td></td>
<td>Meet the Speakers from Plenary session 1</td>
<td>Room 27 Level 2</td>
</tr>
<tr>
<td></td>
<td>Prof Kathryn Wood</td>
<td>10.00–11.00</td>
</tr>
<tr>
<td></td>
<td>Prof Fabio Ciceri</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Prof Dolores Schendel</td>
<td></td>
</tr>
<tr>
<td>11.30 - 11.45</td>
<td>Presentation of the 17th International HLA and Immunogenetics Workshop 2017</td>
<td>Room A1 Level 4</td>
</tr>
<tr>
<td></td>
<td>Prof Marcelo A. Fernández-Viña, Ph.D.</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Stanford, CA, USA</td>
<td></td>
</tr>
<tr>
<td>11.45 - 13.30</td>
<td>Poster viewing, lunch &amp; exhibition</td>
<td>Hall M1 Level 2, 4 &amp; 5</td>
</tr>
<tr>
<td></td>
<td><em>Even numbered posters</em></td>
<td></td>
</tr>
<tr>
<td>Time</td>
<td>Room A1</td>
<td>Room A2</td>
</tr>
<tr>
<td>---------</td>
<td>---------</td>
<td>---------</td>
</tr>
<tr>
<td>12.15-13.15</td>
<td><strong>INDUSTRY SPONSORED SATELLITE SYMPOSIA</strong></td>
<td><strong>INDUSTRY SPONSORED SATELLITE SYMPOSIA</strong></td>
</tr>
<tr>
<td></td>
<td><strong>One Lambda, Inc. part of Thermo Fischer Scientific</strong></td>
<td><strong>Abbott</strong></td>
</tr>
<tr>
<td></td>
<td>A paradigm in flux: understanding the role of antibodies in transplant rejection</td>
<td>Abbott Molecular Transplant Genetics</td>
</tr>
<tr>
<td></td>
<td><em>Speakers:</em> Dr Duska Dragun University of Berlin Berlin, Germany</td>
<td><strong>Talk 1:</strong> Introduction to Abbott Molecular’s Transplant Genetics Products</td>
</tr>
<tr>
<td></td>
<td>Dr Carmen Lefaucheur Hôpital Saint-Louis Paris, France</td>
<td><em>Speaker:</em> Paul Kyle, Abbott Molecular, Ghent, Belgium</td>
</tr>
<tr>
<td></td>
<td><strong>Talk 2:</strong> Recent Improvements and Developments with SSPGo Products</td>
<td><strong>Talk 3:</strong> Monitoring after hematopoietic stem cell transplantation: Evaluation of the AlleleSEQR® Chimerism Assay</td>
</tr>
<tr>
<td></td>
<td><em>Speaker:</em> Dr Mike Bunce, CSO Biofortuna, Liverpool, UK</td>
<td><em>Speaker:</em> Dr Andrea Dick, University Hospital, LMU, Munich, Germany</td>
</tr>
</tbody>
</table>
### Thursday 26 June

<table>
<thead>
<tr>
<th>13.30–15.00</th>
<th><strong>PARALLEL SESSIONS:</strong> Meet the Experts/Abstract/Educational</th>
</tr>
</thead>
</table>
|             | Room A1  
              Level 4
              13.30–15.00 | Room A2
              Level 6
              13.30–15.00 | Room C1/C2
              Level 2
              13.30–15.00 | Room 27
              Level 2
              13.30–14.30 |
|             | **Educational session 2:** Making sense of antibody testing  
                Dr Constanze Schönemann, Charité University Medicine, Berlin, Germany  
                Dr Susan Martin; Manchester Royal Infirmary, Manchester, UK |
|             | **Abstract session 3:** Autoimmunity, disease association and cancer  
                O26-33  
                Chairs: B. Möller, C. Voorter |
|             | **Abstract session 4:** Antigen presentation, peptides and non-HLA polymorphism  
                O34-41  
                Chairs: M. Ivanova, C. Seidl |
|             | **Meet the Experts:** Standard and accreditation  
                Dr Andrea Harmer, National Blood Service, Sheffield, UK  
                Dr Kay Poulton, Manchester Royal Infirmary, Manchester, UK |

| 15.00–15.30 | **Refreshment break**  
                Hall M1  
                Level 4 |
|-------------|-------------------------------------------------|
| 15.30–17.00 | **Plenary session 2:** NK-cells: Old killers in new light  
                Chairs: A.-M. Little, F. Garrido  
                Prof Klas Kärre, Karolinska Institutet, Stockholm, Sweden  
                *MHC class I dependent education of NK-cells: implications for immunotherapy to tumors*  
                Prof Andrew Brooks, University of Melbourne, Australia  
                *Recognition of polymorphic ligands by polymorphic receptors: Bw4 recognition by KIR3DL1*  
                Prof Karl-Johan Malmberg, University of Oslo, Norway  
                *Harnessing NK Cell Repertoire Diversity in Cancer Immunotherapy*  
                Room A1  
                Level 4 |
| 17.00–18.15 | **Poster session**  
                Level 2 and 5 |
| 18.15–19.00 | **Concert at Stockholm Waterfront Congress Centre**  
                Janne Schaffer with band  
                Room A1  
                Level 4 |
| 19.30       | **Ceppellini and invited speakers dinner**  
                *NOTE! By invitation only!* |
## Friday 27 June

<table>
<thead>
<tr>
<th>Time</th>
<th>Event</th>
<th>Room/Level</th>
</tr>
</thead>
<tbody>
<tr>
<td>07.30–18.00</td>
<td><strong>Registration</strong></td>
<td></td>
</tr>
<tr>
<td>08.00–09.30</td>
<td><strong>Plenary session 3: Survival of the organ transplant</strong></td>
<td>Room A1, Level 4</td>
</tr>
<tr>
<td></td>
<td>Chairs: B. Nilsson, C. Süsal</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Prof Steven Sacks, Kings College, London, UK</td>
<td></td>
</tr>
<tr>
<td></td>
<td><em>Role of local complement networks in organ transplantation</em></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Dr Carmen Lefaucheur, St Louis University Hospital, Paris, France</td>
<td></td>
</tr>
<tr>
<td></td>
<td><em>Complement binding anti-HLA antibodies in solid organ transplantation</em></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Dr Menna Clatworthy, University of Cambridge, UK</td>
<td></td>
</tr>
<tr>
<td></td>
<td><em>B cell regulation in transplantation</em></td>
<td></td>
</tr>
<tr>
<td>09.30–10.00</td>
<td><strong>Refreshment break</strong></td>
<td>Hall M1, Level 4</td>
</tr>
<tr>
<td>10.00–11.30</td>
<td><strong>PARALLEL SESSIONS:</strong> Meet the Speakers/Abstract/Educational</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Room A1, Level 4, 10.00–11.30</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Room A2, Level 6, 10.00–11.30</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Room C1/C2, Level 2, 10.00–11.30</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Room 27, Level 2, 10.00–11.00</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Educational session 3: Next generation sequencing</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Dr Ingrid Fae, Medical University Vienna, Vienna, Austria</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Dr Kaimo Hirv, Center for Human Genetics, Martinsried, Germany</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Abstract session 5: Solid organ transplantation O42-49</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Chairs: E. Spierings, T Slavcev</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Abstract session 6: Population genetics/anthropology O50-57</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Chairs: D. Middleton, C. Papasteriades</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Meet the Speakers from Plenary session 3</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Prof Steven Sacks, Dr Carmen Lefauchuer, Dr Menna Clatworthy</td>
<td></td>
</tr>
<tr>
<td>11.30–13.30</td>
<td><strong>Poster viewing, lunch &amp; exhibition</strong></td>
<td>Hall M1, Level 2, 4 &amp; 5</td>
</tr>
<tr>
<td></td>
<td><em>Uneven numbered posters</em></td>
<td></td>
</tr>
</tbody>
</table>
## Friday 27 June

<table>
<thead>
<tr>
<th>12.15–13.15</th>
<th><strong>INDUSTRY SPONSORED SATELLITE SYMPOSIA</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td>Room A1 Level 4</td>
<td>Room A2 Level 6</td>
</tr>
</tbody>
</table>
| **Histogenetics**  
NGS, NNGS and NNNGS technologies and HLA typing  
*Speaker:* Nezih Cereb M.D, CEO Histogenetics, USA | **Olerup**  
Improving Clinical Results in Stem Cell Transplantation  
*The impact of tissue typing and donor characteristics on outcome after allogenic stemcell transplantation*  
*Speaker:* Jonas Mattsson, M.D., Ph.D., Medical Director, Center for allogeneic Stem Cell Transplantation, Karolinska University Hospital, Sweden | **Immucor**  
HLA antibody detection is more than MFI  
*Speaker:* Frans H.J. Claas, Prof, IHB, Leiden University Medical Center |
| **NGS Meta-data & Mega-data**  
*Speaker:* Martin Maiers, Director, Bioinformatics Research, National marrow Donor Programme, Be The Match, USA |  |  |
| **The development of Haplobanks of Induced Pluripotent Stem Cells in XXIst century HLA matching landscape**  
*Speaker:* Pierre-Antoine Gourraud, Assistant Prof, UCSF, USA |  |  |
|  |  |  |

*Back to the Future: Improving HSCT outcomes by matching MHC genomic blocks*  
*Speaker:* David Sayer, Ph.D, CEO Connexio Genomics, Perth, Australia |
### Friday 27 June

<table>
<thead>
<tr>
<th>Time</th>
<th>Event</th>
</tr>
</thead>
<tbody>
<tr>
<td>13.30–15.00</td>
<td><strong>PARALLEL SESSIONS:</strong>&lt;br&gt;Meet the Experts/Abstract/Education</td>
</tr>
<tr>
<td></td>
<td><strong>Room A1</strong>&lt;br&gt;Level 4&lt;br&gt;13.30–15.00</td>
</tr>
<tr>
<td></td>
<td><strong>Room A2</strong>&lt;br&gt;Level 6&lt;br&gt;13.30–15.00</td>
</tr>
<tr>
<td></td>
<td><strong>Room C1/C2</strong>&lt;br&gt;Level 2&lt;br&gt;13.30–15.00</td>
</tr>
<tr>
<td></td>
<td><strong>Room 27</strong>&lt;br&gt;Level 2&lt;br&gt;13.30–14.30</td>
</tr>
<tr>
<td>Educational 4</td>
<td>Clinical Chimerism testing&lt;br&gt;Dr Marco Andreani, IME, Policlinic of Tor Vergata, Rome, Italy&lt;br&gt;Dr Mehmet Uzunel, Karolinska Institutet, Stockholm, Sweden</td>
</tr>
<tr>
<td>Abstract 7</td>
<td>Stem cell transplantation&lt;br&gt;O58-65&lt;br&gt;Chairs: M. Fernandez Viña, V. Dubois</td>
</tr>
<tr>
<td>Abstract 8</td>
<td>NK immunity and immunogenetics&lt;br&gt;O66-73&lt;br&gt;Chairs: M. Toungouz Névessignsky, G. Guidicelli</td>
</tr>
<tr>
<td>Meet the</td>
<td>Experts:&lt;br&gt;External Proficiency Testing (EPT)&lt;br&gt;Dr. Falko Heinemann, University Hospital Essen, Germany</td>
</tr>
<tr>
<td>15.00–15.30</td>
<td>Refreshment break</td>
</tr>
<tr>
<td>15.30–17.00</td>
<td><strong>Plenary session 4: Tolerance mechanisms</strong>&lt;br&gt;Chairs: J.-M. Tiercy, E Naumova&lt;br&gt;Dr Michael Uhlin, Karolinska Institutet, Stockholm, Sweden&lt;br&gt;Adoptive T cell therapy after allogeneic stem cell transplantation&lt;br&gt;Dr Niloufar Safinia, Kings College, London, UK&lt;br&gt;Approaching clinical transplantation tolerance&lt;br&gt;Prof David H. Sachs, Harvard Medical School, Boston, USA&lt;br&gt;Tolerance in Organ Transplantation</td>
</tr>
<tr>
<td>17.00–18.30</td>
<td><strong>EFI General Assembly</strong></td>
</tr>
<tr>
<td>19.30–01.00</td>
<td><strong>Conference Dinner Party</strong></td>
</tr>
</tbody>
</table>
## Saturday 28 June

<table>
<thead>
<tr>
<th>Time</th>
<th>Event</th>
<th>Location</th>
</tr>
</thead>
<tbody>
<tr>
<td>07.30–13.30</td>
<td>Registration</td>
<td></td>
</tr>
<tr>
<td>08.00–09.30</td>
<td><strong>Best abstracts session O1-9</strong> Chairs: J. Holgersson, J. Mytilineos</td>
<td>Room A1 Level 4</td>
</tr>
<tr>
<td>09.30–10.00</td>
<td>Refreshment break</td>
<td>Hall M1 Level 4</td>
</tr>
<tr>
<td>10.00–11.30</td>
<td><strong>Plenary session 5: Autoimmunity and Immunogenetics</strong> Chairs: E. Thorsby, B. Vidan-Jeras</td>
<td>Room A1 Level 4</td>
</tr>
<tr>
<td></td>
<td>Prof Andrew Fontenot, University of Colorado, USA</td>
<td></td>
</tr>
<tr>
<td></td>
<td><em>T Cell Recognition of Beryllium: Genetic Susceptibility and Neoantigen Generation</em></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Prof Marta E. Alarcón-Riquelme, University of Granada, Spain</td>
<td></td>
</tr>
<tr>
<td></td>
<td><em>The Developing Story of Lupus Susceptibility Gene: From Discovery to Mechanisms</em></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Prof Olle Korsgren, Uppsala University, Sweden</td>
<td></td>
</tr>
<tr>
<td></td>
<td><em>The past, the present and the future of clinical islet transplantation</em></td>
<td></td>
</tr>
<tr>
<td>11.45–12.30</td>
<td><strong>Closing Lecture</strong> Chair: M. Bengtsson</td>
<td>Room A1 Level 4</td>
</tr>
<tr>
<td></td>
<td>Prof Olle Ringdén, Karolinska Institutet, Stockholm, Sweden</td>
<td></td>
</tr>
<tr>
<td></td>
<td><em>Hematopoietic Stem Cell Transplantation – The Karolinska Experience</em></td>
<td></td>
</tr>
<tr>
<td>12.30–13.00</td>
<td>Closing Ceremony Chair: G. Fischer</td>
<td>Room A1 Level 4</td>
</tr>
</tbody>
</table>
Own your HLA work flow with One Lambda

A COMPLETE PORTFOLIO OF HLA TYPING TECHNOLOGIES

NOW

Serology • SSP • rSSO • SBT

FUTURE

qPCR • Next Generation Sequencing

ADVANCED TRANSPLANT MONITORING

LABScreen®
Single Antigen
DSA Detection

C1qScreen™
Identifies Complement
Binding Antibodies

AT1R | ETAR
Detecting
Non-HLA Antibodies
with Ease & Confidence

CE / IVD Marked
(EU only)

CE / IVD Marked
(EU only)

For Research Use Only.
Not for use for diagnostic procedures (USA)

For Research Use Only.
Not for use for diagnostic procedures (USA & Canada)
Conference Programme

Wednesday 25 June

08.00–18.30  Registration
14.00–15.30  Open Meeting: EFI population genetics working group
              Room 35/36  Level 3
              Chair: A. Sanchez-Mazas
16.00–18.00  Welcome and Opening Ceremony
              Room A1  Level 4
              Chairs: G. Fischer, M. Bengtsson,
                     M. Schaffer, A.-C. Wikström
16.10-16.15  Welcome address
              Room A1  Level 4
              Dean of Research, Professor Hans-Gustaf Ljunggren,
              Karolinska Institutet, Stockholm, Sweden
16.15–16.45  Julia Bodmer Award Lecture
              Room A1  Level 4
              Chair: K. Fleischhauer
16.45-17.30  Ceppellini Lecture
              Room A1  Level 4
              Chair: G. Fischer
              Prof Marco Colonna, Dept of Pathology
              & Immunology, Washington University
              Medical School, St Louis, MA, USA
17.30–18.00  Music with “Little Green”
              Room A1  Level 4
19.00–21.00  Welcome Reception at Stockholm City Hall
              Stockholm
22.00        Run for Fun

Thursday 26 June

07.30–18.00  Registration
08.00–09.30  Plenary session 1: New concepts in cell therapies
              Room A1  Level 4
              Chairs: M. Tilanus, A.-C. Wikström
Prof Kathryn Wood, University of Oxford, UK
Regulatory T cells – from mechanisms to medicine

Prof Fabio Ciceri, San Raffaele Scientific Institute, Milan, Italy
Haploidentical Stem Cell Transplantation in acute leukemias

Prof Dolores Schendel, Helmholtz Zentrum, Munich, Germany
Adaptive T cell therapy with high-affinity TCRs for hematopoietic malignancies

09.30–10.00 Refreshment break

10.00–11.30 PARALLEL SESSIONS:
Meet the Speakers/Abstract/Educational

10.00–11.30 Abstract session 1: Room A2
Immunogenetics O10-17
Chairs: P. Horn, M.-L. Lokki
Level 6

10.00–11.30 Abstract session 2: Room C1/C2
Bioinformatics O18-25
Chairs: C. Carcassi, W. Helmberg
Level 2

10.00–11.00 Meet the Speakers from Plenary session 1 Room 27
Prof Kathryn Wood, Fabio Ciceri, Dolores Schendel
Level 2

10.00–11.30 Educational session 1: Room A1
NK cells and their receptors
Prof Steven Marsh, Anthony Nolan Research Institute, London, UK
Level 4

Prof Karl-Johan Malmberg, University of Oslo, Norway

11.30–11.45 Presentation of the 17th International HLA and Immunogenetics Workshop 2017 Room A1
Prof Marcelo A. Fernández-Viña, Ph.D.
Stanford, CA, USA
Level 4

11.45–13.30 Poster viewing, lunch & exhibition Hall M1
Level 2, 4 & 5

12.15–13.15 INDUSTRY SPONSORED SATELLITE SYMPOSIA

12.15–13.15 One Lambda, Inc. Room A1
part of Thermo Fisher Scientific
A paradigm in flux: understanding the role of antibodies in transplant rejection
Level 4
Speakers:
Dr Duska Dragun, University of Berlin
Berlin, Germany
Dr Carmen Lefaucheur
Hôpital Saint-Louis, Paris, France

12.15–13.15  **Abbott**  
**Abbott Molecular Transplant Genetics**  

**Talk 1:** Introduction to Abbott Molecular’s Transplant Genetics Products  
**Speaker:**
Paul Kyle, Abbott Molecular, Ghent, Belgium  

**Talk 2:** Recent Improvements and Developments with SSPGo Products  
**Speaker:**
Dr Mike Bunce, CSO Biofortuna, Liverpool, UK  

**Talk 3:** Monitoring after hematopoietic stem cell transplantation: Evaluation of the AlleleSEQR® Chimerism Assay  
**Speaker:**
Dr Andrea Dick, University Hospital, LMU, Munich, Germany

12.15–13.15  **Illumina**  
**Introducing Illumina TruSight HLA Sequencing Panel**  

**Speakers:**
Alex Lindell  
Senior Marketing Manager, HLA typing Illumina  
Dr Matthew W. Andersson  
Medical Director, Diagnostic Laboratories  
Blood Center of Wisconsin

13.30–15.00  **PARALLEL SESSIONS:**  
**Meet the Experts/Abstract/Educational**

13.30–15.00  **Abstract session 3:**  
**Autoimmunity, disease association and cancer O26-33**  
**Chairs:** B. Möller, C. Voorter
13.30–15.00 Abstract session 4: Antigen presentation, peptides and non-HLA polymorphism O34-41 Room C1/C2

Chairs: M. Ivanova, C. Seidl

13.30–14.30 Meet the Experts: Standard and accreditation Room 27

Dr Andrea Harmer, National Blood Service, Sheffield, UK
Dr Kay Poulton, Manchester Royal Infirmary, Manchester, UK

13.30–15.00 Educational Session 2: Making sense of antibody testing Room A1

Dr Constanze Schönemann, Charité University Medicine, Berlin, Germany
Dr Susan Martin, Manchester Royal Infirmary, Manchester, UK

15.00–15.30 Refreshment break

15.30–17.00 Plenary session 2: NK-cells: Old killers in new light Room A1

Chairs: A.-M. Little, F. Garrido Level 4

Prof Klas Kärre, Karolinska Institutet, Stockholm, Sweden
MHC class I dependent education of NK-cells: implications for immunotherapy to tumors

Prof Andrew Brooks, University of Melbourne, Australia
Recognition of polymorphic ligands by polymorphic receptors: Bw4 recognition by KIR3DL1

Prof Karl-Johan Malmberg, University of Oslo, Norway
Harnessing NK Cell Repertoire Diversity in Cancer Immunotherapy

17.00–18.15 Poster session Level 2 and 5

18.15–19.00 Concert at Stockholm Waterfront Room A1

Congress Centre Level 4

Janne Schaffer with band

19.30 Ceppellini and invited speakers dinners

NOTE! By invitation only!
Friday 27 June

07.30–18.00  Registration

08.00–09.30  Plenary session 3: Room A1
    *Survival of the organ transplant*
    Level 4
    Chairs: B. Nilsson, C. Süsal
    Prof Steven Sacks, Kings College, London, UK
    *Role of local complement networks in organ transplantation*
    Dr Carmen Lefaucheur, St Louis University Hospital, Paris, France
    *Complement binding anti-HLA antibodies in solid organ transplantation*
    Dr Menna Clatworthy, University of Cambridge, UK
    *B cell regulation in transplantation*

09.30–10.00  Refreshment break

10.00–11.30  PARALLEL SESSIONS:
    *Meet the Speakers/Abstract/Educational*

10.00–11.30  Abstract session 5: Room A2
    *Solid organ transplantation O42-49*
    Level 6
    Chairs: E. Spierings, T Slavcev

10.00–11.30  Abstract session 6: Room C1/C2
    *Population genetics/anthropology O50-57*
    Level 2
    Chairs: D. Middleton, C. Papasteriades

10.00–11.00  Meet the Speakers from plenary session 3 Room 27
    Prof Steven Sacks,
    Carmen Lefaucheur, Menna Clatworthy

10.00–11.30  Educational session 3: Room A1
    *Next generation sequencing*
    Level 4
    Dr Ingrid Fae, Medical University Vienna,
    Vienna, Austria
    Dr Kaimo Hirv, Center for Human Genetics,
    Martinsried, Germany

11.30–13.30  Poster viewing, lunch & exhibition Hall M1
    Level 2, 4 & 5
INDUSTRY SPONSORED SATELLITE SYMPOSIA

12.15–13.15

**Histogenetics**

*NGS, NNGS and NNNGS technologies and HLA typing*

*Speaker:* Nezih Cereb, M.D.
CEO Histogenetics, USA

*NGS Meta-data & Mega-data*

*Speaker:* Martin Maiers
Director, Bioinformatics Research
National marrow Donor Programme,
Be The Match, USA

The development of Haplobanks of Induced Pluripotent Stem Cells in XXIst century HLA matching landscape

*Speaker:* Pierre-Antoine Gourraud, Assistant Prof
UCSF, USA

12.15–13.15

**Olerup**

*Improving Clinical Results in Stem Cell Transplantation*

*The impact of tissue typing and donor characteristics on outcome after allogeneic stem cell transplantation*

*Speaker:* Jonas Mattsson, M.D., Ph.D.
Medical Director, Center for Allogeneic Stem Cell Transplantation
Karolinska University Hospital, Sweden

*Back to the Future: Improving HSCT outcomes by matching MHC genomic blocks*

*Speaker:* David Sayer, Ph.D.
CEO Connexio Genomics
Perth, Australia
12.15–13.15  **Immucor**  Room C1/C2

*HLA antibody detection is more than MFI*  
Level 2

*Speaker:*  
Frans H.J. Claas, Prof, IHB, Leiden University Medical Center

13.30–15.00  **PARALLEL SESSIONS:**

*Meet the Experts/Abstract/Education*

13.30–15.00  **Abstract session 7:**  Room A2

*Stem cell transplantation O58-65*  
Level 6

*Chairs:* M. Fernandez Viña, V. Dubois

13.30–15.00  **Abstract session 8:**  Room C1/C2

*NK immunity and immunogenetics O66-73*  
Level 2

*Chairs:* M. Toungouz Névessignsky, G Guidicelli

13.30–14.30  **Meet the Experts:**  Room 27

*External Proficiency Testing (EPT)*  
Level 2

Dr. Falko Heinemann, University Hospital Essen, Germany

13.30–15.00  **Educational session 4:**  Room A1

*Clinical Chimerism testing*  
Level 4

Dr Marco Andreani, IME, Policlinic of Tor Vergata, Rome, Italy

Dr Mehmet Uzunel, Karolinska Institutet, Stockholm, Sweden

15.00–15.30  **Refreshment break**

15.30–17.00  **Plenary session 4:**  Room A1

*Tolerance mechanisms*  
Level 4

*Chairs:* J.-M. Tiercy, E. Naumova

Dr Michael Uhlin, Karolinska Institutet, Stockholm, Sweden

*Adoptive T cell therapy after allogeneic stem cell transplantation*

Dr Niloufar Safinia, Kings College, London, UK

*Approaching clinical transplantation tolerance*

Prof David H. Sachs, Harvard Medical School, Boston, USA

*Tolerance in Organ Transplantation*

17.00–18.30  **EFI General Assembly**  Room A1

Level 4

19.30–01.00  **Conference Dinner Party**  Münchenbryggeriet
Saturday 28 June

07.30–13.30  **Registration**

08.00–09.30  **Best Abstracts session O1-9**
Chairs: J. Holgersson, J. Mytilineos
Room A1  Level 4

09.30–10.00  **Refreshment break**

10.00–11.30  **Plenary session 5:**
**Autoimmunity and Immunogenetics**
Chairs: E. Thorsby, B. Vidan-Jeras
Room A1  Level 4

Prof Andrew Fontenot,
University of Colorado, USA
*T Cell Recognition of Beryllium: Genetic Susceptibility and Neoantigen Generation*

Prof Marta E. Alarcón-Riquelme,
University of Granada, Spain
*The Developing Story of Lupus Susceptibility Gene: From Discovery to Mechanisms*

Prof Olle Korsgren, Uppsala University, Sweden
*The past, the present and the future of clinical islet transplantation*

11.45–12.30  **Closing Lecture**
Chair: M. Bengtsson
Room A1  Level 4

Prof Olle Ringdén, Karolinska Institutet,
Stockholm, Sweden
*Hematopoietic Stem Cell Transplantation – The Karolinska Experience*

12.30–13.00  **Closing Ceremony**
Chair: G. Fischer
Room A1  Level 4
*Jon van Rood Award*
Metamorphosis
(mēt’a-môr-fə-sĭs) n.
A transformation, as by magic or sorcery.

Though it may seem like magic, eleven-locus HLA typing can be completed in 90 minutes with only 10 minutes of hands-on time. LinkSeq™ integrates the power of real-time PCR to simplify the HLA typing process — just add DNA and reagent to the plate, and press go.

Transform. Learn how LinkSeq can work its magic in your laboratory.

Real-Time PCR HLA Typing
See how easy HLA typing can be!
Come to booth #B9 for a FREE process demonstration.

For more information, visit us at www.linkagebio.com
The FluoVista System

AUTOMATED FLUORESCENCE PCR

For molecular HLA-, HPA- and RBC-typing

- PCR-SSP method without gel electrophoresis
- one pipetting step: addition of DNA and H2O to ready-to-use FluoMix
- typing result within 90 minutes after DNA-extraction
- no hybridization and washing steps
- display of typing results immediately after the post-read
- no risk of post-PCR contaminations
- low DNA consumption, i.e. 780 ng per HLA-ABDR typing
- automated calculation of results by the FluoGene Software
- same system/protocol for HLA-, HPA- and RBC
General Information

Venue

Stockholm Waterfront Congress Centre, which opened in January 2011, is located between the Central Station and the City Hall. Waterfront is surrounded by hotels, restaurants, pubs and coffee shops, all within walking distance.

Stockholm Waterfront Congress Centre
Nils Ericsons plan 4
111 64 Stockholm
Tel: +46 8 5050 6000
Web: www.stockholmwaterfront.com

Conference App

The full programme and other information about the conference can be accessed with the 28th EFI 2014 conference app which is available for iOS and Android. To download the app, search for “EFI 2014” in the App Store or Google play on your mobile device or tablet or scan the QR code.

EFI Booth

The EFI booth is situated in the exhibition hall on level 5.

Membership secretary is available:
Thursday 26 June 09.00–17.00
Friday 27 June 09.00–17.00

The EFI Treasurer is available during refreshment breaks and Lunch Symposia at the EFI booth.

Exhibition

The Exhibition will be held on level 4 and 5.

Opening hours:
Thursday 26 June 09.00–18.30
Friday 27 June 08.00–17.30
Saturday 28 June 08.00–13.30
Catering

Refreshments and lunch will be provided at the catering points in the exhibition and poster area during the official breaks.

Insurance

Neither the Conference Organisers nor the Conference Secretariat accepts any liability for personal injuries sustained, or for loss or damage to property belonging to conference participants, either during or as a result of the conference. It is strongly recommended that you purchase an insurance policy of your choice as you register for the conference and book your travel. The insurance should be purchased in your country of origin.

Internet

Complimentary Wi-Fi is provided for all delegates and exhibitors attending the conference.

Network: Waterfront
Password: meet/waterfront

Messages

You may leave and collect messages at the registration desk during opening hours.

Name badges

All participants are requested to wear their name badge during the conference. Access to all events and to lunch and refreshment breaks is only possible with your personal badge.

Posters

Posters will be displayed on level 2 and 5 of the Stockholm Waterfront Congress Centre. Posters P1-P180 will be displayed on level 5 and posters P181-326 will be displayed on level 2.

Posters can be mounted on the boards from 07.30 on Thursday 26 June and all posters should be in place by 11.00. Materials to mount you poster will be available in the poster area. Posters should be removed by 13.00 on Saturday 28 June and any posters remaining on poster boards after this time may be disposed of.

The presenting author should be present at the poster in order to discuss the data with the attendants. Poster presenters with an even numbered poster should be present 11.45–12.15 on Thursday 26 June and poster presenters with an uneven numbered poster should be present 11.30 to 12.00 on Friday 27 June. All poster presenters are asked to stand by their poster during the official poster session on Thursday 26 June between 17.00 and 18.15.
The three best posters will be selected by a dedicated Poster Committee and will receive a financial award that will be awarded during the Conference Closing Ceremony in the morning of Saturday 28 June.

Thursday 26 June 11.45–12.15 (Posters with even numbers)
Thursday 26 June 17.00–18.15 (All posters)
Friday 27 June 11.30–12.00 (Posters with uneven numbers)

Public transport

Stockholm has a well-developed local transport system. For more information please visit www.sl.se/en/

Registration and Information desk opening hours

The Registration desks are located on level 4, main entrance of the Stockholm Waterfront Congress Centre.

Opening hours:
Wednesday 25 June 08:00 to 18:30
Thursday 26 June 07:30 to 18:00
Friday 27 June 07:30 to 18:00
Saturday 28 June 07:30 to 13:30

Social media

All participants are encouraged to please join the debate and air their thoughts via Twitter, Facebook and LinkedIn. Please use #EFI2014 in all your tweets.

Facebook EFI Stockholm 2014
LinkedIn Annual EFI Conference
Twitter https://twitter.com/EFI_Stockholm

Speaker Ready Room

The Speaker Ready Room is located in Room 23, level 2 and is fully equipped in order for speakers to hand in and review their presentations. To ensure that the presentations are well prepared, speakers should bring their presentations to the room at least 2 hours before their presentation.

Opening hours:
Wednesday 25 June 09.00–17.30
Thursday 26 June 07.30–18.00
Friday 27 June 07.30–18.00
Saturday 28 June 07.30–13.00
Stockholm

We are delighted to welcome you to Stockholm, the beautiful capital of Sweden! The city is built on 14 islands connected by 57 bridges. The beautiful preserved buildings of the Old Town, the greenery, the fresh air and the proximity to water are distinctive traits of this city.

With its 750-year history and rich cultural life, Stockholm offers a wide selection of world-class museums and attractions. Most of the city’s attractions can be reached on foot, but public transportation is smooth and efficient.

Tourist information

For tourist information about Stockholm, Sweden, please visit the following website:
www.visitstockholm.com

Tourist Information Centre once in Stockholm

Stockholm Visitor Centre
Kulturhuset, Sergels Torg 3
10327 Stockholm
Tel: +46 (0) 8 508 28 508
Email: touristinfo@stockholm.se

Opening hours:
Monday to Friday 09.00–19.00
Saturday 09.00–16.00
Sunday 10.00–16.00
Continuing to pioneer MHC typing technology.
LIFECODES®
HLA-SSO Typing
A Rapid Approach to Typing

Our HLA-SSO typing kits offer speed and accuracy with a simplified approach using Luminex® xMAP® technology.

Results in less than 2 hours.

www.immucor.com/LIFECODES
Social Programme

EFI Inspectors’ Dinner (by invitation only)

Tuesday 24 June, 19.00
Restaurant Fem små hus
Nygränd 10, 111 30 Stockholm

Directions from congress venue: 25 minutes walking distance or walk to T-Centralen where you take the green metro line towards Hagsätra, Farsta Strand or Skarpnäck. Get off at Gamla Stan, and walk approx. 10 minutes to Restaurant Fem små hus.

Welcome Reception

Wednesday 25 June, 19.00–21.00
Stockholm City Hall
Hantverkargatan 1, 111 52 Stockholm

Directions from congress venue: 8 minutes walking distance to Stockholm City Hall. All delegates and registered accompanying guests are invited to attend the Welcome Reception kindly hosted by the City of Stockholm and Stockholm County Council.
Run for Fun

Wednesday 25 June, 22.00
Starting outside Stockholm City Hall

Directions from congress venue:
8 minutes walking distance to Stockholm City Hall.

To take advantage of the light Nordic midsummer night you can participate in a running event around Riddarfjärden.

Concert

Janne Schaffer:
A Tribute to ABBA’s 40 Year Anniversary

Thursday 26 June, 18.15–19.00
Stockholm Waterfront Congress Centre, Room A1

Don’t miss this opportunity to listen to Janne Schaffer, an acclaimed Swedish guitarist, composer and ABBA original musician. Together with a group of well known Swedish musicians he will present a tribute to ABBA’s 40 Year Anniversary. The concert is included in the registration fee.

Ceppellini Dinner (by invitation only)

Thursday 26 June, 19.30
The Nobel Museum
Stortorget 2, Old Town, 103 16 Stockholm

Transportation:
A coach will pick up all invited guests at 19.15 outside the Stockholm Waterfront Congress Centre.
Speakers Dinner *(by invitation only)*

Thursday 26 June, 19.30  
*Junibacken*  
Galärvarvsvägen 8, 115 21 Stockholm

**TRANSPORTATION:**  
A coach will pick up all invited guests at 19.15 outside the Stockholm Waterfront Congress Centre.

---

**One Lambda Party**

Thursday 26 June, 22.00–01.00  
*Wallmans salonger*  
Teatergatan 3, 111 48 Stockholm

**DIRECTIONS FROM CONGRESS VENUE:**  
20 minutes walking distance

---

**Conference Dinner Party**

Friday 27 June, 19.30–01.00  
*The Brewery (Münchenbryggeriet)*  
Torkel Knutssonsgatan 2, 104 62 Stockholm

**DIRECTIONS FROM CONGRESS VENUE:**  
Walk to T-Centralen where you take the red metro line towards Fröängen or Norsborg. Get off at Mariatorget, take exit Torkel Knutssonsgatan and walk approx. 5 minutes to Münchenbryggeriet.

Münchenbryggeriet is an old brewery active working until 1971, located at the waterfront of Södermalm. The venue for the “Dinner and Dance Party“, Mälarsalen is on the top floor of the building and includes a large terrace with a spectacular view of the City Hall, the Stockholm Waterfront Congress Centre as well as the city centre of Stockholm and the water that surrounds it. After the buffet dinner you can enjoy dancing to a live soul band, or enjoy the Nordic light summer night from the terrace.

The Conference Dinner Party incurs an additional charge and if you purchased a ticket it will be included in your envelope with your badge. Additional tickets may be available to purchase from the registration desk.
Awards

The Julia Bodmer Young Scientist Award

As a tribute to the late EFI president Julia Bodmer (1934–2001), who encouraged many young researchers in the field of Immunogenetics, an award has been established in her name. This award is given to a young scientist in recognition of his or her outstanding work in the field of Immunogenetics.

The Ceppellini Lecture

The Ceppellini Lecture is named in honour of Ruggero Ceppellini (1917–1988) an Italian geneticist who was greatly influential in the HLA field. This award is given by EFI to a scientist who has made a substantial contribution to the field of Immunogenetics.

The EFI medal

The EFI medal is awarded annually by the EFI Executive Committee to recognise the achievements of individuals who during the course of their career have made a significant contribution to EFI. The award is given at the General Assembly.

Jon van Rood Award and Best Abstract prices

All abstracts submitted for presentations at this meeting have been anonymously reviewed and scored by the EFI Scientific Committee. Top scoring abstracts have been selected for presentation in the ”Best Abstract Session”. A committee will review these presentations with the EFI President and a group of Past Presidents. The highest scoring presenter will receive the ”Jon van Rood Award”. This award was established at the 25th anniversary of EFI to honour the founder of EFI, Jon van Rood. In addition the next two scoring abstracts will receive ”Best Abstract price”. The Prices will be announced during the Closing Ceremony.

Best Poster awards

The posters are being assessed by the poster evaluation committee. The three best posters will be awarded during the Closing Ceremony.
Associated meetings

**Tuesday 24 June**

*EBTI meeting*
Chair: J. Mytilineos  
08.00–09.30, Room C4, level 2

*Accreditation Inspectors Workshop*
Chair: A. Harmer  
10.00–16.30, Room C4, level 2

*Education Committee and EBTI Executive Board*
Chair: J. Mytilineos  
14.00–17.00, Room 21, level 2

**Wednesday 25 June**

*EFI Executive Committee Meeting*
Chair: G. Fischer  
09.00–16.00, Room 26, level 2

*Accreditation Commissioners Meeting*
Chair: A. Harmer  
09.00–16.00, Room 24 and 25, level 2

*External Proficiency Testing Committee Meeting*
Chair: F. Heineman  
09.00–16.00, Room 21, level 2

*EFI populations genetics working group: open meeting*
Chair: A. Sanchez-Mazas  
14.00–15.30, Room 35+36, level 3
Thursday 26 June

*EFI Scientific Committee Meeting*
Chair: K. Fleischhauer
11.30–13.30, Room 26, level 2

Friday 27 June

*Executive Committee and Coordinators meeting*
Chair: G. Fischer
11.30–12.30, Room 21, level 2

*EFI General Assembly*
17.00–18.30, Room A1, level 4

---

**Plenary sessions**

**Welcome and Plenary Lectures**

*Julia Bodmer Award Lecture*

*Ceppellini Lecture*
Wednesday 25 June, 16.15–17.30
Room A1, Level 4

*Plenary Session 1 – New concepts in cell therapies*
Thursday 26 June, 08.00–09.30
Room A1, Level 4

*Plenary Session 2 – NK-cells: Old killers in new light*
Thursday 26 June, 15.30–17.00
Room A1, Level 4

*Plenary Session 3 – Survival of the organ transplant*
Friday 27 June, 08.00–09.30
Room A1, Level 4
Plenary Session 4 – Tolerance mechanisms
Friday 27 June, 15.30–17.00
Room A1, Level 4

Plenary Session 5 – Autoimmunity and immunogenetics
Saturday 28 June, 10.00–11.30
Room A1, Level 4

Closing Lecture
Saturday 28 June, 11.45–12.30
Room A1, Level 4

Awards and Closing Ceremony
Saturday 28 June, 12.30–13.00
Room A1, Level 4

Oral sessions

Best Abstract Session O1-09
Saturday 28 June, 08.00–09.30
Room A1, Level 4

Abstract session 1: Immunogenetics O10-17
Thursday 26 June, 10.00–11.30, Room A2/Level 6

Abstract session 2: Bioinformatics O18-25
Thursday 26 June, 10.00–11.30, Room C1+C2/Level 2

Abstract session 3: Autoimmunity, disease association and cancer O26-33
Thursday 26 June, 13.30–15.00, Room A2/Level 6

Abstract session 4: Antigen presentation, peptides and non-HLA polymorphism O34-41
Thursday 26 June, 13.30–15.00, Room C1+C2/Level 2

Abstract session 5: Solid organ transplantation O42-49
Friday 27 June, 10.00–11.30, Room A2/Level 6

Abstract session 6: Population genetics/anthropology O50-57
Friday 27 June, 10.00–11.30, Room C1+C2/Level 2
Abstract session 7: Stem cell transplantation 058-65
Friday 27 June, 13.30–15.00, Room A2/Level 6

Abstract session 8: NK immunity and Immunogenetics 066-73
Friday 27 June, 13.30–15.00, Room C1+C2/Level 2

Educational sessions

Education session 1- NK cells and their receptors
Thursday 26 June, 10.00–11.30, Room A1/Level 4

Education session 2- Making sense of antibody testing
Thursday 26 June, 13.30–15.00, Room A1/Level 4

Education session 3- Next generation sequencing
Friday 27 June, 10.00–11.30, Room A1/Level 4

Education session 4- Clinical chimerism testing
Friday 27 June, 13.30–15.00, Room A1/Level 4

Meet the Speakers

Meet the Speakers from Plenary session 1
Prof Wood, Schendel, Ciceri
Thursday 26 June, 10.00–11.00, Room 27/Level 2

Meet the Speakers from Plenary session 3
Prof Sacks, Clatworthy, Lefaucheur
Friday 27 June, 10.00–11.00, Room 27/Level 2

Meet the Experts

Meet the Experts in Accreditation and Standards
Thursday 26 June, 13.30–14.30, Room 27/Level 2

Meet the EPT Experts
Friday 27 June, 13.30–14.30, Room 27/Level 2
See the Whole Gene
Fully phased sequences for allele-specific HLA typing

Interested to learn more?
Please come and see us at Stand 8

For Research Use Only. Not for use in diagnostic procedures.
Protrans Domino Stones

get high!

A*02

save lives!

A*02:39

Combine

SSO

SSP

SSP

SBT

www.protrans.info
Posters will be displayed on level 2 and 5 of the Stockholm Waterfront Congress Centre. Posters P1-P180 will be displayed on level 5 and posters P181-326 will be displayed on level 2. Posters can be mounted on the boards from 07.30 on Thursday 26 June and all posters should be in place by 11.00. Materials to mount you poster will be available in the poster area. Posters should be removed by 13.00 on Saturday 28 June and any posters remaining on poster boards after this time may be disposed of.

The presenting author should be present at the poster in order to discuss the data with the attendants. Poster presenters with an even numbered poster should be present 11.45–12.15 on Thursday 26 June and poster presenters with an uneven numbered poster should be present 11.30 to 12.00 on Friday 27 June. All poster presenters are asked to stand by their poster during the official poster session on Thursday 26 June between 17.00 and 18.15.

The three best posters will be selected by a dedicated Poster Committee and will receive a financial award that will be awarded during the Conference Closing Ceremony in the morning of Saturday 28 June.

Thursday 26 June 11.45–12.15 (Posters with even numbers)
Thursday 26 June 17.00–18.15 (All posters)
Friday 27 June 11.30–12.00 (Posters with uneven numbers)

**Poster Group No 1** – Hematopoietic Stem Cell Transplantation- P1-51
**Poster Group No 2** – Antigen presentation, peptides, Non-HLA polymorphism- P52-68
**Poster Group No 3** – Solid Organ Transplantation-P69-150
**Poster Group No 4** – Immunogenetics/Miscellaneous-P151-217
**Poster Group No 5** – Bioinformatics- P218-228
**Poster Group No 6** – Population Genetics/Anthropology-P229-259
**Poster Group No 7** – Autoimmunity, Disease Association, and Cancer- P260-312
**Poster Group No 8** – NK Immunity and Immunogenetics-P313-326
Industry Sponsored Satellite Symposia

Thursday 26 June, 12.15–13.15

One Lambda, Inc. part of Thermo Fisher Scientific

A paradigm in flux: understanding the role of antibodies in transplant rejection
Room A1, Level 4

Speaker: Dr Duska Dragun  Dr Carmen Lefaucheur
University of Berlin  Hôpital Saint-Louis
Berlin, Germany  Paris, France

Abbott

Abbott Molecular Transplant Genetics
Room A2, Level 6

Talk 1: Introduction to Abbott Molecular’s Transplant Genetics Products
Speaker: Paul Kyle, Abbott Molecular, Ghent, Belgium

Talk 2: Recent Improvements and Developments with SSPGo Products
Speaker: Dr Mike Bunce, CSO Biofortuna, Liverpool, UK

Talk 3: Monitoring after hematopoietic stem cell transplantation: Evaluation of the AlleleSEQR® Chimerism Assay
Speaker: Dr Andrea Dick, University Hospital, LMU, Munich, Germany

Illumina

Introducing Illumina TruSight HLA Sequencing Panel
Room C1/C2, Level 2

Speaker: Alex Lindell  Dr Matthew W. Andersson
Senior Marketing Manager, Medical Director, Diagnostic
HLA typing  Laboratories
Illumina  Blood Center of Wisconsin
Friday 27 June, 12.15–13.15

**Histogenetics**

*NGS, NNGS and NNNGS technologies and HLA typing*
Room A1, Level 4

Speaker: Nezih Cereb, M.D.
CEO Histogenetics, USA

**NGS Meta-data & Mega-data**

Speaker: Martin Maiers
Director, Bioinformatics Research
National marrow Donor Programme, Be The Match, USA

**The development of Haplobanks of Induced Pluripotent Stem Cells in XXIst century HLA matching landscape**

Speaker: Pierre-Antoine Gourraud, Assistant Prof
UCSF, USA

**Olerup**

*Improving Clinical Results in Stem Cell Transplantation*

Room A2, Level 6

**The impact of tissue typing and donor characteristics on outcome after allogeneic stem cell transplantation**

Speaker: Jonas Mattsson, M.D., Ph.D.
Medical Director, Center for Allogeneic Stem Cell Transplantation
Karolinska University Hospital, Sweden

**Back to the Future: Improving HSCT outcomes by matching MHC genomic blocks**

Speaker: David Sayer, Ph.D
CEO Connexio Genomics
Perth, Australia

**Immucor**

*HLA antibody detection is more than MFI*

Room C1/C2, Level 2

Speaker: Frans H.J. Claas, Prof
IHB, Leiden University Medical Center
General Assembly

To all EFI members

On behalf of the EFI Executive Committee I invite you to attend the General Assembly. It represents your opportunity, as an EFI member, to actively participate in discussing the activities of the Executive Committee and other EFI committees. Your ideas and opinions are most welcome.

The EFI General Assembly will take place on Friday 27 June 2014, 17.00–18.30 in room A1, Level 4 and I strongly encourage you to attend.

All the best,
Gottfried Fischer, EFI President

Agenda

1. Opening
2. Minutes of the General Assembly May 13th,
   2013 Maastricht (EFI Newsletter September 2013 Issue 71)
3. Report of the EFI President
4. Report of the EFI Secretary
5. Report of the EFI Treasurer
6. Report of the EFI Committees
   a) Accreditation
   b) Education
   c) External Proficiency Testing
   d) Scientific
   e) Standards and Quality Assurance
8. EFI Medal
### Detailed Scientific Programme

#### Wednesday 25 June

<table>
<thead>
<tr>
<th>Time</th>
<th>Event</th>
<th>Room</th>
</tr>
</thead>
<tbody>
<tr>
<td>16.00–18.00</td>
<td>Welcome and Opening Ceremony</td>
<td>Room A1/Level 4</td>
</tr>
<tr>
<td>16.10–16.15</td>
<td>Welcome address</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Dean of Research, Professor Hans-Gustaf Ljunggren,</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Karolinska Institutet, Stockholm, Sweden</td>
<td></td>
</tr>
<tr>
<td>16.15–16.45</td>
<td>Julia Bodmer Award Lecture</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Chair: K. Fleischhauer</td>
<td></td>
</tr>
<tr>
<td>16.45–17.30</td>
<td>Ceppellini Lecture</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Chair: G. Fischer</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Prof Marco Colonna, Washington University</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Medical School, St Louis, MA, USA</td>
<td></td>
</tr>
<tr>
<td>17.30–18.00</td>
<td>Music with ”Little Green”</td>
<td></td>
</tr>
<tr>
<td>19.00–21.00</td>
<td>Welcome Reception at Stockholm City Hall</td>
<td></td>
</tr>
</tbody>
</table>

#### Thursday 26 June

<table>
<thead>
<tr>
<th>Time</th>
<th>Event</th>
<th>Room</th>
</tr>
</thead>
<tbody>
<tr>
<td>08.00–09.30</td>
<td>Plenary session 1: New concepts in cell therapies</td>
<td>Room A1/Level 4</td>
</tr>
<tr>
<td></td>
<td>Chairs: M. Tilanus, A.-C. Wikström</td>
<td></td>
</tr>
<tr>
<td></td>
<td>REGULATORY T CELLS</td>
<td></td>
</tr>
<tr>
<td></td>
<td>– FROM MECHANISMS TO MEDICINE</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Prof Kathryn Wood, University of Oxford, UK</td>
<td></td>
</tr>
<tr>
<td></td>
<td>HAPLOIDENTICAL STEM CELL TRANSPLANTATION</td>
<td></td>
</tr>
<tr>
<td></td>
<td>IN ACUTE LEUKEMIAS</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Prof Fabio Ciceri, San Raffaele Scientific Institute, Milan, Italy</td>
<td></td>
</tr>
<tr>
<td></td>
<td>ADOPTIVE T CELL THERAPY WITH HIGH-AFFINITY TCRS FOR</td>
<td></td>
</tr>
<tr>
<td></td>
<td>HEMATOPOIETIC MALIGNANCIES</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Prof Dolores Schendel, Helmholtz Zentrum, Munich, Germany</td>
<td></td>
</tr>
<tr>
<td>09.30–10.00</td>
<td>Refreshment Break</td>
<td></td>
</tr>
<tr>
<td>10.00–11.30</td>
<td>Abstract session 1: Immunogenetics O10-17</td>
<td>Room A2/Level 6</td>
</tr>
<tr>
<td></td>
<td>Chairs: P.Horn, M-L Lokki</td>
<td></td>
</tr>
</tbody>
</table>

**O10**

**ALTERNATIVE EXPLANATIONS FOR HLA AND DISEASE ASSOCIATIONS**

SK Singh, MT Dorak (Liverpool)
O11
IDENTIFICATION OF GENETIC DEFECTS IN PRIMARY IMMUNODEFICIENCIES BY WHOLE EXOME SEQUENCING
M Christiansen, JB Jensen, JE Veirum, BK Møller (Aarhus N)

O12
A NEXT GENERATION SEQUENCING BASED STRATEGY FOR BLOOD GROUP TYPING
K Lang, K Birkner, C Heder, B Schöne, J Sauter, J Hofmann, J Pingel, C Schwarzelt, V Lange, I Böhme, AH Schmidt (Dresden)

O13
ALLOCATION OF EPSTEIN-BARR VIRUS-SPECIFIC CYTOTOXIC T-CELLS – THE ROLE OF HLA AND HLA ANTIBODIES
V Robertson, A Abel, SD Lockhart, E Ross, N Robinson, G Wilkie, M Vickers, D Turner, M Turner (Edinburgh)

O14
SEMAPHORIN 3A INCREASES TUMOUR-SPECIFIC T-CELL MEDIATED CYTOTOXICITY IN AN AUTOLOGOUS AND ALLOGENEIC SETTING
C Figueiredo, L Schlaha, H Zhang, L Goudeva, B Eiz-Vesper, S Immenschuh, R Blasczyk (Hannover)

O15
INFLUENCE OF HLA CLASS II ANTIGENS ON THE RESPONSE TO A THIRD GENERATION HEPATITIS B VACCINE IN NON- AND LOW-RESPONDERS
C Ludwig, A Krawczyk, FM Heinemann, PA Horn, M Fiedler, M Roggendorf, H Roggendorf, M Lindemann (Essen)

O16
IMMUNOGENICITY OF HUMAN PLURIPOTENT STEM CELLS AND THEIR DERIVATIVES: FOCUS ON NATURAL KILLER CELLS
J Villard, C de Rham, V Tieng Caulet, Y Avila, B Tournier, N Ginovart, K Krause, M Dubois-Dauphin (Geneva)

O17
GENERATION OF MULTIPLE FULL LENGTH HLA CLASS I GENE SEQUENCES IN A SINGLE SEQUENCING REACTION USING SMRT DNA SEQUENCING TECHNOLOGY

10.00–11.30 Abstract session 2: Bioinformatics O18-25
Chairs: C.Carcassi, W. Helmberg
Room C1/C2, Level 2
O18
VALIDATION AND IMPLEMENTATION OF NEXT GENERATION SEQUENCING-BASED HLA TYPING FOR CLINICAL DIAGNOSTICS
TA de Hoop, R Kooter, AC de Graaff, EH Rozemuller, M Penning, E Spierings (Utrecht)

O19
THE IMMPUTE PROJECT: EVALUATING SNP IMPUTATION METHODOLOGIES FOR HLA-A, -B, -C, -DRB1 AND -DQB1 GENOTYPES
D Pappas, V Paunic, AM Lizée, K Taylor, S Leslie, J Meller, X Zheng, L Zhao, P Gourraud, JA Hollenbach, M Maiers, SJ Mack (Oakland)

O20
SNP-BASED IMPUTATION OF HLA ALLELES: WHICH SNP MATTERS?
AM Lizée, D Pappas, V Paunic, JA Hollenbach, M Maiers, SJ Mack, P Gourraud (San Francisco)

O21
HLA EPITOPE FREQUENCIES IN WORLDWIDE POPULATIONS
L Takeshita, AR Jones, D Middleton (Liverpool)

O22
MIRING (MINIMUM INFORMATION FOR REPORTING IMMUNOGENOMIC NGS GENOTYING): REPORTING GUIDELINES FOR HLA GENOTYING VIA NEXT GENERATION SEQUENCING.
BD Gifford, RP Milius, J Robinson, CL Holcomb, EH Rozemuller, M Penning, ML Salit, C Mueller, T Hague, GF Fischer, M Maiers, PJ Norman, MA Fernandez-Vina, JA Hollenbach, SJ Mack (Brown Deer, WI)

O23
HLA-NET NOW: IMMUNOGENETICS FOR ALL
J Nunes, S Buhler, D Roessli, A Sanchez-Mazas (Geneva)

O24
TYPING AMBIGUITY SCORE: A NEW MEASURE FOR QUANTIFYING HLA TYPING AMBIGUITY AND ITS INCORPORATION INTO HAPLOSTATS
V Paunic, E William, J Schneider, J Klug, L Gragert, J Ayim, M Maiers (Minneapolis)

O25
PATIENT GENOTYPE FREQUENCY CAN PREDICT BE THE MATCH REGISTRY UNRELATED DONOR SEARCH PRODUCTIVITY
K Wadsworth, R Fonstad, M Albrecht, S Spellman, M Maiers, J Dehn (Minneapolis, MN)

10.00–11.30 Educational session 1: NK cells and their receptors
Chairs: S Marsh, K-J Malmberg
Room A1, Level 4
10.00–11.00  Meet the speakers from Plenary session 1
Prof. Kathryn Wood, Fabio Ciceri, Dolores Schendel
Room 27, Level 2

11.45–13.30  Poster viewing, lunch & exhibition
Hall M1, Level 2, 4 & 5

12.15–13.15  INDUSTRY SPONSORED SATELLITE SYMPOSIA

13.30–15.00  Abstract session 3: Autoimmunity, disease association and cancer O26-33
Chairs: B. Möller, C. Voorter
Room A2, Level 6

O26
PROMOTER DNA METHYLATION AND MRNA EXPRESSION OF HLA DQA1 GENE IN RELATION TO TYPE 1 DIABETES MELLITUS
M Cerna, M Zajacova, P Cepek, A Kotrbova-Kozak (Prague)

O27
VOXELOGENOMICS: GENOME-WIDE ANALYSIS OF BRAIN-WIDE VOXEL-BASED LESION DISTRIBUTION IN MULTIPLE SCLEROSIS.
P Gourraud, M Sidkaa, P KhanKhanian, R Henry, A Beheshtiana, P Matthews, S Hauser, J Oksenberg, D Pelletier, S Baranzini (San Francisco)

O28
FACTOR ANALYSIS REVEALS PATTERNS IN HLA DISEASE ASSOCIATION OTHERWISE MISSED BY LOGISTIC REGRESSION
S DiPrima, M Albrecht, M Kalaycio, B Hill, L Gragert, M Maiers (Minneapolis)

O29
REDUCED LYMPHOCYTE PROLIFERATION AND IFN-ɤ PRODUCTION AFTER SELECTIVE INTERNAL RADIOTHERAPY
A Domouchtsidou, V Barsegian, J Best, J Ertle, SP Mueller, S Bedreli, PA Horn, A Bockisch, M Lindemann (Essen)

O30
SOLUBLE NKG2DL ARE RELEASED BY TUMOUR CELL LINES IN A MUTUALLY EXCLUSIVE FASHION AS FREE MOLECULES OR VIA EXTRACELLULAR VESICLES
V Rebmann, LF Manvailer, B Wagner, A Rieb, M Collenburg, PA Horn, K Pajtler, A Schramm (Essen)

O31
MONITORING IMMUNE RESPONSES TO DEVELOP A CELLULAR IMMUNOTHERAPY FOR HUMAN PAPILLOMA VIRUS ASSOCIATED TUMOURS
S Haller, TP Wehrs, S Brandau, PA Horn, M Lindemann (Essen)
O32
BAT1-NFKBIL1-LTA OF MHC CLASS III IS A PREDISPOSING GENE REGION TO PERIODONTITIS
M Lokki, M Marchesani, E Kallio, E Vlachopoulou, P Mäntylä, S Paju, K Buhlin, AL Suominen, J Contreras, M Knuutila, M Hernandez, MS Nieminen, M Perola, J Sinisalo, PJ Pussinen (Helsinki)

O33
RISK GENE PROFILE IN FINNISH PANDEMRIX ASSOCIATED NARCOLEPSY
PM Saavalainen, T Jaatinen, A Vuorela, J Kere, M Partinen, J Ilonen, O Vaarala (Helsinki)

13.30–15.00 Abstract session 4: Antigen presentation, peptides and Non-HLA Polymorphism O34-41
Chairs: M Ivanova, C Seidl
Room C1/C2, Level 2

O34
LEVELS OF HLA-G EXPRESSION DEFINE THE TOLEROGENIC ACTIVITY OF DC-10
G Amodio, M Roncarolo, S Gregori (Milan)

O35
THE HLA-DRB1 GENOTYPE AND T-HELPER EPITOPE MUTATION OF INDIVIDUALS WITH SERONEGATIVE OCCULT HEPATITIS B VIRUS INFECTION
RS Wijaya, SI Ie, Y A, T Turyadi, KE El-khobar, AR Harahap, DH Muljono (Jakarta)

O36
DONOR GENOTYPE AND INTRAGRAFT EXPRESSION OF CYP3A5 REFLECT THE RESPONSE TO STEROID TREATMENT DURING ACUTE RENAL ALLOGRAFT REJECTION
NV Rekers, MJ Spruyt-Gerrits, MJ Mallat, M Zandbergen, JD Anholts, IM Bajema, MC Claehsen-van Groningen, HW de Fijter, FH Claas, M Eikmans (Leiden)

O37
IDENTIFICATION OF NOVEL MHC CLASS I EPITOPES FROM POTENTIALLY LETHAL ADENOVIRUS STRAINS IMPROVE DIAGNOSTIC AND THERAPEUTIC OPTIONS IN ADOPTIVE T-CELL THERAPY
S Tischer, C Figueiredo, C Bunse, A Heim, R Geyeregger, C Figueiredo, R Blaszyk, B Maecker-Kolhoff, B Eiz-Vesper (Hannover)

O38
WORLDWIDE DISTRIBUTION AND POPULATION DIFFERENTIATION OF HLA-A AND HLA-B SUPERTYPES: FUNCTIONALITY, NATURAL SELECTION AND ADAPTATION TO LOCAL PATHOGENS
R dos Santos Francisco, S Buhler, J Nunes, D Meyer, A Sanchez-Mazas (Geneva)
O39
ERAP1-ERAP2 DIMERIZATION INCREASES PEPTIDE TRIMMING EFFICIENCY
I Evnouchidou, M Weimershaus, L Saveanu, P van Endert (Paris)

O40
T REGULATORY TYPE 1 (TR1) CELLS CO-EXPRESSING CD49B AND LAG-3 ARE PRESENT IN TRANSPLANTED B−THALASSEMIC WITH PERSISTENT MIXED CHIMERISM
S Gregori, ME Gianolini, R Bacchetta, M Testi, M Battarra, M Andreani, M Roncarolo (Milan)

O41
MODULATION OF HEME OXYGENASE (HO)-1 ENZYME ACTIVITY BY METALLOPORPHYRINS AFFECTS THE ANTIVIRAL T-CELL RESPONSE
V Fortmeier, C Bunse, S Tischer, N Moraw, E Zilian, C Figueiredo, R Blasczyk, S Immenschuh, B Eiz-Vesper (Hannover)

13.30–15.00 Educational session 2: Making sense of antibody testing
Chairs: C Schönemann, S Martin
Room A1, Level 4

13.30–14.30 Meet the Experts: Standard and accreditation
Chairs: A Harmer, K Poulton
Room 27, Level 2

15.00–15.30 Refreshment break

15.30–17.00 Plenary session 2: NK-cells: Old killers in new light
Chairs: A-M. Little, F. Garrido
Room A1, Level 4

MHC CLASS I DEPENDENT EDUCATION OF NK-CELLS: IMPLICATIONS FOR IMMUNOTHERAPY TO TUMORS
Prof Klas Kärre, Karolinska Institutet, Stockholm, Sweden

RECOGNITION OF POLYMORPHIC LIGANDS BY POLYMORPHIC RECEPTORS: BW4 RECOGNITION BY KIR3DL1
Prof Andrew Brooks, University of Melbourne, Australia

HARNESSING NK CELL REPERTOIRE DIVERSITY IN CANCER IMMUNOTHERAPY
Prof Karl-Johan Malmberg, University of Oslo, Norway

17.00–18.15 Poster session
Level 2, 4 & 5
Friday 27 June

08.00–09.30  Plenary session 3: Survival of the organ transplant
Chairs: B. Nilsson, C. Süsal
Room A1, Level 4

ROLE OF LOCAL COMPLEMENT NETWORKS IN ORGAN TRANSPLANTATION
Prof Steven Sacks, Kings College, London, UK

COMPLEMENT BINDING ANTI-HLA ANTIBODIES IN SOLID ORGAN TRANSPLANTATION
Dr Carmen Lefaucheur, St Louis University Hospital, Paris, France

B CELL REGULATION IN TRANSPLANTATION
Dr Menna Clatworthy, University of Cambridge, UK

09.30–10.00  Refreshment break

10.00–11.30  Abstract session 5: Solid organ transplantation O42-49
Chairs: E. Spierings, T Slavcev
Room A2, Level 6

O42
MECHANISMS OF CHRONIC VASCULAR REJECTION INDUCED BY ANTIBODIES TOWARDS HLA CLASS I ANTIGENS
M Trayssac, S Galvani, N Augé, D Calise, E Mucher, F Sallusto, R Salvayre, A Nègre-Salvayre, M Thomsen (Toulouse)

O43
IGA ANTI HLA ALLOANTIBODIES AUGMENT THE NEGATIVE EFFECT OF IGG ALLOANTIBODIES ON GRAFT SURVIVAL
M Arnold, FM Heinemann, N Lachmann, A Dick, A Ender, A Muchlbacher, M Ziemann, C Seidl, W Hitzler, D Thammanichanond, M Hallersleben, J Mytilineos, GF Fischer, S Schaub, II Doxiadis (Erlangen)

O44
B CELL MARKERS OF OPERATIONAL TOLERANCE CAN DISCRIMINATE ACUTE KIDNEY ALLOGRAFT REJECTION FROM STABLE GRAFT FUNCTION
S Heidt, M Vergunst, JD Anholts, JW de Fijter, M Eikmans, FH Claas (Leiden)

O45
TOWARDS DETECTION OF HLA CLASS II SPECIFIC MEMORY B CELL RESPONSES IN SENSITIZED PATIENTS
GE Karahan, YJ de Vaal, DL Roelen, R Buchli, FH Claas, S Heidt (Leiden)
O46
HLA-E EXPRESSION AND ITS IMPACT ON RENAL TRANSPLANT OUTCOME
H Guberina, V Rebmann, P Dziallas, S Dolff, J Wohlschlaeger, FM Heinemann, O Witzke, YM Zoet, FH Claas, PA Horn, A Kribben, II Doxiadis (Essen)

O47
DETECTION OF C3D-BINDING DONOR-SPECIFIC ANTI-HLA ANTIBODIES AT DIAGNOSIS OF HUMORAL REJECTION PREDICTS RENAL GRAFT LOSS
A Sicard, V Dubois, S Ducreux, M Rabeyrin, B Mc Gregor, L Badet, J Scoazec, E Morelon, O’Thaunat (Lyon)

O48
COMPARISON OF CD4 AND CD8 MEMORY PHENOTYPES IN OPERATIONALLY TOLERANT AND CHRONICALLY REJECTING KIDNEY TRANSPLANTED PATIENTS
CM Alvarez, KD Alvarez, C Morath, LF Garcia, G Opelz, M Zeier, C Suesal (Medellin)

O49
OCCURRENCE, DISTRIBUTION AND AMPLITUDE OF THE COMPLEMENT INTERFERENCE PHENOMENON IN SINGLE ANTIGEN FLOW BEAD ASSAY
G Guidicelli, N Franchini, C Borg, L Couzi, P Merville, J Visentini, J Taupin (Bordeaux)

Abstract session 6:
Population genetics/anthropology O50-57
Chairs: D.Middleton, C. Papasteriades
RoomC1/C2, Level 2

O50
THE BALANCE AMONG HLA LIGANDS FOR KIR INHIBITORY RECEPTORS SHAPES THE HLA-A, B AND HLA-B,C HAPLOTYPES IN DIFFERENT ETHNIC GROUPS FROM ASIA, EUROPE, MIDDLE ORIENT AND NORTH AFRICA
C Capittini, M Guarene, C Tinelli, A Pasi, C Badulli, C Pizzochero, L Salvaneschi, M Andreani, M TESTI, M Martinetti (Pavia)

O51
SHARED MHC MOLECULAR DIVERSITY PATTERNS BETWEEN CHIMPANZEEs AND HUMANS
C Vangenot, J Nunes, NG De Groot, ES Poloni, GG Doxiadis, A Sanchez-Mazas (Geneva)

O52
THE REGIONAL GENETIC DIVERSITY OF HLA IN EUROPE: A COMPREHENSIVE MAP DRAWN FROM 145 POPULATION SAMPLES
M Spyropoulou-Vlachou, G Sulcebe, TA Suslova, M Testi, J Tiercy, M Toungouz Nevessignsky, A Varnavidou, B Vidan-Jeras, A Sanchez-Mazas (Geneva)

O53
EXTENDED COVERAGE BY NEXT GENERATION SEQUENCING METHODS REFINES THE CHARACTERIZATION OF THE COMMON AND WELL DOCUMENTED HLA ALLELES
MA Fernandez-Vina, C Wang, S Krishnakumar, D Levinson, RW Davis, MN Mindrinos (Palo Alto)

O54
AFFECTED FAMILY-BASED CONTROL HAPLOTYPES FROM THE TYPE 1 DIABETES GENETICS CONSORTIUM: SIZE DOES MATTER
JA Noble, AM Valdes, W Helmberg, HA Erlich, SJ Mack (Oakland)

O55
CONVERGENT EVOLUTION AND SELECTION ARE COMMON EVENTS IN THE EVOLUTION OF THE HLA SYSTEM
MA Fernandez-Vina, K Barsakis, Babrzadeh, DD Hiraki, DB Tyan, MN Mindrinos (Palo Alto)

O56
HARDY-WEINBERG EQUILIBRIUM TESTING OF AMBIGUOUS HLA TYPING
L Gragert, M Albrecht, S DiPrima, M Maiers (Minneapolis)

O57
AMERINDIAN AND PACIFIC ISLANDERS RELATEDNESS ACCORDING TO HLA AUTOSOMIC GENES
A Arnaiz-Villena, C Areces, M Enriquez-de-Salamanca, S Abd-El-Fatah-Khalil, J Alonso-Rubio, C Puerto, M Fernández-Honrado, D Rey (Madrid)

10.00–11.00  Meet the Speakers from Plenary session 3
Room 27, Level 2
Profs. Steven Sacks, Carmen Lefaucheur, Menna Clatworthy

10.00–11.30  Educational session 3: Next generation sequencing
Chairs: I Fae, K Hirv
Room A1, Level 4

11.30–13.30  Poster viewing, lunch & exhibition
Hall M1, Level 2, 4 & 5

12.15–13.15  INDUSTRY SPONSORED SATELLITE SYMPOSIA

13.30–15.00  Abstract session 7: Stem cell transplantation O58-65
Chairs: M. Fernandez Viña, V. Dubois
Room A2, Level 6
O58
THE PROGRESSION FREE SURVIVAL IN HEMATOPOIETIC STEM CELL TRANSPLANT RECIPIENTS WITH MYELO- AND LYMPHOPROLIFERATIVE CANCERS IS STRONGLY REDUCED BY INHIBITORY KIR-LIGAND MISMATCH OF GVH DIRECTION

O59
NON-LINEAR CLONAL EVOLUTION OF LEUKEMIA DRIVEN BY THE SELECTIVE IMMUNE PRESSURE OF ALLOGENEIC HSCT
L Vago, D Cittaro, D Lazarevic, C Toffalori, G Oliveira, C Brambati, L Chiesa, B Mazzi, M Ponzoni, M Carrabba, M Bernardi, J Peccatori, C Bordignon, C Bonini, K Fleischhauer, F Ciceri, E Stupka (Milano)

O60
MICRORNA (MIR)-155 IS ASSOCIATED WITH THE LEUKEMOGENIC POTENTIAL OF THE GRANULOCYTE-COLONY STIMULATING FACTOR RECEPTOR (G-CSFR) CLASS IV IN CD34+ PROGENITOR CELLS
H Zhang, D Ratuszny, C Gras, B Eiz-Vesper, R Blasczyk, C Figueiredo (Hannover)

O61
HLA-ASSOCIATED RISK INCREASES WITH AGE IN UNRELATED HEMATOPOETIC STEM CELL TRANSPLANTATION
D Fuerst, C Zollikofer, C Mueller, D Niederwieser, D Bunjes, RG Meyer, M Gramatzki, G Wulf, R Arnold, H Einsele, B Glass, G Stuhler, M Pfreundschuh, H Schrezenmeier, J Mytilineos (Ulm)

O62
IDENTIFYING PERMISSIBLE HLA-MISMATCHES: PREDICTED INDIRECTLY RECOGNIZABLE HLA EPITOPEs
KA Thus, D Fuerst, D Niederwieser, D Bunjes, RG Meyer, H van Deutekom, J Calis, E Borst, C Kesmir, J Kuball, J Mytilineos, E Spierings (Utrecht)

O63
AN INCREASING SEVERITY OF CGVHD IS ASSOCIATED TO A MORE ACTIVATED AND CYTOTOXIC T-CELL MEDIATED IMMUNE-PHENOTYPE
A Stikvoort, E Rådestad, J Gertow, M Sundin, J Mattsson, M Uhlin (Stockholm)

O64
WILMS’ TUMOR 1 (WT-1)-SPECIFIC T LYMPHOCYTES AS A TOOL FOR CELLULAR IMMUNOTHERAPY IN ACUTE MYELOID LEUKAEMIA
T Danielzik, E Hermann, U Buttkereit, DW Beelen, PA Horn, M Lindemann (Essen)
O65
HAPLOTYPE-DEPENDANT VARIABILITY IN HLA-B AND -C MRNA EXPRESSION AS DETERMINED BY LOCUS AND ALLELE-SPECIFIC QPCR
F Bettens, L Brunet, J Tiercy (Genève)

13.30–15.00  Abstract session 8:
NK immunity and immunogenetics O66-73
Chairs: M. Toungouz Névessignsky, G Guidicelli
RoomC1/C2, Level 2

O66
NK CELLS EXPANDED WITH THE ZRP CULTIVATION SYSTEM RETAIN THEIR ALLOREACTIVE AND CYTOTOXIC CAPACITY
L Wieten, EE Boumans, A Reichardt, E Sinelnikov, S Sarkar, MG Tilanus, H Hoffmeister, GM Bos, M Gelder (Maastricht)

O67
STREPTAMER SORTED KIR+ NK CELL SUBSETS FOR ADOPTIVE NK CELL THERAPIES
PS Becker, DA Szypkowski, A Kleppinger, JF Hennecke, N Stricker, R Richter, E Seifried, C Seidl (Frankfurt)

O68
THE ROLE OF KILLER CELL IMMUNOGLOBULIN-LIKE RECEPTORS (KIR) EXPRESSED BY NATURAL KILLER CELLS DURING ACUTE CMV INFECTION AFTER KIDNEY TRANSPLANTATION
J Villard, C de Rham, K Hadaya, C Bandelier, S Ferrari-Lacraz (Geneva)

O69
RESOLUTION OF STRUCTURALLY COMPLEX KIR HAPLOTYPES VIA CONTINUOUS LONG READS SPANNING 30 TO 40 KB FULL-LENGTH FOSMID SEQUENCES GENERATED USING SINGLE MOLECULE, REAL-TIME (SMRT®) TECHNOLOGY
S Ranade, K Eng, R Hall, L Hon, C Pyo, K Wang, R Wang, YS Pyon, D Geraghty (Menlo Park)

O70
INTERIM REPORT OF A CLINICAL STUDY WITH HAPLOIDENTICAL NK-CELLS AGAINST HIGH RISK MDS AND AML
AT Björklund, M Carlsten, L Liu, M Schaffer, E Watz, S Cooley, JS Miller, E Hellström-Lindberg, PT Ljungman, H Ljunggren, K Malmberg (Stockholm)

O71
CONTRIBUTION OF KIR AND FCGR3A RECEPTORS GENE CONTENT IN NK MODULATION OF IMMUNE RESPONSE TO COLORECTAL MALIGNANT CELLS.
A Canossi, A Aureli, T Del Beato, O Buonomo, R Arriga, G Sconochia (L’Aquila)
O72
MYELOMA IS ASSOCIATED WITH GENETIC REPertoireS OF KIR2D RECEPTORS WITH LOWER DIVERSITY AND AFFINITY FOR COGNATE HLA-C.

O73
ROLE FOR DNAM-1 AS A MARKER AND EFFECTOR MOLECULE IN NATURAL KILLER CELL EDUCATION
M Enqvist, E Forsslund, EH Ask, M Carlsten, G Abrahamsen, V Béziat, S Andersson, M Schaffer, A Spurkland, Y Bryceson, B Önfelt, K Malmberg (Oslo)

Meet the Experts: External Proficiency Testing (EPT)
Chair: F Heinemann
Room 27, Level 2

Educational session 4: Clinical Chimerism testing
Chairs: M Andreani, M Uzunel
Room A1, Level 4

Refreshment break

Plenary session 4: Tolerance mechanisms
Chairs: J.-M. Tiercy, E. Naumova
Room A1, Level 4

ADOPTIVE T CELL THERAPY AFTER ALLOGENEIC STEM CELL TRANSPLANTATION
Dr Michael Uhlin, Karolinska Institutet, Stockholm, Sweden

APPROACHING CLINICAL TRANSPLANTATION TOLERANCE
Dr Niloufar Safinia, Kings College, London, UK

TOLERANCE IN ORGAN TRANSPLANTATION
Prof David H. Sachs, Harvard Medical School, Boston, USA

EFI General Assembly
Room A1 Level 4

Conference Dinner Party
Münchenbryggeriet
Saturday 28 June

08.00–09.30  **Best Abstracts Session O1-9**  
Chairs: J. Holgersson, J. Mytilineos  
Room A1, Level 4

**O1**  
**PLURIPOTENT STEM CELLS VARYING IN A SINGLE MINOR HISTOCOMPATIBILITY ANTIGEN ELICIT CELLULAR AND HUMORAL IMMUNE RESPONSES THAT CAN MEDIATE GRAFT REJECTION**  
S Monecke, C Hamann, L Elsner, J Nolte, W Engel, G Hasenfuss, K Guan, A Mansouri, R Dressel (Göttingen)

**O2**  
**CIITA-DEPENDENT TRANSCRIPTIONAL DOWNREGULATION OF HLA CLASS II RESULTS IN LEUKEMIA IMMUNE ESCAPE AND RELAPSE AFTER ALLOGENEIC HSCT**  

**O3**  
**COMPREHENSIVE ANALYSIS OF MIRNA EXPRESSION IN NAIVE AND MEMORY TREG SUBSETS OF RHEUMATOID ARTHRITIS PATIENTS**  
K Smigielska-Czepiel, A van den Berg, J Kluiver, H Maat, P Jellema, R van der Lei, M Boots, L Brouwer, B Kroesen (Groningen)

**O4**  
**M. TUBERCULOSIS PEPTIDE LIGAND PRESENTATION BY NON-CLASSICAL HLA-E**  
C McMurtrey, M Harriff, LM Liles, G Swarbrick, W Bardet, ET Canfield, K Jackson, D Lewinsohn, D Lewinsohn, W Hildebrand (Oklahoma City)

**O5**  
**HLA CLASS II ANTIBODY BINDING TO ENDOTHELIAL CELLS PROMOTES ALLO-EXPANSION OF PRO-INFLAMMATORY TH17 AND DISRUPTS EXPANSION OF REGULATORY T LYMPHOCYTES**  
J Lion, C Taflin, M Robledo, D Charron, A Haziot, D Glotz, NA Mooney (Paris)

**O6**  
**DYSREGULATION OF INNATE IMMUNE RESPONSES DUE TO PROMISCUOUS PEPTIDE REPERTOIRE OF HLA-E*01:01**  
T Kraemer, T Huyton, H Kunze-Schumacher, W Abels, R Blaszyk, C Bade-Doeding (Hannover)
O7
IDENTIFICATION OF NOVEL PUBLIC CROSS-REACTIVE ALLO-HLA RESPONSES OF CD8+ T CELLS DIRECTED AGAINST CMV AND FLU PEPTIDES
H van den Heuvel, EM van der Meer-Prins, KM Heutinck, IJ ten Berge, FH Claas (Leiden)

O8
HLA CLASS-II PRESENTED PREDICTED INDIRECTLY RECOGNIZABLE HLA EPITOPES ARE RELATED TO THE FORMATION OF CHILD-SPECIFIC HLA ANTIBODIES DURING PREGNANCY
K Geneugelijk, G Hönger, H van Deutekom, S Schaub, E Spierings (Utrecht)

O9
FUNCTIONAL PLASTICITY OF THE MHC CLASS I REGION: DUPLICATED B-LOCUS COMPENSATES FOR THE LOSS OF C
NG de Groot, CM Heijmans, MK van der Wiel, JH Blokhuis, A Mulder, LA Guethlein, GG Doxiadis, FH Claas, P Parham, RE Bontrop (Rijswijk)

09.30–10.00 Refreshment break
10.00–11.30 Plenary session 5: Autoimmunity and Immunogenetics
Chairs: E. Thorby, B.Vidan-Jeras
Room A1, Level 4
T CELL RECOGNITION OF BERYLLIUM: GENETIC SUSCEPTIBILITY AND NEOANTIGEN GENERATION
Prof Andrew Fontenot, University of Colorado, USA

THE DEVELOPING STORY OF LUPUS SUSCEPTIBILITY GENE: FROM DISCOVERY TO MECHANISMS
Prof Marta E. Alarcón-Riquelme, University of Granada, Spain

THE PAST, THE PRESENT AND THE FUTURE OF CLINICAL ISLET TRANSPLANTATION
Prof Olle Korsgren, Uppsala University, Sweden

11.45–12.30 Closing Lecture
Chair: M. Bengtsson
Room A1, Level 4

HEMATOPOIETIC STEM CELL TRANSPLANTATION – THE KAROLINSKA EXPERIENCE
Prof Olle Ringdén, Karolinska Institutet, Stockholm, Sweden

12.30–13.00 Best abstract, best posters, Jon van Rood Award and Closing Ceremony
Poster presentations – Level 2 and 5

Posters P1-P180 will be displayed on level 5
Posters P181-326 will be displayed on level 2

POSTER GROUP NO 1
– Hematopoietic Stem Cell Transplantation

P1
WHY DOES GAMMA-TYPE MATCHING IN UNRELATED HEMATOPOIETIC STEM CELL TRANSPLANTS (HSCT) RESULT IN A GREATER LIKELIHOOD OF SURVIVAL AND REDUCED RISK OF SEVERE ACUTE GRAFT-VERSUS-HOST-DISEASE?
H Hogan, LE Banister, K Dimovski, DC Sayer (Fremantle)

P2
INTEREST OF BLASTS PHENOTYPING FOR THE CHOICE OF MARKERS OF INTEREST FOR CHIMERISM ANALYSIS: 2 CASE REPORTS
C Rene, J Ferran, A Thuizat, M Moussière, O Avinens, JF Eliaou (Montpellier)

P3
HLA COMPATIBILITY AND CHIMERISM ANALYSIS AS IMPORTANT TOOLS FOR POST-HEMATOPOIETIC STEM CELL TRANSPLANTATION MONITORING
T Lukanov, M Ivanova, A Georgieva, V Atanasova, A Nedyalkova, M Yordanova, B Avramova, V Varbanova, P Ganeva, S Kandilarova, A Mihaylova, G Arnaudov, D Konstantinov, E Naumova (Sofia)

P4
PERIPHERAL BLOOD CELLS CHIMERISM AFTER UNRELATED CORD BLOOD TRANSPLANTATION IN CHILDREN: KINETICS, PREDICTIVE FACTORS AND IMPACT ON POST-TRANSPLANT OUTCOME
C Picard, E Elkaim, C Galambrun, V Barlogis, A Loundou, C Curtillet, C Oudin, I Thuret, H Chambost, G Michel (Marseille)

P5
CYCLOSPORIN AND METHOTREXATE-RELATED PHARMACOGENOMICS PREDICTORS OF ACUTE GRAFT-VS-HOST DISEASE
I Laverdière, C Guillemette, R Tamouza, P Loiseau, R Peffault de Latour, M Robin, F Couture, A Filion, M Lalancette, D Charron, G Socié, É Lévesque (Paris)
P6
NEGATIVE IMPACT OF HLA-DPB1 T CELL EPITOPE MISMATCHES ON SURVIVAL AFTER UNRELATED HEMATOPOIETIC STEM CELL TRANSPLANTATION FOR AML IN A GERMAN SINGLE CENTER STUDY
A Heinold, S Riebschläger, M Lindemann, FM Heinemann, DW Beelen, K Fleischhauer, PA Horn (Essen)

P7
DONOR-RECIPIENT MISMATCHES FOR THE MINOR HISTOCOMPATIBILITY ANTIGEN HA-8 ARE SIGNIFICANTLY ASSOCIATED WITH REJECTION OF HAEMATOPOIETIC STEM CELL TRANSPLANTATION FOR THALASSEMIA
M Andreani, M Testi, M Troiano, J Gaziev, G Lucarelli, F Sizzano, K Fleischhauer (Rome)

P8
EXTENSIVE REAL HAPLOTYPE DIVERSITY IN SLOVENIANS: APPLICATION IN SEARCH FOR UNRELATED HEMATOPOIETIC STEM CELL DONORS

P9
IMPACT OF MHC GAMMA BLOCK (GAMMA TYPE) MISMATCHING IN THE OUTCOME OF UNRELATED HEMATOPOIETIC STEM CELL TRANSPLANTATION
J Getz, DC Sayer, R Pasquini, VM Funke, CS Bonfim, VR Colturato, H Hogan, MA Torres, ME Moraes, NF Pereira (Curitiba)

P10
THE IMPACT OF KIR RECEPTOR-HLA LIGAND INTERACTION ON THE OUTCOME OF PATIENTS RECEIVING HLA-MATCHED SIBLING DONOR HAEMATOPOIETIC STEM CELL TRANSPLANTATION
M Burek Kamenaric, Z Grubic, K Stingl Jankovic, Z Peric, R Serventi Seiwerth, M Maskalan, R Zunec (Zagreb)

P11
ANALYSING THE FACTORS ASSOCIATED WITH UMBILICAL CORD BLOOD BANKING QUALITY AND THEIR CORRELATION WITH CD34+ HEMATOPOIETIC STEM CELLS
B Sadeghi, M Farzanehkah, S Abroun, M Zarrabi (Tehran)

P12
A CAUTIONARY TALE – HAPLOTYPE SPECIFIC AMPLIFICATION IN A REFRACTORY AML PATIENT.
S Vivers, M Bushara, S Hemmatpour, D Sage (London)
P13
KIR GENOTYPE MATCH IN HEMATOPOIETIC STEM-CELL TRANSPLANTATION BETWEEN HLA IDENTICAL SIBS
A Pasi, A Brigo, A Cremaschi, M Monti, C Badulli, E Alessandrino, D Caldera, L Salvaneschi, M Martinetti (Pavia)

P14
ASSOCIATION BETWEEN CTL PRECURSOR FREQUENCY TO HLA-C* MISMATCHES AND HLA-C ANTIGEN CELL SURFACE EXPRESSON
M Israeli, DL Roelen, M Carrington, EW Petersdorf, FH Claas, M Oudshoorn (Leiden)

P15
EXTERNAL QUALITY ASSESSMENT FOR HAEMOPOIETIC CHIMAERISM AND ENGRAFTMENT (HCE) MONITORING: A PILOT STUDY
A Dick, A Volgger, K Witter, M Spannagl, R Reibke (Munich)

P16
HLA-A, -B, -C AND -DRB1 HIGH RESOLUTION MATCHING CAN IMPROVE PATIENT’ OUTCOME AFTER DOUBLE UMBILICAL ALLOGENEIC STEM CELL TRANSPLANTATION (ALLO-SCT)
F Malard, K Gagne, P Chevallier, A Devys, T Guillaume, P Herry, J Delaunay, S Castagnet, P Moreau, M Mohty, A Cesbron (Nantes)

P17
EARLY LEVELS OF SJKRECS OF HSCT PATIENTS CORRELATES WITH RECOVERY OF LATE DIFFERENTIATED B-CELLS
O Abade, M Abecasis, A Lima, G Teixeira, I Ferreira, N Miranda, C Espadinha, H Trindade, D Ligeiro (Lisbon)

P18
IGNORED CYTOGENETIC ABNORMALITIES CAN LEAD TO ERRONEOUS CHIMERISM RESULTS
X Lafarge, S Vigouroux, R Tabrizi, E Lippert, F Belloc, A Assal, N Milpied (Bordeaux)

P19
IMPACT OF HAPLOTYPE STUDY BEFORE SEARCH ON DONOR IDENTIFICATION

P20
QUANTITATIVE CHIMERISM MONITORING IN HEMATOPOIETIC STEM CELL TRANSPLANTATION: NOVEL APPROACHES TO IMPROVED RELIABILITY AND SALVAGING BORDERLINE SAMPLES
D Kristt, T Klein (Petach Tikvah)
P21
DONOR KIR B-HAPLOTYPE REDUCES THE RISK OF RELAPSE IN HLA IDENTICAL ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION IN FINLAND
J Partanen, S Koskela, N Alakulppi, T Linjama, U Impola, J Peräsaari, L Volin (Helsinki)

P22
AMPLICON BASED HIGH-THROUGHPUT HLA GENOTYPING OF REGISTRY DONORS AND FRAGMENT BASED ULTRA-HIGH RESOLUTION TYPING OF PATIENT AND DONOR PAIRS BY NEXT GENERATION SEQUENCING (NGS)
HE Rabenstein, B Bangol, M Haberl, K Hirv (Martinsried)

P23
GENERATION OF CLINICAL-GRADE CMV-SPECIFIC T-CELLS: T-CELL DONOR SELECTION AND MANUFACTURING OF T CELLS
S Tischer, C Priesner, L Arseniev, L Goudeva, K Aleksandrova, H Heuft, C Figueiredo, B Maecker-Kolhoff, R Blasczyk, U Koehl, B Eiz-Vesper (Hannover)

P24
STABLE ENGRAFTMENT AFTER HAPLOIDENTICAL STEM CELL TRANSPLANTATION WITH DONOR SPECIFIC HLA C ANTIBODY: CASE REPORT
I Romon, D San Segundo Arribas, L Valcazar, M Lopez, F Jurado, E Asensio, C Burgueño, M Gomez, C Richard (Santander)

P25
EVALUATION OF CD45, CD3, CD19, CD8, CD56, CD4 AND CD14 SUBSETS IN CORD BLOOD UNITS FROM THE MEXICAN ALTRUISTIC CORD BLOOD BANK-BACECU/FUNDACIÓN COMPARTE VIDA, A.C., AS COMPARED WITH HEALTHY ADULT INDIVIDUALS.
A Vázquez-A, F Pérez, D Rodriguez, E Solís, C Gorodezky (Mexico City)

P26
A CASE STUDY DEMONSTRATING EVIDENCE FOR A DE NOVO MUTATION RESULTING IN THE NEW ALLELE HLA-A*24:02:71

P27
HLA-A*, B*, C*, DRB1*, DQB1* DIVERSITY IN MOTHERS AND THEIR CORD BLOOD UNITS: AN ANALYSIS OF THE NON INHERITED HLA MATERNAL ANTIGENS-NIMA, OF 173 MEXICAN CORD BLOOD UNITS, BELONGING TO THE MEXICAN ALTRUISTIC CORD BLOOD BANK-BACECU
H Flores-A, C Alaez, F Pérez, D Sánchez, D García, M Valencia, C Gorodezky (Mexico City)

P28
EFFECT OF HLA MATCHING ON THE RISK OF SEVERE ACUTE GVHD IN THE PATIENTS AFTER ALLOGENEIC UNRELATED HSCT
E Kuzmich, O Makarenko, A Alyanskiy, M Vladovskaya, S Bondarenko, B Afanasyev (Saint-Petersburg)
P29
QPCR CHIMERISM DETECTION AFTER HEMATOPOIETIC STEM CELL TRANSPLANTATION: THE RUSSIAN CHILDREN’S CLINICAL HOSPITAL EXPERIENCE
A Pospelov, P Busurin, L Gracheva, K Kirgizov, E Skorobogatova, A Bologov (Moscow)

P30
VALIDATION OF AUTOMATED CELL SEPARATION FOR CHIMERISM ANALYSIS USING THE DIASORIN ARROW NUCLEIC ACID EXTRACTION AND CELL SEPARATION INSTRUMENT.
M Uzunel, R Lövlie, JM Eriksson, M Stenström, D Hauzenberger (Stockholm)

P31
VALIDATION STUDY OF REAL-TIME POLYMERASE CHAIN REACTION MONOPLEX AND MULTIPLEX ANALYSIS IN CHIMERISM TESTING
M Leontoycova, H Cechova, K Pegova, R Prerovska, D Brezinova, P Hrabakova, M Stankova, S Nadvornikova (Prague 2)

P32
ALLELE AND HAPLOTYPE FREQUENCIES OF HLA AND KIR IN RUSSIAN BONE MARROW DONORS
L Bubnova, I Pavlova, I Sokolova, L Moiseeva, V Bakay, A Berkos, E Belyayeva, L Erokhina (St.-Petersburg)

P33
FLOQSWABS AND ENAT MEDIUM ARE FACILITATING DONORS’ RECRUITMENT FOR HLA TESTING
L Muncher (Rehovot)

P34
GENETIC DEPENDENCE OF THE PROLIFERATIVE RESPONSE IN MIXED LYMPHOCYTE CULTURE
AP Shpakova, LL Golovkina (Moscow)

P35
ALLELE POLYMORPHISM AND HAPLOTYPE DIVERSITY OF HLA-A, B, DRB1 LOCI IN AZARI PEOPLE OF IRAN
N Bagheri, F Yari, M Jamali, M Shaiegan, F Sabaghi, M Zaman vaziri, F Farahi, M Sobhani (Tehran)

P36
THE INCIDENCE OF FETAL-MATERNAL HLA-DRB1 MICROCHIMERISM IN KOREAN CORD BLOOD UNITS AND MOTHERS
E Roh, S Shin, J Yoon, M Park (Seoul)

P37
DESENSITIZATION PROCEDURE IN ALLOGENEIC HSCT: A CASE REPORT.
G Cornacchini, G Bertani, S Rossini, G Grillo, P Marenco (Milano)
P38
HLA HAPLOTYPE-SPECIFIC PCR-SBT OF PATIENTS AWAITING ALLOGENEIC STEM CELL TRANSPLANTATION FROM UNRELATED DONOR
EG Khamaganova, BV Biderman, IA Yakutik, LA Kuzmina, EN Parovichnikova, AB Sudarikov, VG Savchenko (Moscow)

P39
COMPLETE LOSS OF HLA CLASS I HETEROZYGOSITY IN AN ACUTE MYELOID LEUKEMIA PATIENT
C Zollikofer, M Ringhoffer, L Kündgen, H Schrezenmeier, J Mytilineos (Ulm)

P40
ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION IN PATIENTS WITH AML - A SINGLE CENTRE RETROSPECTIVE STUDY
M Vrana, M Dobrovolna, M Markova, V Valkova, E Matejkova (Prague 2)

P41
HEMATOPOIETIC STEM CELLS TRANSPLANTATION WITH REDUCED INTENSITY CONDITIONINGS IN HEMATOLOGICAL MALIGNANCIES: INFLUENCE OF THE SOURCE OF STEM CELLS ON THE ENGRAFTMENT
C Rene, V Georgescu, M Moussière, J Ferran, O Avinens, C Elong-Bertard, A Halkovitch, G Tachon, T Kanouni, L Zhao-Yang, P Ceballos, A Sirvent, N Fegueux, N Molinari, JF Eliaou (Montpellier)

P42
IMPROVED SBTENGINE® BATCH ANALYSIS MODULE
EH Rozemuller, J Geerligs, M Penning, W Mulder (Utrecht)

P43
SOLUBLE HUMAN LEUKOCYTE ANTIGEN G LEVELS DIFFER AFTER HLA-IDENTICAL HEMATOPOIETIC STEM CELL TRANSPLANTATION WITH RESPECT TO THE SEVERITY OF GRAFT VERSUS HOST DISEASE
V Rebmann, B Wagner, F Da Silva Nardi, PA Horn, DW Beelen, L Kordelas (Essen)

P44
AN EXTRA HLA HAPLOTYPE IN PERIPHERAL BLOOD: CELLS ACQUIRED FROM A SIBLING IN UTERO.
C Matthews, AN Dunn, M Collin, W Howell (Newcastle upon Tyne)

P45
IMPLEMENTATION OF HLA-B*44/HLA-C HAPLOTYPE DIVERSITY IN UNRELATED HSC DONOR SEARCHES
D Svilicic, M Maskalan, Z Grubic, M Burek Kamenaric, R Zunec (Zagreb)

P46
EVALUATION OF 3 COMMERCIAL STR KITS FOR CHIMERSIM QUANTIFICATION.
A Tous, V Ferreira, J Di Cristofaro, C Picard (Marseille)
P47
SHORT DELETION IN THE EXON 3 OF THE HLA-B GENE WAS ASSOCIATED WITH CIRCULATING ACUTE MYELOGENOUS LEUKEMIA BLASTS
F Mrazek, J Onderkova, Z Ambruzova, P Rohon, N Königova, L Raida, M Petrek (Olomouc)

P48
INVESTIGATION OF LINEAGE-SPECIFIC AND PERIPHERAL BLOOD CHIMERISM ANALYSIS IN POST-STEM CELL TRANSPLANT PATIENTS.
Y Ogret, F Oguz, SK Besisik, D Sargin (Istanbul)

P49
RESTORING OF DONOR CHIMERISM BY THYROSINE KINASE INHIBITOR TREATMENT IN RELAPSED CHRONIC MYELOID LEUKEMIA AFTER ALLOGENIC TRANSPLANTATION
Y Ogret, E Erkek, E Osmanbasoglu, I Yonal, Y Ogret, F Oguz, M Nalcaci, S Yavuz, F Aydin, SK Besisik (Istanbul)

P50
THE IMPACT OF DONOR SPECIFIC ANTI-HLA AND ANTI-GSTT1 ANTIBODIES ON THE OUTCOME OF ALLOGENEIC STEM CELL TRANSPLANTATION
C Kekik, I Yonal, F Oguz, S Usta, S Temurhan, D Batu, S Kalayoglu Besisik, D Sargin (Istanbul)

P51
IN VITRO INDUCED HLA-G+T CELLS: A PROMISING ADOPTIVE CELL IMMUNOSUPPRESSIVE THERAPY AFTER HEMATOPOIETIC STEM CELL TRANSPLANTATION?
AG Vittoraki, PK Stamou, DV Kokkinou, DI Marioli, EC Theofani, VD Goudogianni, NN Zoudiari, GA Oikonomopoulou, PM Zikos, AG Spyridonidis (Patra)

POSTER GROUP NO 2 – Antigen presentation, peptides, Non-HLA polymorphism

P52
NO MAJOR ROLE FOR INSULIN-DEGRADING ENZYME IN ANTIGEN PRESENTATION BY MHC MOLECULES
F Mauvais, S Culina, H Hsu, S Guénette, A Moser, P van Endert (Paris)

P53
WEAKLY REACTIVE NON-SELF+SELF EPLET PAIR SPECIFIC ANTIBODIES PRODUCE POSITIVE FLOW CYTOMETRY CROSS MATCH
AL Lobashevsky, KM Rosner (Indianapolis)
P54
BAT2 AND BAT3 POLYMORPHISMS AS NOVEL GENETIC RISK FACTORS FOR REJECTION AFTER HLA-RELATED STEM CELL TRANSPLANTATION
IS Piras, A Angius, M Andreani, M Testi, M Floris, S Marktel, F Ciceri, G La Nasa, K Fleischhauer, M Roncarolo, A Bullfone, R Bacchetta, S Gregori (Milan)

P55
GENETIC POLYMORPHISM OF CYTOCHROME P450 (2C19) IN PATIENTS WITH RENAL TRANSPLANT
H Senturk Ciftci, T Tefik, A Turkmen, I Nane, F Savran Oguz, F Aydin (Istanbul)

P56
THE EFFECT OF MDR1 GENE POLYMORPHISM ON THE BLOOD CONCENTRATIONS OF CYCLOSPORINE AFTER RENAL TRANSPLANTATION IN TURKISH PATIENTS
H Senturk Ciftci, T Tefik, Y Caliskan, I Nane, A Turkmen, F Savran Oguz, F Aydin (Istanbul)

P57
MHC-I INTRATUMOR HETEROGENEITY DETERMINES ONCOGENIC AND METASTATIC CAPACITY, AND IMMUNE RESPONSE
I Romero-García, I Linares, I Algarra, A Collado, F Garrido, A García-Lora (Granada)

P58
SEQUENCED ALLELIC LADDERS OBTAINED FROM IHWG SAMPLES FOR A STANDARDISED GENOTYPING OF HLA-MICROSATELLITES
E Dauber, S Wenda, WR Mayr (Vienna)

P59
DIFFERENTIAL PEPTIDES BOUND BY HLA CLASS I CAN INDUCE CONFORMATIONAL VARIATION TO HLA CLASS I EPITOPES – TO A DEGREE WHICH MAY INFLUENCE BINDING AND FUNCTION?
R Battle, B Clark, D Turner (Edinburgh)

P60
AUSTRIAN SEQUENCE AND POPULATION DATA OF THE DINUCLEOTIDE SHORT TANDEM REPEAT POLYMORPHISM D6S2789 (TNFD) LOCATED IN THE HLA CLASS III REGION
E Dauber, WR Mayr (Vienna)

P61
COMPARATIVE STUDY OF ALLELE AND GENOTYPE FREQUENCIES OF HLA-E GENE IN EMBRYO IMPLANTATION FAILURE, ASSISTED REPRODUCTION TREATMENT AND FERTILE CONTROLS COUPLES.
GF Gelmini, Fd Nardi, CH Costa, A Schuffner, TF Michelon, J Neumann, Md Bicalho (Curitiba)
P62
DIFFERENT BINDING MOTIFS OF THE CELIAC DISEASE ASSOCIATED HLA MOLECULES DQ2.5, DQ2.2 AND DQ7.5 REVEALED BY QUANTITATIVE MASS SPECTROMETRY-BASED ANALYSIS OF ENDOGENOUS PEPTIDE REPERTOIRES
E Bergseng, S Dørum, MØ Arntzen, M Nielsen, S Buus, GA de Souza, LM Sollid (Oslo)

P63
THE TTTT HAPLOTYPE OF BAFF PROMOTER POLYMORPHISM IS ASSOCIATED WITH IDIOPATHIC INFLAMMATORY MYOPATHIES IN CZECH COHORT OF PATIENTS.
T Svitalkova, O Krystufkova, H Hulejova, M Svetla, L Plestilova, M Remakova, H Mann, J Vencovský, P Novotá (Prague)

P64
STRUCTURAL ASPECT OF ANTI-HLA-A, -B, -DR, -DQB1 AND -DQA1 ANTIBODIES REACTIVE EPITOPE DETERMINATION WITH HLAMATCHMAKER
M Resse, R Paolillo, A Casamassimi, F Cavalca, C Fiorito, C Maiello, C Napoli (Naples)

P65
SINGLE NUCLEOTIDE POLYMORPHISM HAPLOTYPES OF NKG2D AND NKG2F IN NORTHEASTERN THAIS
M Kaewmanee, C Leelayuwat, A Romphruk, A Romphruk (Pathumthani)

P66
TNF-ALPHA -857T A GENETIC RISK MARKER FOR EARLY ONSET ANKYLOSING SPONDYLITIS IN ALGERIAN PATIENTS
H Amroun, R Allat, S Salah (Algiers)

P67
DETECTION OF A NOVEL ALLELE, HLA DQB1*03:82 IN A PATIENT OF KAZAKHS NATIONALITY WITH ACUTE MYELOID LEUKAEMIA
A Turganbekova, Z Burkitbaev, S Abdrahmanova, I Ramilyeva, D Yakiyayeva, D Baimukasheva, T Li, B Daniarova, S Ashim (Astana)

P68
NOVEL QUANTITATIVE BEAD-BASED MICROARRAY ASSAY FOR DNMT3A R882 MUTATIONS WITH BNA-MODIFIED OLIGONUCLEOTIDE PROBES
M Ivanova, VS Shivarov, A Nedyalkova, E Naumova (Sofia)
POSTER GROUP NO 3
– Solid Organ Transplantation

P69
ANALYSIS OF CYTOKINE SYNTHESIS IN DONOR-RECIPIENT MIXED LYMPHOCYTE REACTIONS IN KIDNEY TRANSPLANT PATIENTS: RAPAMYCINE IS SUPERIOR TO CALCINEURIN INHIBITORS IN DOWN-REGULATING IL-2 PRODUCTION
MD Xavier, SN Sampaio, P Aires, F Freitas, JG Oliveira (Porto)

P70
CLINICAL RELEVANCE OF PRE- AND POST-LUNG TRANSPLANT APPEARANCE OF ANTI-HLA- AND MICA ANTIBODIES AS A MARKER FOR CHRONIC GRAFT DYSFUNCTION
T Kauke, A Dick, N Kneidinger, C Neurohr, M Spannagl, H Winter (Munich)

P71
INHIBITION OF THE DETECTION OF ANTI-HLA ANTIBODIES BY LUMINEX ASSAY: PROBABLE MaskING DUE TO C3/C3B DEPOSITION.
N Congy-Jolivet, A Aarnink, D Milongo, A Del Bello, N Kamar, L Rostaing, A Blancher (Toulouse)

P72
DETECTION OF HLA AB BY SINGLE ANTIGEN BEAD ASSAY (LUMINEX) IS RELATED TO AN INCREASED RISK FOR LONG TERM KIDNEY GRAFT LOSS
R Richter, A Schödel, L Holschuh, S Feuchtinger, S Qidan, M Brzoska, A Asbe-Vollkopf, S Büttner, C Betz, S Gauer, E Seifried, H Geiger, I Hauser, C Seidl (Frankfurt)

P73
DECIPHERING COMPLEMENT INTERFERENCE WITH ANTI-HLA ANTIBODY DETECTION IN FLOW BEADS ASSAYS
J Visentin, M Vigata, S Daburon, C Contin-Bordes, V Frémeaux-Bacchi, C Dromer, M Billes, M Neau-Cransac, G Guidicelli, J Taupin (Bordeaux)

P74
MODULATION OF CYTOKINE SYNTHESIS IN DONOR-RECIPIENT MIXED LYMPHOCYTE REACTIONS IN KIDNEY TRANSPLANT RECIPIENTS UNDER RAPAMYCINE THERAPY BY FINE-NEEDLE ASPIRATION BIOPSY CULTURES SUPERNATANTS
MD Xavier, SN Sampaio, P Aires, F Freitas, JG Oliveira (Porto)

P75
THE DYNAMICS OF SERUM FREE LIGHT CHAIN IMMUNOGLOBULINS AFTER KIDNEY TRANSPLANTATION
TH Habets, SJ Molenbroeck, JJ Frijns, E Bielen, CE Voorter, GM Bos, FA Redegeld, MH Christiaans, MG Tilanus, J Vanderlocht (Maastricht)
P76
HLA-SPECIFIC ANTIBODY POST RENAL TRANSPLANT MONITORING: PRELIMINARY FINDINGS IN A SINGLE CENTER
A Varnavidou-Nicolaidou, R Mean, D Georgiou, G Stylianou, M Prikis, N Michael, P Loizou, V Hadjianastassiou (Nicosia)

P77
PRETRANSPLANT DSA BUT NOT COMPLEMENT FIXING HLA ANTIBODIES ARE ASSOCIATED WITH INCREASED RISK FOR ANTIBODY MEDIATED REJECTION IN KIDNEY TRANSPLANTATION
FM Heinemann, D Keles, A Heinold, O Witzke, A Kribben, A Paul, HA Baba, JU Becker, PA Horn, U Eisenberger (Essen)

P78
THE INHERENT WEAKNESS OF CONSENSUS-BASED EXTERNAL PROFICIENCY TESTING EXPOSED IN FLOWCYTOMETRIC CROSSMATCHING
P Koefoed-Nielsen, BK Møller, MS Petersen (Aarhus N)

P79
THE EFFECT OF A POSITIVE CDC CROSSMATCH ON CLINICAL OUTCOMES IN ADULT-TO-ADULT LIVING DONOR LIVER TRANSPLANTATION
M Chowdhry, R Makroo, M Mishra, Y Thakur, S Sharma, P Srivastava, M Singh, S Gupta, M Wadhawan (New Delhi)

P80
ALLOGENEIC, BONE MARROW DERIVED, MESENCHYMAL STROMAL CELLS AS ADJUNCTIVE THERAPY FOR REFRACTORY RENAL ALLOGRAFT REJECTION
SJ Fidler, R Swaminathan, A Warger, M Stuurm, R Herrmann, A Irish (Perth)

P81
SUCCESSFUL RENAL TRANSPLANTATION ACROSS HIGH TITER DONOR SPECIFIC ANTIBODY (DSA) AND STRONG POSITIVE B CELL IGG FLOW CROSSMATCH DUE TO DRB1*04:02 ALLELE MISMATCH
A Dada, A Bokhari, K Masbate, N Zabani, W Habhab, N Al Baz, S Hassen (Jeddah)

P82
PROZONE EFFECT: WHAT IS THE CAUSE?
A Nocco, A Innocente, E Longhi, V Sioli, C Brambilla, N Cagni, N De Fazio, M Ramondetta, F Drago, M Cardillo, G Piccolo (Milano)

P83
DETERMINANTS OF C1Q-BINDING IN THE SINGLE ANTIGEN BEAD ASSAY
S Schaub, G Hönger, MT Koller, R Liwski, P Amico (Basel)
P84
A CASE-STUDY – A SUCCESSFUL LIVING-DONOR RENAL TRANSPLANT IN THE PRESENCE OF A STRONG DONOR-SPECIFIC ANTIBODY
C Rosser, S Khan, R Fowle, S Jordan, S Hemmatpour, D Sage (London)

P85
IMMUNOADSORPTION USING PROTEIN A COLUMNS COMPLICATES INTERPRETATION OF CYTOTOXIC CROSSMATCH.
P Koefoed-Nielsen, C Bistrup, M Christiansen (Aarhus N)

P86
PRE-TRANSPLANT ANTI-HLA ANTIBODY MONITORING BY LUMINEX C1Q ASSAY AND UNACCEPTABLE DONOR ANTIGENS DEFINITION: A CASE REPORT
A Innocente, A Nocco, E Longhi, V Sioli, C Brambilla, N Cagni, T Brambilla, M Ramondetta, G Puglisi, L Crespiatico, M Cardillo, G Piccolo (Milano)

P87
CLINICALLY RELEVANT DIFFERENCES BETWEEN FLOWCYTOMETRIC CROSSMATCH-ING AND LUMINEX-BASED LABSCREEN TESTING MAY EXIST FOR SERA WITH LOW TO INTERMEDIATE LABSCREEN REACTIVITY.
P Koefoed-Nielsen, MS Petersen, BK Møller (Aarhus N)

P88
DIFFERENTIAL ALLELE SPECIFIC HLA ANTIBODY DEFINITION AND THE RESOLUTION OF DECEASED DONOR HLA TYPING CAN IMPACT UPON THOSE PATIENTS WITH AN ALLELE SPECIFIC HLA ANTIBODY
R Battle, D Turner, D Middleton, L David (Edinburgh)

P89
INTRACELLULAR ATP SYNTHESIS ASSAY AS A USEFUL TOOL TO PREDICT EARLY ACUTE REJECTION AND GRAFT OUTCOME IN KIDNEY TRANSPLANTATION
C Caorsi, A Ranghino, A Giordano, Z Drace, A Lavacca, F Novelli, L Biancone, S Roggero, A Amoroso (Torino)

P90
HLA-E POLYMORPHISMS IMPACTS ON HUMAN CYTOMEGALOVIRUS REINFECTION IN SIMULTANEOUS KIDNEY-PANCREAS TRANSPLANTATION
Fd Nardi, P Kühn, A Wunsch, Md Bicalho, FM Heinemann, PA Horn, R Viebahn, V Rebmann (Curitiba)

P91
IMPACT OF TOLL LIKE RECEPTOR 2 AND 4 MRNA EXPRESSION IN RENAL ALLOGRAFT OUTCOME
M Sharbafi Eskandani (Tehran)
P92
A STRATEGY FOR THE IDENTIFICATION OF DENATURED ANTIGEN REACTIVE ANTIBODIES - A CASE REVIEW REVEALS A NATURAL ANTIBODY CAPABLE OF GENERATING A POSITIVE CROSSMATCH
R Battle, SD Lockhart, A Abel, E Ross, A Edwards, D Turner (Edinburgh)

P93
GENETIC POLYMORPHISMS AND DELAYED KIDNEY GRAFT FUNCTION
A Goncalves-Primo, ÉF Campos, H Tedesco-Silva, JO Medina-Pestana, M Gerbase-DeLima (São Paulo)

P94
NK CELL SUBSETS AND IL2,15,18 GENE EXPRESSION IN CHRONIC ALLOGRAFT NEPHROPATHY
A Amirzargar, A Sepanjnia, S Asadiasl, P Ahmadpoor, F Pourrezagholi, M Parvin, M Nafar (Tehran)

P95
HLA ANTIBODY DETECTION ON PGM(TM)
B Zhao, D Dinauer, B Irish, S Conradson (Brown Deer)

P96
A NOVEL METHOD FOR MONITORING DONOR-DERIVED CELL-FREE DNA LEVELS AS A BIOMARKER FOR ACUTE REJECTION AFTER KIDNEY TRANSPLANTATION
M Adamek, G Opelz, C Morath, M Sadeghi, T Tran (Heidelberg)

P97
THE IMPACT OF ANTI-HLA DONOR-SPECIFIC ANTIBODIES ON ULTRASTRUCTURAL DAMAGE IN ABO-COMPATIBLE AND INCOMPATIBLE RENAL ALLOGRAFTS
FM Heinemann, JU Becker, A Pfaffenbach, A Habicht, C Chatzikyrkou, HH Kreipe, H Haller, I Scheffner, W Gwinner, E Zilian, S Immenschuh, A Schwarz, PA Horn, V Bröcker (Essen)

P98
ESTIMATING HLA-DP INCOMPATIBILITY WHEN DONOR DP TYPING INFORMATION IS UNAVAILABLE USING DPB1 AND DPA1 ALLELE FREQUENCIES
Z Antovich, M Frome, N Ly, F Grumet, D Maurer (South San Francisco, CA)

P99
COMBINATION OF C1Q AND HLA-MATCHMAKER ANALYSIS TO REDUCE VPRA IN HYPERSENSITIZED PATIENTS AWAITING FOR KIDNEY TRANSPLANTATION
D San Segundo Arribas, ML Valcárcel, C Burgueño, M Gómez-Fernández, I Romón, M López-Hoyos (Santander)
THE HIGHLY SENSITIZED PATIENT: A GROUP WITH DIFFERENT OPPORTUNITIES.
MJ Pando, YM Desmarteau, R Valdez (Phoenix)

EVALUATION OF A C3D SOLID PHASE BEAD ASSAY TO DETECT ANTI- HLA COMPLEMENT FIXING ANTIBODIES IN KIDNEY TRANSPLANTATION
G Ercilla, N Suarez, M Digón, F Oppenheimer, S Gil-Vernet, J Martorell (Barcelona)

DONOR SPECIFIC HLA ANTIBODIES DETECTED BY LUMINEX CANNOT PREDICT THE OUTCOME OF A CDC OR FLOW CYTOMETRIC CROSSMATCH IN AN INDIVIDUAL PATIENT
DL Roelen, S Brand-Schaaf, S Stein, FH Claas (Leiden)

FROM CDC TO AHG CDC CROSSMATCH IN KIDNEY TRANSPLANT RECIPIENTS: A WELCOME CHANGE
M Chowdhry, R Makroo, M Mishra, Y Thakur, S Sharma, P Srivastava, M Singh, S Pandit, S Saha (New Delhi)

SENSITIZATION STATUS OF PATIENTS IN A DANISH HLA LABORATORY
H Bruunsgaard, JS Hansen, C Larsen (Copenhagen)

METHODS FOR ABOLISHING INHIBITORY SERUM FACTORS IN LUMINEX SINGLE ANTIGEN ASSAY
R de Marco, M Gerbase-DeLima (São Paulo)

MEDIATOR COMPLEX, HUMAN LEUKOCYTE ANTIGEN AND CARDIAC TRANSPLANTATION
V Grimaldi, C Schiano, A Casamassimi, A Picascia, R Fabbricini, C Amarelli, C Maiello, C Napoli (Naples)

LABSCREEN MIXED-BASED STRATEGY FOR THE DETECTION AND IDENTIFICATION OF ANTI-HLA ANTIBODIES IN PRETRANSPLANTATION SETTING
V Kheav, C Gautreau, J Reine, J Siemowski, D Charron, C Suberbielle, M Carmagnat (Paris)

UNDERESTIMATION OF MEAN FLUORESCENCE INTENSITY OF CYTOTOXIC ANTIBODIES IDENTIFIED BY LUMINEX SINGLE ANTIGEN ASSAY.
A Ouedrani, M Carmagnat, V Kheav, D Charron, C Suberbielle, C Gautreau (Paris)
P109
NEW APPROACH FOR THE ASSESSMENT OF ANTIBODY MEDIATED REJECTION: DETECTION OF C3D FIXING DONOR SPECIFIC ANTIBODIES
E Rigol-Monzó, A Sanchez-Escuredo, M Digón, F Oppenheimer, J Martorell, G Ercilla (Barcelona)

P110
A NATIONAL KIDNEY ALLOCATION PROGRAM FOR LONG WAITING HLA BROADLY SENSITIZED PATIENTS: THE NORTH ITALY TRANSPLANT EXPERIENCE
M Cardillo, E Longhi, L Crespiatico, T De Feo, A Nocco, V Sioli, A Innocente, C Brambilla, T Brambilla, N Cagni, F Marangoni, G Rossini, G Piccolo (Milano)

P111
MICA-SPECIFIC ANTIBODIES MAY PREDICT LONG-TERM KIDNEY GRAFT SURVIVAL
A Slavcev, E Svobodova, S Valhova, J Slatinska, O Viklicky (Prague)

P112
EXTERNAL PROFICIENCY TESTING WITHIN EUROTRANSPLANT: TOWARDS A WEB-BASED DATA ENTRY
YM Zoet, MD Witvliet, GW Haasnoot, N Korfage, G Wams, II Doxiadis, FH Claas (Leiden)

P113
IMPACT OF DONOR SPECIFIC ANTIBODIES PRESENT ON THE DAY OF TRANSPLANTATION FOR A RENAL TRANSPLANT: THE EVOLUTION OF THESE ANTIBODIES AND THEIR FLUORESCENCE VALUES ARE ESSENTIAL CRITERIA TO BE TAKEN INTO ACCOUNT
A Parissiadis, C Flick, S Caillard, V Renner, N Froelich, G Gautier-Vargas, J Olagne, B Moulin, C Gachet (Strasbourg)

P114
ASSOCIATION OF KIDNEY GRAFT LOSS WITH POSTTRANSPLANT PRESENCE OF HLA ANTIBODIES DETECTED BY SINGLE ANTIGEN TESTING
C Suesal, C Suesal, T Tran, S Scherer, C Morath, A Slavcev, M Zeier, P Schemmer, G Opelz (Heidelberg)

P115
A PROPOSAL FOR A NEW KIDNEY ALLOCATION SYSTEM
BA Lima, M Mendes, H Alves (Vilar Formoso)

P116
THE NUMBER OF MISMATCHES AND ITS IMPACT ON THE SENSITIZATION OF KIDNEY RE-TRANSPLANT CANDIDATES AFTER FIRST GRAFT FAILURE
L Ramalhete, M Sancho, M Silva, H Trindade (Lisbon)

P117
MEASURING ACCESS TO KIDNEY TRANSPLANTATION
BA Lima, M Mendes, H Alves (Vilar Formoso)
P118
ALL THAT GLITTER IS NOT GOLD: PERSISTENT AND STRONG DE NOVO ANTI-DSA ANTIBODIES AT HIGH TITER COULD NOT BE ASSOCIATED WITH HUMORAL ACUTE REJECTION WHEN SOLID PHASE SAB C1Q-BINDING ASSAY IS NEGATIVE IN POST-TRANSPLANTATION

P119
COMPLEX IMMUNOLOGY ISSUE IN RENAL TRANSPLANTED CHRONIC HBV/HCV CARRIERS
V Nastase, A Dinu, A Moise, F Nedelcu, M Toader, G Mircescu, I Sinescu, I Constantinescu (Bucharest)

P120
OUR EXPERIENCE IN USING VIRTUAL CROSSMATCH. CHALLENGES AND CLINICAL SIGNIFICANCE.
A Dinu, V Nastase, A Moise, M Toader, F Nedelcu, G Mircescu, I Sinescu, I Constantinescu (Bucharest)

P121
ANTI-DENATURED CLASS I HLA ANTIBODIES IN SENSITIZED KIDNEY RECIPIENTS: PREVALENCE, RELEVANCE, IMPACT ON ORGAN ALLOCATION
J Visentin, G Guidicelli, T Bachelet, C Jacquelinet, B Audry, T Nong, V Dubois, J Moreau, J Lee, L Couzi, P Merville, J Taupin (Bordeaux)

P122
6-YEAR FOLLOW UP OF KIDNEY TRANSPLANTS: IMPACT OF IMMUNOGENETICS FACTORS ON GRAFT LOSS
A Gaafar, A Iqneibi, A Sheereen, A Eldali, H Turpeinen, K Al Meshari, K Al Hussein (Riyadh)

P123
PRE-TRANSPLANT ANTI-ENDOTHELIAL IGM ANTIBODY POSITIVE KIDNEY PATIENTS SHOW INCREASED RISK OF ACUTE REJECTION
M Alheim, D Hauzenberger, A Wikström (Stockholm)

P124
DEVELOPMENT OF A RAPID PROTOCOL FOR LIFECODES SSO TYPING ASSAYS
S Patel, M Osada, B Ray (Stamford)

P125
BLOOD TRANSFUSIONS IN ORGAN WAITING LIST PATIENTS
N Katalinic, H Kurtovic, M Fucak, M Curkovic, A Mujic, T Crnic, S Balen (Rijeka)
DECREASE IN THE PERCENTAGE OF PERIPHERAL BLOOD CXCR3HIGH CD4+ LYMPHOCYTES AFTER RENAL TRANSPLANTATION
A Caballero, P Ruiz-Esteban, E Palma, P Ramirez, A Alonso, N Fernandez, A Serrano, M Bravo, D Hernandez (Málaga)

KIR AND HLA-C LIGANDS INFLUENCE THE CHRONIC REJECTION RISK AND LONG-TERM LIVER GRAFT SURVIVAL.
I Legaz, G Salgado, M López-Álvarez, JA Campillo, B Las Heras, JM Bolarin, M Miras, AM Garcia Alonso, MR Alvarez-Lopez, A Minguela (El Palmar-Murcia)

EVALUATION OF THE DELETERIOUS NATURE OF DONOR-SPECIFIC ANTIBODIES (DSA) CAPABLE TO BIND C1Q: RESULTS OF A STUDY IN 947 PATIENTS WITH A FUNCTIONAL RENAL TRANSPLANT
A Parissiadis, G Gautier-Vargas, N Froelich, J Olagne, C Muller, C Gachet, B Moulin, S Caillard (Strasbourg)

PREFORMED ANTI-MICA ANTIBODIES NEGATIVELY IMPACT ON RENAL ALLOGRAFT EVOLUTION DURING THE FIRST MONTHS POST-TRANSPLANTATION
E Sánchez Zapardiel, E Mancebo, M Castro Panete, M Castillo Rama, P Morales, D Lora Pablos, D Valero Hervás, R Ruiz García, J Apaza, A Andrés, J Morales, E Paz Artal (Madrid)

C1QSCREEN IN KIDNEY TRANSPLANTATION: FIRST STEPS. SINGLE CENTRE EXPERIENCE
S Mistretta, R Bavetta, E Collura, T Traina, V Cappuzzo, F Ingrassia, M Blando, I Vega, R Marcenò (Palermo)

ANTI-HLA ANTIBODY CHARACTERISATION IN RENAL TRANSPLANT RECIPIENTS AND IMPACT FOR TRANSPLANTATION OUTCOME (REPORT FROM ONGOING STUDY)
Z Ambruzova, K Krejci, J Zadrazil, J Zapletalova, M Petrek (Olomouc)

IMPACT OF THE INTRODUCTION HLA - C AND DQ IN RENAL ALLOCATION ALGORITHM
L Ramalhete, M Sancho, M Silva, H Trindade (Lisbon)

SUCCESSFUL TRANSPLANTATION FOR HIGHLY SENSITIZE RENAL TRANSPLANT CANDIDATES
A Siorenta, M Apostolaki, G Paterakis, A Iniotaki (Athens)
P134
DISCORDANCE BETWEEN THE RESULTS OF A SEARCH FOR ANTIBODIES USING THE LYMPHOCYTOTOXICITY AND SINGLE ANTIGEN LUMINEX TECHNIQUES REVEALS A PROZONE EFFECT
A Parissiadis, N Froelich, V Renner, S Caillard, B Moulin, C Gachet (Strasbourg)

P135
CORRELATION OF POSITIVE CDC CROSSMATCH RESULTS WITH PRESENCE OF DONOR-SPECIFIC C1Q-FIXING ANTIBODIES
M Ziemann, S Goerg (Luebeck)

P136
TRANSPLANTATION DONOR-RECIPIENT CROSSMATCH ASSAY BY TWO METHODS (CDC AND LUMINEX) AND ASSOCIATION WITH LUMINEX ANTIBODY DETERMINATION
A Fylaktou, G Miserlis, M Chouridi, F Makrobasili, G Chatzika, C Zaras (Thessaloniki)

P137
DE NOVO ANTI-HLA ANTIBODIES IN PRE-TRANSPLANT UNSENSITIZED PATIENTS
S Tafulo, J Malheiro, E Osório, C Mendes, F Freitas (Porto)

P138
AN APPROACH TO REDUCE THE CONFOUNDING INFLUENCE OF DENATURED ANTI-GENS WITHIN THE TESTING FOR HLA CLASS I ANTIBODY SPECIFICITIES
A Abel, D Turner, R Battle, SD Lockhart (Edinburgh)

P139
HARMONY AND DISHARMONY IN ANTI-HLA ANTIBODY TESTING (ON BEHALF OF THE ASHI PROFICIENCY TESTING PROGRAM)
M Israeli, MS Pollack, CA Shaut, D Youngs, A Halpin, SL Saidman (Leiden)

P140
RELATIONSHIP BETWEEN PREGNANCY AND ANTI-HLA ANTIBODIES IN PATIENTS WITH CHRONIC RENAL FAILURE
I Pirim, M Soyoz, T Kilicaslan Ayna, A Ozkizilcik Kocyigit, B Cerci Gurbuz, C Tugmen, Y Kurtulmus, B Ozyilmaz (Izmir)

P141
LIMIT MFI VALUES IN LUMINEX PRA IDENTIFICATION TESTS
H Tutkak, T Duman, S Özartam, S Özgüçlü, R Aksoy, A Tüzüner, K Keven (Ankara)

P142
GENETIC ANALYSIS OF PATIENTS FROM MACEDONIAN WAITING LIST FOR KIDNEY TRANSPLANTATION
A Hristova-Dimcheva, E Velkova, N Veljanovski, O Damevska-Todorovska, T Makarova-Bojadzieva, R Grubovik, V Petkovska, K Dimitrovski (Skopje)
P143
SPEEDY LUMINEX: TOWARDS SSO HLA-TYPING OF ORGAN DONORS
N Kouprie, L Bungener, T Jongsma, B Kroesen, B Hepkema (Groningen)

P144
LUMINEX CROSSMATCH AS A SUBSTITUTE FOR SINGLE ANTIGEN TESTING IN INDIA
MN Mishra, V Lal (New Delhi)

P145
HLA PROFILE OF DECEASED ORGAN DONORS FROM CROATIA
S Salamunovic, M Maskalan, K Stingl Jankovic, D Svilicic, M Burek Kamienaric, Z Grubic, R Zunec (Zagreb)

P146
DE NOVO DONOR SPECIFIC ANTIBODIES AND RENAL GRAFT SURVIVAL
K Tarassi, V Kitsiou, T Athanassiades, D Kouniaki, K Psarra, M Koukoulaki, T Apostolou, S Drakopoulos, C Papasteriades (Athens)

P147
DETECTION OF ANTI-HLA (HUMAN LEUKOCYTE ANTIGEN) ANTIBODIES IN RENAL PATIENTS BY SINGLE ANTIGEN BEAD FLOW CYTOMETRY ASSAY
T Kilicaslan Ayna, I Pirim, A Ozkizilcik Kocyigit, I Totur, B Cerci Gurbuz, M Soyoz (Izmir)

P148
FLUOGENE HLA TYPING FOR DECEASED DONORS.
S McConnell, L Syme, SD Lockhart, D Turner (Edinburgh)

P149
IMPACT OF POST-TRANSPLANT DE NOVO ANTI-DSA ANTIBODIES APPARITION AND CAPABILITY OF SOLID PHASE C1Q-FIXING-COMPLEMENT IN HUMORAL KIDNEY REJECTION DEVELOPMENT AND TRANSPLANT OUTCOME

P150
LATE ANTIBODY-MEDIATED REJECTION AND TRANSPLANT GLOMERULOPATHY: HOW TO AVOID CHRONIC REJECTION?
S Ferrari-Lacraz, Y Bouatou, B Ponte, S Moll, P Martin, J Villard, K Hadaya (Geneva)
POSTER GROUP NO 4
– Immunogenetics/Miscellaneous

P151
CYTOTOXIC CROSSMATCHING METHOD VARIABILITY – A VIEW FROM UK NEQAS FOR H&I SAMPLE TESTING
D Singleton, S Corbin, J Worthington, C Darke (Pontyclun)

P152
MULTIPLEXED REAGENTS AND NOVEL SOFTWARE FOR QPCR-BASED MICROCHIMERISM ANALYSIS
J Adema, D Roovers, M Bacelar, L Kröl, C Rebel, N Westerink, M Penning, W Mulder, EH Rozemuller, D Bost (Utrecht)

P153
CHIMERISM REPRESENTING BOTH PATERNAL ALLELES DETECTED BY HLA TYPING BEFORE KIDNEY TRANSPLANTATION.
M Christiansen, MS Petersen, BK Møller (Aarhus N)

P154
THE IMPLEMENTATION OF LONG RANGE PCR AND ION TORRENT SEQUENCING INTO THE ROUTINE DIAGNOSTIC HLA LABORATORY
D De Santis, I Vukovic, S Doran, I Góre, WS Campbell, DC Sayer, D Goodridge, J Shi, D Dinauer, P Martinez (Perth)

P155
GENOMIC DNA SEQUENCES OF HLA CLASS I ALLELES GENERATED USING MULTI-PLEXED BARCODES AND SMRT® DNA SEQUENCING TECHNOLOGY

P156
ULTIMATE HLA TYPING RESOLUTION BY OPTIMIZED NGS WORKFLOW
J Adema, M Bacelar, R Kooter, FP Ruzius, EH Rozemuller, M Penning, L vd Pasch, N Westerink, W Mulder (Utrecht)

P157
LUMINEX METHOD VARIABILITY IN HLA ANTIBODY SPECIFICITY TESTING FOR UK NEQAS FOR H&I SAMPLES
D Singleton, S Corbin, C Darke (Pontyclun)
P158
PERFORMANCE VALIDATION OF AN INTEGRATED ASSAY AND SOFTWARE FOR HLA SEQUENCING ON THE ION TORRENT(TM) PERSONAL GENOME MACHINE(R)
D Dinauer, C Bialozynski, T Agostini, R Mordini, C Rosenau, M Radick, M Hunsicker, J Shi, I Veldre, S Conradson (Brown Deer)

P159
SOLUBLE HLA-G IN THE CORD: THE FETUS’ RESPONSE TO MATERNAL INFLAMMATION
C Badulli, G Garbin, M Simonetta, A Pasi, A Cremaschi, C Tinelli, C Alpini, F Beneventi, A Spinillo, L Salvaneschi, M Martinetti (Pavia)

P160
ASSOCIATION STUDY BETWEEN FUNCTIONALLY-RELEVANT POLYMORPHISMS OF TOLL-LIKE RECEPTORS 2 AND 4 AND BIPOLAR DISORDER

P161
GENE EXPRESSION ANALYSIS OF THE CLASSICAL HLA-GENES, CAN IT BE TRUSTED?
MK Viken, F Kaveh, ST Flåm, BA Lie (Oslo)

P162
LOSS OF HETEROZYGOCITY AND THE SENSITIVITY OF HLA TYPING METHODS
T Linjama, J Peräsaari, J Partanen, S Koskela (Helsinki)

P163
EXPRESSION OF HLA-B*44 IN CERVIX HUMAN TUMOR CELLS BY GENE TRANSFER USING AN ADENOVIRAL VECTOR.
JA Rodríguez, LM Martinez, N Cruz, JA Lineros, WL Cely, VL Medina, AL Cómbita (Bogotá)

P164
COMPARISON OF SEVERAL HLA GENOTYPING METHODS FOR HIGH RESOLUTION ASSIGNMENT OF HLA ALLELES USING THE COMMON AND WELL DOCUMENTED CATALOGUE.
C Frassati, J Dicristofaro, S Santiago, N Cherouat, S Simon, A Basire, C Picard (Marseille)

P165
THE NOD2 P268S POLYMORPHISM CONFERNS PROTECTION AGAINST BIPOLAR DISORDER

P166
EVIDENCE FOR FUNCTIONAL FLEXIBILITY OF MHC CLASS I GENE PRODUCTS
MK van der Wiel, N Otting, NG de Groot, GG Doxiadis, RE Bontrop (Rijswijk)
P167
REVISION OF THE DATA PROTECTION DIRECTIVE IN EUROPE: CONSEQUENCES FOR IMMUNOGENETICS PROFESSIONALS AND RESEARCHERS
A Cambon-Thomsen, G Chassang, V Anastasova, A Pigeon, E Rial-Sebbag (Toulouse)

P168
THE DEGREE OF FULL LENGTH EXON DIVERSITY IN DRB1
KE Gerritsen, FA Massij, M Groeneweg, CE Voorter, MG Tilanus (Maastricht)

P169
COMPARATIVE ANALYSIS OF SEQUENCING DATA ON SANGER AND ILLUMINA MISEQ PLATFORMS
N Cereb, R Hitzel, J Kim, H Chung, V Bharathi, S Yang (Ossining, New York)

P170
VALIDATION OF A BEAD-BASED HUMAN PLATELET ANTIBODY DETECTION ASSAY COMPARED TO AN ELISA-BASED ASSAY AND A BEAD-BASED HUMAN LEUKOCYTE ANTIBODY DETECTION ASSAY FOR THE ROUTINE DIAGNOSIS OF ALLOIMMUNE THROMBOCYTOPENIA.
A Heroes, K Deiteren, A Torfs, M Hidajat, M Emonds (Mechelen)

P171
HIGH THROUGHPUT HIGH RESOLUTION TYPING HLA TYPING USING ILLUMINA MISEQ AS A MAINSTREAM PLATFORM
N Cereb, J Kwon, J Jeon, T Zhang, R Hitzel, R Gupta, D Kim, V Seshadri, S Yang (Ossining, New York)

P172
A PROPOSED STATISTICS-BASED STRATEGY FOR DROP OUTS DETECTION IN HLA TYPING
X Lafarge (Bordeaux)

P173
THE QUESTIONABLE A*23:19Q IS A NULL ALLELE
KE Gerritsen, M Joannis, L Wieten, J Vanderlocht, BL Senden-Gijsbers, F Agis, CE Voorter, MG Tilanus (Maastricht)

P174
HLA TYPING BY NEXT GENERATION SEQUENCING: HIGH-THROUGHPUT SCALED TO THE NEXT LEVEL
V Lange, I Böhme, P Paul, JM Andreas, B Schöne, P Quenzel, K Lang, C Schwarzelt, DM Baier, J Hofmann, J Sauter, J Pingel, AH Schmidt (Dresden)
P175
DETERMINING THE FREQUENCY OF THE C-C CHEMOKINE RECEPTOR 5 DELTA32 MUTATION IN HAEMOPOIETIC STEM CELL DONORS IN ENGLAND USING AN IN-HOUSE LUMINEX ASSAY AND A TQMAN METHOD
W Chong, H Patel, SP Cardoso, G Miqueles, C Brown, C Navarrete (London)

P176
A STREAMLINED, HIGHLY-SCALABLE WORKFLOW FOR PHASE-RESOLVED HLA SEQUENCING ON ILLUMINA MISEQ
K Chang, A Kuraishy, T Royce, E Upsall, N Kim, J Perrott, C Glidewell-Kenney, J Nytes, J Schiller, M Anderson, C Lin (San Diego)

P177
ASSOCIATION OF MHC HAPLOTYPES WITH IDIOPATHIC INFLAMMATORY MYOPATHY IN COHORT OF CZECH PATIENTS
M Remakova, T Svitalkova, L Plestilova, H Mann, J Vencovsky, P Novota (Prague)

P178
APPLICATION OF RNA TEMPLATES FOR HLA CLASS I AND II TYPING USING LUMINEX SSO
TI Olieslagers, KE Gerritsen, CE Voorter, MG Tilanus (Maastricht)

P179
DIFFERENTIAL RECOMBINATION DYNAMICS WITHIN THE MHC OF HUMANS AND MACAQUE SPECIES
N de Groot, GG Doxiadis, N Otting, AJ de Vos-Rouweler, RE Bontrop (Rijswijk)

P180
POLYMORPHISMS IN THE INTRON 2 MAY LEAD TO AN ALLELIC LOSS OF EXONS IN AMPICON TYPING
S Wenda, GF Fischer, I Faé (Vienna)

P181
CCR5 – A LOCUS WITH UNUTILIZED POSSIBILITIES
K Lang, C Heder, B Schönê, J Sauter, J Hofmann, J Pingel, C Schwarzelt, V Lange, I Böhme, AH Schmidt (Dresden)

P182
LIFECODES AND ONE LAMBDA LUMINEX-BASED HLA ANTIBODY KITS COMPARED – DATA FROM AN EXTERNAL QUALITY ASSESSMENT EXERCISE
D Singleton, S Corbin, C Darke (Pontyclun)

P183
COMPLETE GENOMIC SEQUENCING OF NOVEL HLA ALLELES USING NEXT GENERATION SEQUENCING
V Albrecht, K Lang, C Heder, B Schönê, V Lange, I Böhme, AH Schmidt (Dresden)
P184
HUMAN PLATELET ANTIGENS GENOTYPING BY SEQUENCING BASED TYPING
M Alizadeh, M Cherel, G Semana, G Bertrand, DC Sayer, V Renac (Rennes)

P185
EVALUATION OF AUTOMATED 2-DIGIT HLA HISTO SPOT SSO TYPING ON THE MR.SPOT PROCESSOR FOR ROUTINE DIAGNOSIS
R Zahn, K Witter, A Volgger, S Lübke, A Dick (Munich)

P186
HUMAN LEUKOCYTE ANTIGEN GENES AND INTERFERON BETA PREPARATIONS INFLUENCE RISK OF DEVELOPING NEUTRALIZING ANTI-DRUG ANTIBODIES IN MULTIPLE SCLEROSIS
J Link, M Lundkvist Ryner, K Fink, C Hermanrud, I Lima, B Brynedal, I Kockum, J Hillert, A Fogdell-Hahn (Stockholm)

P187
DNA BANK QUALITY ANALYSIS FROM ITS INCEPTION IN 1989 UP TILL NOW
R Ivanova Derin, M Braha, P Loiseau, D Charron (Paris)

P188
ESTIMATION OF THE 6-DIGIT LEVEL ALLELE FREQUENCIES OF HLA-DR IN KOREANS USING AMBIGUITY-SOLVING DNA TYPING
S Kim, B Park, H Oh, J Jun (Seoul)

P189
ANXA11 ASSOCIATION WITH SARCOIDOSIS SUSCEPTIBILITY: A META-ANALYSIS OF NON-FAMILY-BASED STUDIES
BA Lima, A Morais, H Alves (Vilar Formoso)

P190
GROUP-SPECIFIC AMPLIFICATION OF HLA-DQA1 REVEALED A NUMBER OF GENOMIC FULL LENGTH SEQUENCES INCLUDING THE NOVEL HLA ALLELES DQA1*01:10 AND DQA1*01:11
K Witter, JA Halliwell, J Mautner, G v. Welser, M Spannagl, T Kauke, A Dick (Munich)

P191
THE NOVEL HLA-A* ALLELE A*32:53 IDENTIFIED BY SEQUENCE BASED TYPING
S Ulrich, U Posch, G Lanzer (Graz)

P192
DISCREPANCIES BETWEEN THE HLA REGISTRY TYPINGS AND THE VERIFICATION TYPING RESULTS: CZECH NATIONAL MARROW DONORS REGISTRY 2013 ANNUAL REPORT
P Venigová, P Jindra (Pilsen)
P193
GENETIC VARIATIONS OF HUMAN LEUKOCYTE ANTIGEN IN IRANIAN PATIENTS WITH EROSIIVE ORAL LICHEN PLANUS
S Farjadian, Z Alyasin, S Pourshahidi (Shiraz)

P194
THE GENE EXPRESSION OF CYTOKINES, MAJOR HISTOCOMPATIBILITY COMPLEX CLASS II AND TOLL-LIKE RECEPTORS IN BURN INJURY PATIENTS
EP Kuzminova, AL Burmistrova, JY Philippova (Chelyabinsk)

P195
RS12989760 POLYMORPHISM OF INTERLEUKIN 28B AND THE OUTCOME OF LIVER TRANSPLANTATION IN HCV-INFECTED PATIENTS
FE Bertinetto, R Romagnoli, F Tandoi, P Magistroni, PJ Bogantes Hernandez, E Dametto, E Garino, ME Fasano, M Salizzoni, A Amoroso (Torino)

P196
HLA TYPING BY SMRT SEQUENCING: ADVANTAGES OF FULL LENGTH HLA GENOTYPING IN CLINICAL ROUTINE
N Cahill, A Ameur, C Knutson, U Orebrand, U Gyllensten, M Bengtsson (Uppsala)

P197
INTRODUCTION OF REAL TIME PCR HLA TYPING (LINKSEQ™) IN THE MODERN TISSUE TYPING LABORATORY
C Behr, J Downing, PP Dunn (Auckland)

P198
ORGANIZATION OF AN INTER-LABORATORY EXCHANGE FOR CHIMERISM SAMPLES TESTING BY STR
V Dubois, L Absi, M Drouet, JF Eliaou, X Lafarge, D Masson, I Mollet, C Picard, M Pourtein, B Proust, J Tiercy, I Jollet (Lyon)

P199
HLA SENSITIZATION FROM TRANSFUSIONS IN PATIENTS WITH RED BLOOD CELL ALLOIMMUNIZATION
N Katalinic, L Caser, N Vukelic-Damijani, E Ivankovic, M Fucak, H Kurtovic, A Mujic, T Crnic, M Curkovic, S Balen (Rijeka)

P200
UK NATIONAL EXTERNAL QUALITY ASSESSMENT SERVICE FOR HISTOCOMPATIBILITY AND IMMUNOGENETICS EDUCATIONAL HLA TYPING SCHEME FINDINGS IN 2013
S Corbin, J Street, D Singleton, C Darke (Pontyclun)

P201
A NOVEL HLA-B*08 ALLELE IDENTIFIED IN AN UNRELATED DONOR OF CAUCASIC ORIGIN
S Iannelli, O Buffi, A Iliescu, F Fruet, A Bontadini, S Nesci (Pesaro)
P202
A PROBABLE NOVEL HLA-C*15 ALLELE FOUND IN A SAMPLE OF THE ITALIAN NATIONAL EXTERNAL PROFICIENCY TESTING PROGRAMME
E Bevilacqua, E Longhi, L Crespiatico, S Frison, F Quintieri, MP Perrone, G Pellis, A Fabris, C Michelazzi, LG Mascaretti (Trieste)

P203
MANUMYCIN DOWNREGULATES PROINFLAMMATORY GENES IN TNFÁ STIMULATED HUMAN MACROPHAGES
L Kolesar, E Brabcova, S Valhova, A Sekerkova, M Petricek, I Striz (Prague)

P204
GENERATION OF THE HLA-A*80:01 ALLELE BASED ON THE COMPLETE EXON/INTRON SEQUENCES
I Cervera, M Herraiz, J Vidart, S Ortega, J Martinez-Laso (Majadahonda)

P205
A NEW HLA-B ALLELE IDENTIFIED IN A TWO GENERATION ITALIAN FAMILY
C Fusco, R Azzarone, R Penta, B Di Iulio, L Auríemma, M Pagano, M Toriello, S Coppola, L Gallo, F Papola (Napoli)

P206
TWO NOVEL HLA-C ALLELES: HLA-C*07:49 AND C*05:93
L Bungener, H van der Velde, E van den Boomgaard, N Kouprie, I Bouwman, T Jongsma, B Winter, R Kuntzel, B Hepkema (Groningen)

P207
NEW PCR AND SEQUENCING REAGENTS FOR SEQUENCE BASED TYPING OF HLA-DRB1 EXON 2 AND EXON 3
B Drews, S Jiang, J Korble (Alameda)

P208
COMPLETE BI-DIRECTIONAL SEQUENCING OF HLA-DRB1 EXONS 2 AND 3
T Agostini, D Dinauer, J Shi, S Conradson (Brown Deer)

P209
HLA CLASS I ANTIBODY DETECTABLE ONLY IN SOLID PHASE ASSAY INVOLVED IN POST TRANSFUSION REACTION
HT Bolcková, E Matejkova, J Hruskova, Z Gasova (Prague)

P210
A NOVEL STRATEGY FOR THE DEVELOPMENT OF THE HELLINIC CORD BLOOD BANK (HCBB)
C Stavropoulos-Giokas, HA Papadaki, AG Spyridonidis, T Charzistamatiou, E Michalopoulos, A Dinou, V Gkiokas, M Sarris, A Papassavas (Athens)
P211
SUCCESSFUL IMPLEMENTATION OF AN AUTOMATED LR HLA GENOTYPING PLATFORM IN A CLINICAL LAB
E De Samblanx, V Van Sandt, A Torfs, R Segers, M Emonds (Mechelen)

P212
PLATELET REFRACTORINESS MANAGEMENT ON THE BASIS OF HLA ANTIBODY SPECIFICITY
S Oltean, S Johansson, J Holgersson (Göteborg)

P213
HLA ALLELES AND CONTROL OF VIREMIA IN HIV-1(+) INDIVIDUALS ON ANTIRETROVIRAL THERAPY (ART)
K Tsalimalma, K Adam, A Kontos, T Kordossis, N Kafassi (Athens)

P214
HLA POLYMORPHISMS AND STRS IN DISPUTED PATERNITY TESTING
D Kouniaki, K Tarassi, V Kitsiou, T Athanassiades, M Garofalaki, K Papageorgiou, S Dendrinos, G Creatsas, C Papasteriades (Athens)

P215
HLA ANTIBODY SPECIFICITIES IN HEMATOONCOLOGICAL PATIENTS
E Matejkova, HT Bolcková, I Bartonova, J Hruskova, M Zuckova, J Simackova, A Vitek (Prague)

P216
HEMOLYTIC TRANSFUSION REACTION DUE TO HLA ALLOIMMUNIZATION – CASE REPORT
T Baptista, M Coutinho, S Tafulo, C Mendes, M Figueiredo, D Ferreira, F Freitas (Porto)

P217
VALIDATION OF A NEW REAL-TIME SYSTEM (LINKSEQ) FOR FAST HLA TYPING
M Danzer, M Bischof, H Polin, H Steitzer, C Gabriel (Linz)

POSTER GROUP NO 5
– Bioinformatics

P218
A CASE STUDY FOR HLA TYPING IN CLINICS: REPRODUCIBILITY AND FLOWSPACE ALIGNMENT OF NGS READS
K Rigo, G Horváth, S Juhos, S Canivet, P Pellet, A Boudifà, V Bertrand, I Theodorou (Budapest)
P219 BRIDGING IMMUNOGENOMIC DATA ANALYSIS WORKFLOW GAPS (BIGDAWG): AN INTEGRATED CASE-CONTROL ANALYSIS TOOL
D Pappas, AG Pena, RM Horton, P Francis-Lyon, JA Hollenbach, SJ Mack (Oakland)

P220 TRACING AND MEASURING THE IMPACT OF BIORESOURCES: AN INCENTIVE TO SHARE BIOLOGICAL SAMPLES AND ASSOCIATED DATA
A Cambon-Thomsen, L Mabile, P Gourraud, P De Castro, E Bravo, B Hole, M Thomsen (Toulouse)

P221 AN UPDATE ON NGSENGINE®: THE ULTIMATE TOOL FOR NGS HLA TYPING
R Kooter, FP Ruzius, J Geerligs, W Mulder, EH Rozemuller, M Penning (Utrecht)

P222 ENHANCING HML FOR ELECTRONIC REPORTING OF NGS-BASED HLA AND KIR GENOTYPING RESULTS
KJ Doroschak, RP Milius, J Schneider, M Heuer, M George, J Pollack, S Kim, N Cereb, JA Hollenbach, SJ Mack, M Maiers (Minneapolis)

P223 HIGH ACCURACY AND HIGH PRECISION HLA TYPING USING ILLUMINA READS - TYPING ALGORITHM AND PERSPECTIVES ON NOVEL ALLELE DISCOVERY
G Horváth, K Rigo, T Hague, A Berces, S Juhos (Budapest)

P224 IMPROVING NGS HLA DATA ANALYSIS BY USE OF SURROGATE BASES FOR READ MAPPING ACCURACY
J Shi, T Agostini, D Dinauer, M Radick, C Bialozynski, B Zhao, I Veldre, BD Gifford, S Conradson (Brown Deer)

P225 EVALUATION OF IMPUTATION METHODS FOR CLASSICAL HLA-DRB1 USING A FINNISH DATASET
E Vlachopoulou, E Lahtela, A Wennerström, AS Havulinna, P Salo, M Perola, V Salomaa, MS Nieminen, J Sinisalo, M Lokki (Helsinki)

P226 PRECISION MEDICINE IN A CHRONIC NEUROLOGICAL DISEASE MANAGEMENT: LESSONS LEARNED FROM THE MULTIPLE SCLEROSIS BIOSCREEN
P Gourraud, M Investigators, AM Lizée, A Snataniello, J Crane, B Olson, R Loren, S Baranzini, A Green, B Cree, R Henry, J Oksenberg, S Hauser (San Francisco)
P227
LONG AMPLICON ANALYSIS: A TOOL FOR GENERATING HIGHLY ACCURATE, FULL-LENGTH, PHASED, ALLELE-RESOLVED GENE SEQUENCES FROM MULTIPLEXED SMRT® SEQUENCING DATA
BN Bowman, P Marks, L Hepler, K Eng, J Harting, T Shiina, S Ranade (Menlo Park)

P228
HLA-E POLYMORPHISM IN VIEW OF THE 1000 GENOMES PROJECT: A FULL LENGTH HLA-E SEQUENCING APPROACH REVEALS NEW AND NULL ALLELES.
TI Olieslagers, M Groeneweg, L Wieten, CE Voorter, MG Tilanus (Maastricht)

POSTER GROUP NO 6
– Population Genetics/Anthropology

P229
ASSOCIATION OF GENETIC HOST FACTORS HLA DRB1-DQB1 AND IL28B GENOTYPES WITH CLINICAL OUTCOMES IN A ROMANIAN PATIENT GROUP INFECTED WITH HEPATITIS C VIRUS GENOTYPE 1B
LG Gheorghe, S Rugina, Constantinescu, I Franciuc, M Alina, I Balas (Constanta)

P230
GORGAN (TURKMEN IN IRAN) HLA GENETICS: TRANSPLANTATION, PHARMACOGENOMICS AND ANTHROPOLOGY
D Rey, A Amirzargar, C Areces, M Enriquez-de-Salamanca, J Alonso-Rubio, S Abd-El-Fatah-Khalil, M Fernández-Honrado, L Barbolla, J Martín-Villa, A Arnaiz-Villena (Madrid)

P231
DEMOGRAPHIC HISTORY AND MALARIA PREVALENCE: HOW INDEPENDENT CAUSES MAY EXPLAIN THE HLA MOLECULAR PROFILE OF AFRICAN POPULATIONS IN NIGERIA
M Testi, E Chevallier, O Akinyanju, T Wakama, G Lucarelli, M Andreani, A Sanchez-Mazas (Geneva 4)

P232
ALLELE AND HAPLOTYPE FREQUENCIES IN THE ESTONIAN POPULATION
I Tagen, M Groeneweg, A Tamm, CE Voorter, MG Tilanus (Maastricht)

P233
ESTIMATION OF HIGH RESOLUTION A*, B*, C*,DRB1* & DQB1* ALLELE FREQUENCIES, BASED ON MEXICAN MESTIZOS STEM CELL DONORS REGISTERED AT THE MEXICAN UNRELATED DONOR REGISTRY-DONORMO
C Alaez, H Flores-A, A Munguia, D Sánchez, F Manzanares, M Valencia, C Gorodezky (Mexico City)
P234
GEOGRAPHIC ORIGIN AND REGISTRY ENRICHMENT ARE NOT CORRELATED WITH CBU QUALIFICATION CRITERIA IN MARSEILLES CORD BLOOD BANK
C Bordoni, J Magalon, C Gilbertas, M Gamerre, M Berthomieu, C Chabannon, J Di Cristofaro, C Picard (Marseille)

P235
HLA ALLELES AND HAPLOTYPING FREQUENCIES IN SAMPLES OF THE RUSSIAN POPULATION
D Klyuchnikov, M Groeneweg, L Trusova, MG Tilanus, O Tyumina (Maastricht)

P236
COMPUTER SIMULATION OF HLA GENES SUPPORTS TWO MAIN ROUTES OF COLONIZATION BY HUMAN POPULATIONS IN EAST ASIA
D Di, A Sanchez-Mazas, M Currat (Geneva)

P237
AGE DEPENDENT IMMUNOGENETIC PROFILES OF THE ISRAELI POPULATION: IMPACT ON HEMATOPOETIC STEM CELL DONOR SELECTION
M Israeli, M Oudshoorn, GW Haasnoot, B Zisser, G Bach, FH Claas (Leiden)

P238
REGISTRY GENETIC DIVERSITY: HOW INCREASING BONE MARROW DONOR INSCRIPTION IN MARSEILLES?
S El Fergougui, C Bordoni, O Fettah, C Blaise, S Chafai, E Coustaud, K Slimani, D Nguyen, L Pegoraro, P Lecoq, T Rose, C Fons, C Chabannon, C Picard, J Di Cristofaro (Marseille)

P239
THE DISTRIBUTION OF BLOOD GROUPS IN MOSCOW RESIDENTS
SI Donskov, IV Dubinkin, IP Avramenko, VV Danilets (Moscow)

P240
A NEW ALLELE, MICA*078, IDENTIFIED IN A MOROCCAN INDIVIDUAL WITH CELIAC DISEASE

P241
FREQUENCY OF HLA-C ALLELES IN IRANIAN SUBJECTS
F Yari, F Sabaghi, N Bagheri, M Zaman Vaziri, M Sobhani (Tehran)

P242
DELETION BETWEEN HLA-A AND HLA-G GENES IS ASSOCIATED TO HLA-A*23~HLA-G*01:04~UTR-3~HLA-E*01:01 AND HLA-A*24~HLA-G*01:04~UTR-3~HLA-E*01:03:01 HAPLOTYPES
A Mihidjai, K Barton, V Ferreira, F Carlini, C Picard, J Di Cristofaro (Marseille)
P243
MITOCHONDRIAL DNA VARIATION ANALYSIS OF MENTAWAI POPULATION
T Pediatama, Y Syukriani, N Shahib (Bandung)

P244
DELETION AND GENE CONVERSION AS INDEPENDENT EVENTS IN THE GENERATION
OF THE HLA-B*44:138Q ALLELE
I Faé, S Wenda, GF Fischer (Vienna)

P245
ANALYSIS OF HLA HAPLOTYPE FREQUENCIES IN SOUTH AND CENTRAL ROMANIA
– A MULTICENTER PRELIMINARY STUDY
I Dutescu, R Caisan, L Ulea, O Buturca, L Loga, L Dican, D Luscalov, L Popa, E Gai
(Bucharest)

P246
HLA-A*29 HAPLOTYPES IN NAGAYBAKS AND THEIR COMPARISON WITH THOSE OF
RUSSIANS, TATARS AND BASHKIRS FROM THE CHELYABINSK REGION OF RUSSIAN
SOUTH URALS
MN Vavilov, AL Burmistrova, MS Chernova, EB Khromova, DS Stashkevich, TA Suslova,
C Darke (Chelyabinsk)

P247
DIVERSITY OF HLA-B*15 IN THE IRANIAN POPULATION
M Farzanehkhah, B Sadeghi, S Abroun, M Zarrabi (Tehran)

P248
THE FREQUENCY OF THE TRANSFUSION DANGEROUS ERYTHROCYTE ANTIGENS
IN YAKUTS
LE Davydova, SI Donskov, IV Dubinkin, TV Podgornaya (Moscow)

P249
DEVELOPMENT OF THE ADVANCED SUPER HIGH RESOLUTION SINGLE MOLECULE -
SEQUENCE BASED TYPING (SS-SBT) METHOD
S Suzuki, Y Ozaki, A Shigenari, Y Okudaira, A Masuya, S Mitsunaga, M Ota, H Inoko,
T Shiina (Isehara Kanagawa)

P250
HLA-DRB1 AND HLA-DQB1 ALLELE AND HAPLOTYPE FREQUENCIES IN THE
SERBIAN POPULATION
ZP Andric, B Jovanovic, T Dukic, S Bojic, R Simonovic (Belgrade)

P251
HLA-DQA1 FREQUENCIES AND DRB1, DQA1, DQB1 HAPLOTYPE PREVALENCE
IN BLOOD DONORS RESIDENT IN WALES
AJ Lemin, J Johnson, C Darke (Pontyclun)
P252
SPREADING ALLEL OPTIONS HLA ANTIGENS IN THE REPUBLIC OF KAZAKHSTAN
A Turganbekova, Z Burkitbaev, S Abdrahmanova, S Raissov, I Ramilyeva, D Yakiyayeva, D Baimukasheva, T Li, B Daniarova, S Ashim, D Ramil (Astana)

P253
HLA ANTIGEN DISTRIBUTION COMPARISONS BETWEEN THE HUNGARIAN POPULATION AND THE GYPSY MINORITY AS WELL AS SURROUNDING EUROPEAN AND OTHER GYPSY COHORTS

P254
A COMPARATIVE STUDY TO DETERMINE HLA ALLELE FREQUENCY IN THE EGYPTIAN POPULATION.
AM Kamel, N Hamdy, GI Mossallam, SM Elfishawi, Y Elnahas, A Elhaddad, HM Kamel (Cairo)

P255
HLA CLASS I AND CLASS II AND HAPLOTYPES IN TATARS, LIVING IN THE REPUBLIC OF TATARSTAN, RUSSIA
M Loginova, I Paramonov (Kirov)

P256
COMPLETE ABSENCE OF THE C*04:09N ALLELE IN A LARGE HUNGARIAN COHORT

P257
AN INITIAL REPORT ON MINORITIES REPRESENTED IN THE HELLENIC CORD BLOOD BANK (HCBB) INVENTORY
A Dinou, M Spyropoulou-Vlachou, I Potamiti, T Chatzistamatiou, E Michalopoulos, A Papassavas, C Stavropoulos-Giokas (Athens)

P258
HLA-DRB1 CLASS II GENES IN NAIMANS FROM EAST KAZAKHSTAN
AB Kuranov, MN Vavilov, AR Akilzhanova, ZM Nurkina, PV Tarlykov, EV Zholdybayeva, CA Müller, KT Momynaliev (Tübingen)

P259
COMPREHENSIVE GENOTYPING FOR CLINICALLY RELEVANT TRANSPLANTATION AND TRANSFUSION ANTIGENS IN MAORI AND POLYNESIANS
PP Dunn, HA Edinur, L Hammond, C Selwyn, M Askar, P Reville, P Brescia, C Behr, GK Chambers (Auckland)
POSTER GROUP NO 7
– Autoimmunity, Disease Association, and Cancer

P260
MYELOMA CELLS SIGNALING AND OSTEOCLAST ACTIVATION
B Sadeghi, S Taghavi, S Abroun (Tehran)

P261
ASSOCIATION OF HLA-DRB1 AND DQB1 ALLELES AND HAPLOTYPES WITH TYPE ONE DIABETES IN HAMADAN, WEST-IRAN.
G Solgi, J Kiani, D Fuerst, S Hesami Shahryari, H Rezaei, S Kosari, A Zamani, M Hajilooi (Hamadan)

P262
GENETIC PROFILING OF INTELLECTUAL DISABILITY IN THREE GIPSY SIBLINGS
A Aureli, T Del Beato, P Sebastiani, M Di Rocco, A Marimpietri, A Graziosi, I Rosa, E Sechi, S Di Loreto (L’Aquila)

P263
INCREASED LEVELS OF SOLUBLE HLA-E ARE ASSOCIATED WITH ADVANCED DISEASE STAGE AND EARLY TREATMENT REQUIREMENT IN CHRONIC LYMPHOCYTIC LEUKEMIA
B Wagner, F Da Silva Nardi, S Schramm, T Kraemer, C Bade-Doeding, J Dürig, PA Horn, U Dührsen, H Nückel, V Rebmann (Essen)

P264
LTC4S GENE PROMOTER POLYMORPHISM IN ROMANIAN ASTHMATIC PATIENTS
C Berghea, O Popa, I Dutescu, R Caisan, C Bara (Bucharest)

P265
ORIENTAL TRACES IN THE IMMUNOGENETIC PROFILE OF 100 ITALIAN CHILDREN AFFECTED BY KAWASAKI DISEASE.
A Cremaschi, S Benzo, I Sbarsi, P Salice, M Pietrogrande, R Dellepiane, C Tinelli, S Mannarino, G Bossi, M Martinetti (Pavia)

P266
FICOLIN 3 GENE 1637DELC FRAMESHIFT MUTATION IN THE NORMAL AND DIABETIC PATIENTS OF IRAN
A Zavaran Hosseini, S Pishkhan Dibazar, F Yari (Tehran)

P267
THE HLA-G GENE 3’ UNTRANSLATED REGION VARIABILITY AND THE SOLUBLE HLA-G PLASMA LEVELS DIFFER IN ACUTE MYELOID AND LYMPHOBLASTIC PEDIATRIC LEUKEMIA
N Lucena-Silva, RG Garcia, R Santos, RS Almeida, AL Monteiro, EA Marques, TC Fonseca, F Pedrosa, GT Diniz, EA Donadi (Recife)
P268
MEFV GENE R202Q MIGHT BE A DISEASE CAUSING MUTATION IN FMF PATIENTS
T Duman, S Özgüçlü, M Havan, Ü Ölmez, H Tutkak (Ankara)

P269
PREIMPLANTATION GENETIC DIAGNOSIS (PGD) FOR SINGLE GENE DISORDERS/ACQUIRED DISEASE WITH HLA TYPING: A BRIEF REPORT

P270
HLA POLYMORPHISMS IN CHRONIC INTERSTITIAL NEPHRITIS-ASSOCIATED END-STAGE RENAL DISEASE IN TUNISIAN PATIENTS
K Sakly, S Seri, M Maatouk, I Bannour, M Hammouda, S Aloui, F Haouala, H Skhiri, M Fadli, M Elmay, N Sakly (Monastir)

P271
HLA DRB1 AND DQB1 ALLELE AND HAPLOTYPE POLYMORPHISM IN A SAMPLE OF 198 INDIVIDUALS FROM GREECE WITH TYPE 1 DIABETES
P Lazidou, A Tsinopoulou-Galli, A Fleva, M Emporiadou, A Pavlitou-Tsiontsi (Thessaloniki)

P272
ASSOCIATION OF HLA-E RS1264457 (E*01:01/E*01:03) WITH METHOTREXATE-BASED TREATMENT RESPONSE IN SOUTH INDIAN RHEUMATOID ARTHRITIS PATIENTS
C Mariaselvam, A Sundaresh, S Sofiane, W Boukouaci, K Amokrane, C Fortier, D Charron, R Krishnamoorthy, V Negi, R Tamouza (Paris)

P273
IMMUNOESCAPE OF MHC CLASS I-NEGATIVE TUMOR CELLS: IMPLICATIONS FOR CANCER IMMUNOTHERAPY
N Aptsiauri, F Garrido (Granada)

P274
OLIGOCLONAL BANDS AND AGE AT ONSET CORRELATE WITH GENETIC RISK SCORE IN MULTIPLE SCLEROSIS
H Harbo, N Isobe, P Berg-Hansen, S Bos, S Cailler, M Gustavsen, I Mero, E Gulsowen Celius, S Hauser, J Oksenberg, P Gourraud (San Francisco)

P275
KILLER CELL IMMUNOGLOBULIN-LIKE RECEPTOR (KIR) REPERTOIRE AND THEIR LIGANDS IN PATIENTS WITH BREAST CANCER
T Keramitsoglou, F Antoniou, K Chorianopoulou, N Malamos, M Varla-Leftherioti (Athens)
P276
CO-OCCURRENCE OF TYPE 1 DIABETES AND CELIAC DISEASE IN THE SAME PATIENT IS ASSOCIATED WITH DR3-DQ2-B8-C7 HAPLOTYPE, ALSO THROUGH HLA-CLASS I INTERACTIONS WITH KILLER IMMUNOGLOBULIN-LIKE RECEPTORS
D Smigoc-Schweiger, A Mendez, S Kunilo Jamnik, N Bratanic, N Bratina, T Battelino, B Vidan-Jeras (Ljubljana)

P277
ASSOCIATION OF ERAP1 POLYMORPHISMS WITH THE RISK OF PSORIATIC ARTHRITIS IN ROMANIAN POPULATION
O Popa, M Cherciu, L Popa, I Dutescu, M Bojinca, V Bojinca, C Bara, MI Dutescu (Bucharest)

P278
HLA ASSOCIATIONS IN TWO SUBSETS OF RHEUMATOID ARTHRITIS AND LEVELS OF REGULATORY T CELLS (CD4+CD25HI) FOLLOWING DIFFERENT TREATMENT MODALITIES
E Farid, M Murtadha, R Ali, K Tabbara (Manama)

P279
BUCCAL SWABS AS SOURCE FOR HLA TYPING OF INDIVIDUALS AT HIGH RISK FOR CELIAC DISEASE
MP Adriaanse, AC Vreugdenhil, V Vastmans, L Groeneveld, SJ Molenbroeck, N Schott, CE Voorter, MG Tilanus (Maastricht)

P280
ASSOCIATION OF HLA-G, IL-10 AND TNF REGULATORY SEQUENCE POLYMORPHISMS AND RESPECTIVE GENE EXPRESSION IN BIOPSIES OF BRAZILIAN PATIENTS WITH INFLAMMATORY BOWEL DISEASE
RG Gomes, CA Brito, V Martinelli, LB da Costa, SM Lima, R Santos, EA Donadi, N Lucena-Silva (Recife)

P281
FOCUS ON INTELECTUAL DISABILITY THROUGH CYTOKINE’S INVOLVEMENT
A Aureli, P Sebastiani, T Del Beato, A Marimpietri, A Graziosi, M Luciano, E Sechi, S Di Loreto (L’Aquila)

P282
HLA AND AGE-OF-ONSET IN CHILDHOOD ACUTE LYMPHOBLASTIC LEUKAEMIA
F Savran Oguz, C Kekik, SK Singh, E Saribeyoglu, S Anak, G Ozturk, MT Dorak (Liverpool)

P283
SIGNIFICANCE OF KIR AND HLA GENOTYPES AS PROGNOSTIC FACTORS FOR DEVELOPMENT OF HEPATITIS B INFECTION AND CLINICAL OUTCOME
S Kandilarova, A Georgieva, V Varbanova, M Ivanova, T Lukanov, A Nedyalkova, D Petrova, G Popov, A Mihaylova, E Naumova (Sofia)
P284
KIR/HLA GENES ASSOCIATED WITH ACUTE LYMPHOBLASTIC LEUKEMIA IN ADULTS
EG Khamaganova, AA Yushkova, EP Kuzminova, EN Parovichnikova (Moscow)

P285
A REPORT OF AN UNUSUAL HLA-DQB1-DQA1-DRB1 HAPLOTYPE IN AUTOIMMUNE DISEASE PATIENTS
P Lazidou, A Tsinopoulou-Galli, M Emporiadou, A Pavlitou-Tsiontsi (Thessaloniki)

P286
DETECTION HUMAN LEUKOCYTE ANTIGEN HAPLOTYPES IN LATVIAN PATIENTS WITH TBE
L Kovalchuka, J Eglite, T Sidorcika, M Zalite, G Karelis, I Logina, L Viksna, A Krumina (Riga)

P287
HFE GENE MUTATIONS, PLASMA IRON BIOMARKERS AND GENDER: RELATIONSHIP WITH THE PRESENCE OF COLORECTAL CANCER AND POLyps
M De Juan, L Aragon, A Castiella, F Mugica, E Zapata, L Zubiaurre, A Iribarren, L Alzate, I Gil, G Urdapilleta, J Emparanza (Donostia-San Sebastian)

P288
TLR9 GENE POLYMORPHISM IS ASSOCIATED WITH SUSCEPTIBILITY TO RHEUMATOID ARTHRITIS
K Gebura, J Swierkot, M Warzecha, B Wysoczanska, B Nowak, P Wiland, K Bogunia-Kubik (Wroclaw)

P289
HLA PROFILES REVEAL THAT MIXED CONNECTIVE TISSUE DISEASE IS A DISTINCT SYSTEMIC CONNECTIVE DISEASE AND NOT AN OVERLAP SYNDROME WITH OTHER CONNECTIVE TISSUE DISEASES
ST Flåm, R Gunnarsson, T Garen, BA Lie, Ø Molberg (Oslo)

P290
REAL TIME PCR FOR HLA-TYPING OF HLA-B*27 AND DQ2/DQ8
M Uzunel, A Wikström, D Hauzenberger (Stockholm)

P291
HLA-E GENE POLYMORPHISMS IN RHEUMATOID ARTHRITIS AND PSORIATIC ARTHRITIS
M Iwaszko, J Swierkot, R Sokolik, B Nowak, K Gebura, L Korman, P Wiland, K Bogunia-Kubik (Wroclaw)

P292
HLA B 27 TYPING IN DIAGNOSIS OF SPONDYLOARTHROPATHIES
N Katalinic, T Crnic, M Curkovic, M Fucak, H Kurtovic, A Mujic, S Balen (Rijeka)
P293
HLA AND KIR GENES ARE DIFFERENTIALLY EXPRESSED IN TYPE 1, TYPE 2 AND GESTATIONAL DIABETES MELLITUS PATIENTS
DM Rassi, AF Evangelista, C Collares, DJ Xavier, C Macedo, F Manuel-Caetano, M Foss-Freitas, MC Foss, ET Sakamoto-Hojo, C Nguyen, D Puthier, GA Passos, EA Donadi (Ribeirão Preto)

P294
POLYMORPHISMS WITHIN THE IL-17A, IL-17F AND NFKB-1 GENES IN PATIENTS WITH RHEUMATOID AND PSORIATIC ARTHRITIS
K Gebura, B Wysoczanska, R Sokolik, J Swierkot, M Bielanska, L Korman, P Wiland, K Bogunia-Kubik (Wroclaw)

P295
THE FUNCTIONALLY RELEVANT MICA-129 DIMOPHISM IS ASSOCIATED WITH GASTRO-INTESTINAL TRACT CARCINOMAS IN TUNISIAN PATIENTS
A Ben Chaaben, H Abaza, H Douik, F Ayari, O Baroudi, G Kablouti, T Mamoghli, J Bouassida, R Riahi, C Fortier, L Harzallah, F Guemira, R Tamouza (Tunis)

P296
HLA-G EXPRESSION IN BREAST CANCER: HIGH POSITIVITY FREQUENCY IN TRIPLE NEGATIVE SUBGROUP.
F Breginski, Md Bicalho, M Cavalcanti, E Ribeiro (Curitiba)

P297
GENETIC POLYMORPHISMS OF INTERLEUKIN-1BETA (IL1-B) AND BREAST CANCER RISK IN TUNISIAN WOMEN
A Ben Chaaben, S Chalbi, H Abaza, G Kablouti, H Douik, T Mamoghli, L Harzallah, J Bouassida, B Dorra, C Fortier, F Guemira, R Tamouza (Tunis)

P298
HLA CLASS II HAPLOTYPES AFFECT CLINICAL CHARACTERISTICS AND PROGRESSION OF TYPE 1 AUTOIMMUNE HEPATITIS IN JAPAN
T Umemura, K Yoshizawa, Y Katsuyama, E Tanaka, H Inoko, M Ota (Matsumoto)

P299
ASSOCIATION OF HLA-DRB1 ALLELES WITH RHEUMATOID ARTHRITIS IN KAZAKH POPULATION
AB Kuranov, MN Vavilov, ST Abisheva, CA Müller, KT Momynaliev (Tübingen)

P300
HLA DISEASE ASSOCIATION STUDIES: APPROPRIATENESS OF TYPING REQUESTS RECEIVED IN PADUA HLA LABORATORY
C Anna, F Roberta, B Maria Antonietta, M Alessia, A Maria Paola (Padova)
P301
THE DISTINCT EFFECT OF HLA-B*39:01 AND HLA-B*39:06 ON T1D RISK DEFINED BY DRB1*08-DQB1*04 AND DRB1*04:04-DQB1*03:02 HAPLOTYPES
M Mikk, M Kiviniemi, A Laine, T Härkönen, R Veijola, O Simell, M Knip, J Ilonen (Turku)

P302
THE FREQUENCY OF HLA-A,B,DRB1 ALLELES ACCORDING TO RISK GROUPS IN CHILDREN WITH B-CELL PRECURSOR ACUTE LYMPHOBLASTIC LEUKEMIA
T Patiroglu, HH Akar (Kayseri)

P303
HLA ASSOCIATIONS IN HODGKIN’S AND NON-HODGKIN’S LYMPHOMA GREEK PATIENTS
D Kouniaki, V Kitsiou, T Athanassiades, C Tsamadou, T Karmiris, G Kourti, A Tsirogianni, K Tarassi, A Sanchez-Mazas, C Papasteriades (Athens)

P304
HLA ANTIGEN PROFILE IN AML AND ALL ADULT PATIENTS
C Tsamadou, T Athanassiades, V Kitsiou, D Kouniaki, M Pagoni, M Bakiri, D Symeonidi, K Tarassi, A Sanchez-Mazas, C Papasteriades (Athens)

P305
HLA-B*57:01 ALLELE RESEARCH IN HIV PATIENTS FOR ABACAVIR TREATMENT: A SINGLE CENTER EXPERIENCE
V Cappuzzo, F Ingrassia, M Blando, I Vega, R Bavetta, E Collura, S Mistretta, R Marcenò (Palermo)

P306
EXPRESSION OF MHC CLASS II MOLECULES IN BONE MARROW DERIVED AND CIRCULATING HEMATOPOIETIC PROGENITOR CELLS IN PATIENTS WITH PAROXYSMAL NOCTURNAL HEMOGLOBINURIA

P307
HIGH FREQUENCY OF HLA-DR EXPRESSION AND LEUKOCYTE INFILTRATION IN COLORECTAL CANCERS WITH MICROSATELLITE INSTABILITY
A Concha, J Vazquez, C Delgado, M López, M Otero, M Bernal, T Cabrera, F Garrido, F Ruiz-Cabello (Granada)

P308
THE FREQUENCY OF HLA-A, B, DRB1* ALLELES IN PATIENTS WITH ACUTE MYELOBLASTIC LEUKEMIA
T Patiroglu, HH Akar (Kayseri)
P309
ASSOCIATION WITH HLA-DRB1 GENES AND HASHIMOTO DISEASE IN TURKISH POPULATION: SINGLE CENTER EXPERIENCE
T Patiroglu, A Akay, HH Akar, E Ok (Kayseri)

P310
IL-6 GENE CLUSTER POLYMORPHISMS IN HEALTHY RESIDENTS AND PATIENTS WITH MULTIPLE MYELOMA FROM THE NORTH-WEST REGION OF RUSSIA
I Pavlova, A Pavlova, I Sokolova, L Bubnova, S Bessmeltsev (St. Petersburg)

P311
HLA ANTIGENS AS PROGNOSTIC MARKERS FOR RECRUITMENT OF PROSTATE CANCER PATIENTS FOR IMMUNOTHERAPY
E Anastasopoulou, T Keramitsoglou, P Tzonis, M Papamichail, M Varla-Leftherioti, S Perez, C Baxevanis (Athens)

P312
PROTECTIVE AND PREDISPOSING HLA CLASS I AND CLASS II HAPLOTYPES IN DIABETIC FAMILIES FROM EASTERN CROATIA: A PILOT STUDY
S Tokić, S Marczi, M Štefanić, L Glavaš-Obrovac, I Mihaljević (Osijek)

POSTER GROUP NO 8
– NK Immunity and Immunogenetics

P313
KIR GENE VARIABILITY AND HLA-C DIMORPHISM IN CUTANEOUS MALIGNANT MELANOMA: INFLUENCE OF KIR2D/HLA-C PAIRINGS ON DISEASE SUSCEPTIBILITY AND PROGNOSIS

P314
MATERNAL KIR REPERTOIRE AND MATERNAL KIR/TROPHOBLAST HLA-C COMBINATIONS IN PREGNANCY LOSS
T Keramitsoglou, F Dempegioti, E Promponas, A Dinou, M Spyropoulou-Vlachou, M Varla-Leftherioti (Athens)

P315
NK CELL INTERACTIONS WITH ALLOGENEIC HUMAN CARDIAC-DERIVED PROGENITOR CELLS ARE IN FAVOR OF CARDIAC REPAIR
L Lauden, W Boukouaci, N Dam, J Siewiera, L Borlado, D Charron, N Jabrane-Ferrat, R Al-Daccak (Paris)
P316  
KIR TYPING WITH LINKSEQ™: VALIDATION OF A RAPID, REAL-TIME PCR DETECTION SYSTEM  
R Russnak, N Ly, K Quinto, K Gendzekhadze, D Senitzer, C Newby, T McCann, P Kimball, Z Antovich (South San Francisco, CA)

P317  
KILLER CELL IMMUNOGLOBULIN LIKE RECEPTOR TYPING IN ORANGUTANS  
CM Heijmans, LA Guethlein, NG de Groot, P Parham, RE Bontrop (Rijswijk)

P318  
NOVEL INSIGHTS INTO NK CELL EDUCATION BY MHCI TRANSCRIPTIONAL REGULATION  
K Ludigs, D Utzschneider, S Bessoles, W Held, D Zehn, G Guarda (Epalinges)

P319  
NKG2D AND MICA POLYMORPHISMS AND RISK OF AMOXICILLIN-CLAVULANATE HEPATOTOXICITY (AC-DILI) DEVELOPMENT  
F Ruiz-Cabello, C Stephens, AF Gonzalez, A Moreno-Casares, M López- Nevot, M Lucena, RJ Andrade (Granada)

P320  
THE IMPACT OF KIR-GENE EXPRESSION ON NK CELL MEDIATED KILLING OF MULTIPLE MYELOMA CELLS IN VITRO  
TM Binder, Y Hildebrandt, K Jungk, A Kor, C Giffey, H Sierich, TH Eiermann, N Kröger (Hamburg)

P321  
NATURAL KILLER CELL (FROM PRIMARY NK CELL CULTURES) MEDIATED KILLING OF MULTIPLE MYELOMA CELLS IN VITRO  
TM Binder, Y Hildebrandt, C Giffey, K Jungk, TH Eiermann, H Sierich, N Kröger (Hamburg)

P322  
HLA MATCHED DONORS WITH GROUP B KIR HAPLOTYPES IMPROVE THE SURVIVAL AFTER RELATED HEMATOPOIETIC STEM CELL TRANSPLANTATION  
A Sheereen, A Gaafar, A Iqneibi, A Eldali, MD Aljuruf, K AlHussein (Riyadh)

P323  
ROLE OF KILLER-CELL IMMUNOGLOBULIN-LIKE RECEPTOR AND HLA GENES IN CHAGAS DISEASE  
CM Ayo, JE Visentainer, JE Visentainer, MM Dalalio, PG Reis, CF Oliveira, AM Sell (Maringa)
P324
KIR2DL4 IN COUPLES WHO UNDERWENT ASSISTED REPRODUCTION TREATMENT
CH Costa, GF Gelmine, Fd Nardi, A Schuffner, Md Bicalho (Curitiba)

P325
MHC CLASS I POLYPEPTIDE-RELATED SEQUENCE A GENES AND LINKAGE DISEQUILIBRIUM WITH HLA-B IN CHAGAS DISEASE
PG Reis, AM Sell, CM Ayo, CF Oliveira, MM Dalalio, JV Visentainer, JE Visentainer (Maringa)

P326
HLA-E GENE POLYMORPHISM ASSOCIATES WITH ANKYLOSING SPONDYLITIS IN ALGERIA
H Amroun, S Salah (Algiers)
Exhibition Plan and Listing
<table>
<thead>
<tr>
<th>Company</th>
<th>Booth no.</th>
</tr>
</thead>
<tbody>
<tr>
<td>Abbott GmbH &amp; Co. KG</td>
<td>P5</td>
</tr>
<tr>
<td>BAG Health Care GmbH</td>
<td>S7</td>
</tr>
<tr>
<td>Beckman Coulter AB</td>
<td>E7</td>
</tr>
<tr>
<td>Conexio Genomics</td>
<td>B5</td>
</tr>
<tr>
<td>Copan Flock Technologies</td>
<td>E6</td>
</tr>
<tr>
<td>DiaSorin Ireland Ltd</td>
<td>S5</td>
</tr>
<tr>
<td>DNA Genotek</td>
<td>E8</td>
</tr>
<tr>
<td>GenDx</td>
<td>B1</td>
</tr>
<tr>
<td>Histogenetics</td>
<td>P2</td>
</tr>
<tr>
<td>Illumina</td>
<td>B3</td>
</tr>
<tr>
<td>Immucor, Inc.</td>
<td>P6</td>
</tr>
<tr>
<td>inno-train Diagnostik GmbH</td>
<td>S6</td>
</tr>
<tr>
<td>Linkage Biosciences, Inc.</td>
<td>B9</td>
</tr>
<tr>
<td>Olerup</td>
<td>P1</td>
</tr>
<tr>
<td>Omixon Biocomputing Kft.</td>
<td>B4</td>
</tr>
<tr>
<td>One Lambda, Inc.</td>
<td>P3, P4</td>
</tr>
<tr>
<td>Pacific Biosciences</td>
<td>B8</td>
</tr>
<tr>
<td>PerkinElmer chemagen</td>
<td></td>
</tr>
<tr>
<td>Technologie GmbH</td>
<td>S4</td>
</tr>
<tr>
<td>Protrans GmbH</td>
<td>B6</td>
</tr>
<tr>
<td>ROSE GenTec Ltd</td>
<td>E9</td>
</tr>
<tr>
<td>SystemLink, Inc.</td>
<td>E2</td>
</tr>
<tr>
<td>Texas BioGene</td>
<td>B7</td>
</tr>
</tbody>
</table>
See DiaSorin automated cell separation and nucleic acid extraction products at EFI 2014, Stockholm, Sweden – Stand S5

Visitors to the DiaSorin stand will see at first hand the small footprint, ease-of-use and flexibility of the LIAISON® Ixt instrument, which is ideal for both cell separations and nucleic acid extractions in low to medium throughput laboratories. They will also be among the first to see the new LIAISON® Ixt CellSep Advanced kit for the automated isolation of cells directly from whole blood or buffy coat. Based on proven magnetic bead technology, CellSep Advanced can isolate up to 3 cell types per sample in just 32 minutes per cell type, offering significant time savings compared to manual cell separation methods.

DiaSorin product specialists will be on hand to answer questions about the LIAISON® Ixt products and to explain how the kits are used in applications, such as HLA testing and clinical chimerism analysis.

For more information about the LIAISON® Ixt instrument, cell separation and extraction kits, come and meet the DiaSorin team on stand number S5, located in the sponsor exhibition area outside the main conference hall, or visit www.diasorin.com.

About DiaSorin
Headquartered in Italy and listed in the FTSE MIB Index, DiaSorin is a global leader in the In Vitro Diagnostics (IVD) field. For over 40 years the Company has been developing, producing and marketing reagent kits for IVD worldwide. Through constant investments in research and development, and using its own distinctive expertise in the field of immunodiagnostics to deliver a high level of innovation, DiaSorin offers today the broadest range of specialty tests available in the immunodiagnostics market and new tests in the molecular diagnostics markets which identify DiaSorin Group as the IVD “diagnostics specialist”. The molecular division is based in Dublin, Ireland.
Omixon Target HLA Typing™ has been developed for high resolution HLA genotyping of NGS data

Improve Efficiency ▪ Increase Accuracy ▪ **Reduce Ambiguity**

Visit us at **EFI Booth # B4** to find out more

---

**About Omixon**

Omixon is a privately held, global bioinformatics company, headquartered in Budapest, Hungary, that specializes in the analysis of targeted Next Generation Sequencing (NGS) data. Omixon Target™ HLA offers the most accurate high-resolution HLA genotyping software available. Omixon also helps scientists and clinicians to analyze the most challenging genomic regions including HLA.

For more information, visit [www.omixon.com](http://www.omixon.com)
FOR THE PERFECT MATCH

PerkinElmer’s chemagen Technology

Automated DNA Isolation for HLA-Typing

Based on our patented magnetic beads technology, PerkinElmer offers innovative and reliable automation solutions for your HLA-typing workflow. Process 10 μl to 10 ml sample volumes of blood, buffy coat or saliva/swabs samples at high throughput with only one instrument; ensuring high quality DNA applicable for SSO, SBT and SSP (incl. chip based assays) typing.

- Fast, flexible, reliable
- Extract 1 - 96 samples in less than 45 minutes
- 7 - 10 μg genomic DNA from 250 μl blood

© 2014 PerkinElmer, Inc. All trademarks or registered trademarks are the property of PerkinElmer, Inc. and/or its subsidiaries. For Research Use Only. Not for use in Diagnostic Procedures.
Exhibitor Information

Abbott Molecular  
Booth #P5

Abbott Molecular offers a portfolio of molecular diagnostic products for infectious diseases, oncology, transplantation and human genetics. The transplantation portfolio features products for HLA typing (AlleleSEQR HLA-SBT and SSPGo) and for post-transplant engraftment monitoring (AlleleSEQR Chimerism assays).

Contact: Paul Kyle  
Address: Max-Planck-Ring 2  
65205 Wiesbaden, Germany  
Telephone: +49 6122 583152  
Email: paul.kyle@abbott.com  
Web: www.abbottmolecular.com

BAG Health Care  
Booth #S7

BAG Health Care GmbH is an expanding globally operating, independent and family-owned, mid-size health care company. BAG is dedicated to improve accuracy in patient diagnostics by developing and manufacturing innovative reagents and systems for HLA tissue typing (Serology, SSP, fully automated SSO), and blood grouping (Serology, SSP).

Contact: Gabi Henschel  
Address: Amtsgerichtsstr. 1-5  
35423 Lich, Germany  
Telephone: +49 6404 925470  
Email: export@bag-healthcare.com  
Web: www.bag-healthcare.com

Beckman Coulter AB  
Booth #E7

Beckman Coulter founded in California USA 1935 develops, manufactures and markets products that simplify, automate and improve advanced biomedical analyzes. Our instruments are used in Universities and hospital laboratories around the world for research and to provide patient information for physicians to diagnose diseases. More than 275 000 analytical instruments from Beckman Coulter are installed around the world. The number of employees in the world is 11,000 with representation in over 130 countries. Beckman Coulter’s goal and intention is to be a dedicated business partner who contributes to development and
innovation of our customers’ laboratory and research. We focus on our customers’ needs and operate in effective teams of product specialists, application specialists and service engineers to provide the best possible support and service.

Contact:  
Annika Dahlström
Address:  
Archimedesvägen 7  
168 66 Bromma, Sweden
Telephone:  
+46 (0)8 564 859 00
Email:  
adahlstrom@beckman.com
Web:  
www.beckmancoulter.com

Conexio Genomics

It is difficult to imagine that there has been a company that has made as great a contribution and had more influence in the evolution of DNA sequencing as a HLA typing test than Conexio Genomics. The benefits that improvements in typing accuracy and reduced error rates that HLA Sequencing Based Typing (SBT) have brought to patient health, the understanding of transplantation biology and MHC function cannot be understated. Conexio’s development of the multiplex assay for HLA DRB1 typing and its sequence analysis software, AssignTM SBT, enabled SBT to be used as a routine typing procedure in the early 2000’s. Conexio’s history of innovation brought the first commercial software for Next Gen SBT (Assign ATF 454) and, more recently, Conexio’s new Gamma-TypeTM technology. Gamma-TypeTM is proprietary technology for MHC matching in hematopoietic stem cell transplantation. Gamma-Type matching reduces the risk of severe acute graft versus host disease and improves the likelihood of long term survival. Conexio’s sequence analysis software extends to the much broader discipline of Molecular Genetics. New innovative products for Next Gen HLA typing are well underway and will once again break new ground in HLA and MHC typing. Conexio’s contributions in other areas of Molecular Genetics are also substantial. AssignTM ATF is used widely for the identification of genetic variants associated with inherited disease and Conexio’s work in HIV drug resistance genotyping has seen improvements in accuracy of mutation detection by testing laboratories.

Contact:  
David Sayer or Laura Bowker
Address:  
PO Box 1294, Fremantle  
Western Australia 6959
Telephone:  
+61 422 863 227
Email:  
david@conexio-genomics.com
or laura@conexio-genomics.com
Web:  
www.conexio-genomics.com
Copan Flock Technologies SRL  
Booth #E6

With a reputation for innovation in pre-analytics, COPAN (from the acronym “COllection and Preserva-tion for ANalysis”) is the leading manufacturer of collection and transport systems in the world. Products include FLOQSwabs™ hDNA Free line which is specifically produced and dedicated to DNA collection for Genetic applications. Being sterile, free of amplifiable human DNA, free of detectable DNase and RNase, FLOQSwabs™ hDNA free comprise of essential requirements for applications such as: HLA Typing, SNP genotyping, Food intolerances screening, Predictive Genetic testings, Celiac genetic testing, anti-aging test, ect.

Contact: Elisa Piovanelli  
Address: via Perotti 18  
25125 Brescia, Italy  
Telephone: +39 030 3666100  
Email: elisa.piovanelli@copanitalia.com  
Web: www.copanflocktech.com

DiaSorin  
Booth #S5

Headquartered in Italy and listed in the FTSE MIB Index, DiaSorin is a global leader in the In Vitro Diagnostics (IVD) field. For over 40 years the Company has been developing, producing and marketing reagent kits for IVD worldwide. Through constant investments in research and development, and using its own distinctive expertise in the field of immuno-diagnostics to deliver a high level of innovation, DiaSorin offers today the broadest range of specialty tests available in the immunodiagnostics market and new tests in the molecular diagnostics markets which identify DiaSorin Group as the IVD “diagnostics specialist”. The molecular division is based in Dublin, Ireland.

Contact: DiaSorin Ireland Ltd.  
Address: Unit 13/14 Holly Avenue, Stillorgan Industrial Park  
Blackrock, Co.Dublin, Ireland  
Web: www.diasorin.com
DNA Genotek

DNA Genotek is focused on providing high-quality biological sample collection, stabilization and preparation products for genetic based applications both host and microbial DNA or RNA in oral samples. The company’s Oragene® product line provides an all-in-one system that will improve access to potential donors, maximize compliance, and meet your downstream HLA typing needs.

Contact: Cathy Ford
Address: 2 Beaverbrook Road
          Ottawa, Ontario, Canada
Telephone: +1 613 723 5757
Email: cathy.ford@dnagenotek.com
Web: www.dnagenotek.com

GenDx

GenDx develops and markets innovative, certified diagnostic products, providing crucial information for patient-tailored treatments in and beyond transplantation therapy. Products include the well established SBT<excellerator® reagents and SBTengine® software for HLA-SBT Typing and the ever popular HLA-SBT Training School. Visit our website to learn more about our brand new NGS-go® and NGSengine® products for NGS HLA Typing.

Contact: Morven Brodie
Address: Yalelaan 48
          3584 CM Utrecht, The Netherlands
Telephone: +31 (0) 30 2523799
Email: m.brodie@gendx.com
Web: www.gendx.com/index.php/ngs-mainpage

Histogenetics

Histogenetics, based in New York, USA, is an international leader in DNA sequence-based tissue typing (SBT) services and serves clients around the globe. Histogenetics has been developing sophisticated tools by integrating robotics and bio-informatics to provide the ultimate quality of HLA typing information to the community that could save lives.

Contact: Nezih Cereb
Address: 300 Executive Blvd
          NY 10562
Telephone: +1 914 762 0300
Email: info@histogenetics.com
Web: www.histogenetics.com
Illumina
Booth #B3

At Illumina, we apply innovative technologies for studying genetic variation and function, making studies possible that were not even imaginable just a few years ago. These revolutionary tools for DNA, RNA, and protein analysis are enabling rapid advances in disease research, drug development, and the development of molecular tests in the clinic.

Contact: Kirsty Wallace
Address: Illumina AB, c/o Advokatfirman Lars Berlin AB
          Box 284, 746 26 Balsta
Email: kwallace1@illumina.com
Web: www.illumina.com

Immucor
Booth #P6

Immucor LIFECODES is a leader in transplant diagnostics by providing a broad portfolio of molecular and antibody-based assays using ELISA and xMAP® technology to evaluate HLA compatibility between donors and recipients. Laboratories all over the world use LIFECODES HLA serology and molecular typing assays as part of determining the best path forward for a transplant recipient. The more compatible the donor-recipient match, the less likely for organ or stem cell rejection.

Contact: Christine Heylen
Address: Heuvelstraat 60
         B-2560, Nijlen, Belgium
Telephone: +32 (0)3 3854791
Email: cheylen@immucor.com
Web: www.immucor.com

inno-train Diagnostik GmbH
Booth #S6

The inno-train company is specialized in immunogenetics and transfusion medicine. We produce and distribute worldwide HLA-typing systems including serological tests, PCR-SSP and sequencing kits. With our latest Fluogene product line we offer a novel CE marked automation for HLA-, RBC- and HPA-typings based on fluorescent endpoint detection.

Contact: Dr. Stephan Jacobs
Address: Niederhöchstädters Str. 62
          61476 Kronberg, Germany
Email: info@inno-train.de
Web: www.inno-train.de
**Linkage Bioscience**  
Booth #B9

Real-Time PCR HLA Typing. LinkSèq™️ is the fastest and easiest method available for HLA typing – no more gels or probing and washing. Less hands on time is required, and LinkSèq provides HLA Typing results, including DP, in under 90 minutes. LinkSèq – Accurate, Fast, Easy HLA Typing.

Contact: Stillorgan Industrial Park  
Address: 890 Dubuque Avenue, South San Francisco  
CA 94080 USA  
Telephone: +1 415 346 5262  
Email: info@linkagebio.com  
Web: www.linkagebio.com

**Olerup**  
Booth #P1

Olerup is dedicated to deliver high quality products to laboratories working in the field of transplantation. Our products and services focus on facilitating matching of donors and recipients in hematopoietic stem cell and solid organ transplantations. We are the global distributor of innovative molecular diagnostics such as HLA typing with Olerup SSP®, the leading brand in SSP typing, and sequencing based typing solutions from Conexio Genomics, renowned for its pioneering work in the field of sequencing. Olerup also provides XM-ONE® an innovative product for both HLA and non-HLA antibody detection. Olerup’s product offerings are distributed through Olerup GmbH (Europe, Rest of World) and Olerup Inc. (Americas).

Web: www.olerup.com

**Omixon Biocomputing**  
Booth #B4

Omixon helps clinical and diagnostic labs to adopt next generation sequencing by providing products to support accurate and validated HLA typing using NGS. Omixon Target HLA Typing offers phase resolved, nucleotide-level resolution HLA data analysis. We aim for the highest possible HLA typing precision, providing accurate results from multiple sources of NGS data.

Web: www.omixon.com

**One Lambda, Inc., part of Thermo Fisher Scientific**  
Booth #P3, P4

One Lambda, Inc., is celebrating 30 years as the leader in transplant diagnostics and continues to offer a broad range of products to support clinicians and laboratories in the management of transplant patients. In addition to donor specific antibody (DSA) assays, our line of monitoring products includes both complement and non-complement binding assays. Our
research use only biomarkers, AT1R and ETAR are available as ELISA assays. Now that the Transplant Diagnostic groups from One Lambda, part of Thermo Fisher Scientific and Life Technologies are one, our portfolio of HLA typing technologies continues to expand. This includes a complete and extensive array of typing products, including serology, SSP, R-SSO-LABScan 3D, and Sequence Based Typing (SBT). We look forward to the introduction of real time PCR and Next Generation Sequencing to complete the entire spectrum of typing solutions available to the global HLA community. Visit the One Lambda booth to discover how we can help you improve the standard of care in your transplant programs.

Contact: John M. Hart  
Address: 21001 Kittridge Street  
Canoga Park, CA 91303  
Telephone: +1 818 702 0042  
Email: john.hart@thermofisher.com  
Web: www.onelambda.com

Pacific Biosciences  
Booth #B8

Pacific Biosciences offers the PacBio® RS II Sequencing System to help scientists solve genetically complex problems. Based on our novel Single Molecule, Real-Time (SMRT®) technology, our products enable de novo genome assembly to finish genomes in order to fully identify, annotate and decipher genomic structures; targeted sequencing to more comprehensively characterize genetic variations; and DNA base modification identification to help characterize epigenetic regulation and DNA damage. Our technology provides the industry’s highest consensus accuracy and longest read lengths along with the ability to detect real-time kinetic information. The PacBio RS II System, including consumables and software, provides a simple, fast, end-to-end workflow for SMRT Sequencing. Our customers and our scientific collaborators have published a number of peer-reviewed articles in journals including Nature, Genome Research and The New England Journal of Medicine highlighting the power and applications of the SMRT platform in projects such as finishing genomes, rare mutation discovery and the identification of chemical modifications of DNA related to virulence and pathogenicity. Our R&D efforts are focused on expanding the performance of our platform by exploiting the unique capabilities of our Zero-Mode Waveguide (ZMW)-based technology and by expanding the application space. By providing access to genetic information that was previously inaccessible, Pacific Biosciences enables scientists to increase their understanding of biological systems.

Contact: Jane Percival  
Email: jpercival@pacificbiosciences.com  
Web: www.pacificbiosciences.com
PerkinElmer chemagen Technologie GmbH

PerkinElmer’s chemagen Technology – Automation and Kits for the Isolation of genomic DNA. Based on our patented magnetic beads technology, PerkinElmer offers innovative and reliable automation solutions for your HLA-typing workflow. Process 10 µl to 10 ml sample volumes of blood, buffy coat or saliva/swabs samples at high throughput with only one instrument; ensuring high quality DNA applicable for SSO, SBT and SSP (incl. chip based assays) typing. Visit us at booth #S4 to find out more about our automation solutions.

Contact: Antonia Konzwald
Address: Arnold-Sommerfeld-Ring 2
52499 Baesweiler, Germany
Email: Antonia.Konzwald@perkinelmer.com
Web: www.chemagen.com

Protrans GmGH

Protrans is a company for research, development and production of Diagnostic Products for Organ- and Bone Marrow Transplantation, located in Germany, near Frankfurt and next to the University City of Heidelberg.

Contact: Robert von Drygalski
Address: Ketschau 2
68766 Hockenheim, Germany
Telephone: +49 6205292990
Email: mail@protrans.info
Web: www.protrans.info

ROSE GenTec Ltd.

ROSE Gentec is one of the leading biotech firm worldwide that dedicate itself to the research and development of high quality and cost-efficient in-vitro diagnostic products and services in the HLA. We supply high quality SSP, SBT and NGS HLA Typing kits and can provide a first class HLA typing service from our EFI accredited laboratory.

Contact: Marcello Scala, Marketing & Sales Manager
Address: B12a Unit, Kestrel Court
Harbour Rd, Portishead,
Avon, BS20 7AN, UK
Telephone: +44 (0) 1275 390486
Email: macelloScala@rose-gentec.com
Web: www.rose-gentec.com
SystemLink

SystemLink is the leading provider of software in the histocompatibility testing community. Our software is used to manage the laboratory where potential organ donors and their recipients are tested. Our vision is to provide solutions and services to meet the evolving needs of our customers around the world.

Contact: Michelle Gunessever
Address: 23475 Rock Haven Way, suite 140
          VA 20166, Dulles, USA
Telephone: +1 (0) 440 6276083
Email: mgunessever@systemlink-inc.com
Web: www.systemlink-inc.com

Texas BioGene

Founded in Texas in 1999, Texas BioGene Inc. (TBG) is specialized in molecular HLA SSP/ SBT typing reagents for immune matching of bone marrow, cord blood and solid organ transplantation. Moreover, TBG is now offering laboratory automation instrument, DX-A™ pipettor, to help clinical labs achieve timely and accurate testing.

Contact: Angus Wu
Address: 635 Presidential Dr., Suite #201
          Richardson, Texas, USA
Telephone: +1 972 644 1888
Email: info@texasbiogene.com
Web: www.texasbiogene.com
BOOKING YOUR OWN CONFERENCE TRAVEL IS EASY AS ABC
WITH THE GLOBAL ONLINE BOOKING TOOL FROM STAR ALLIANCE CONVENTIONS PLUS

No matter where you are travelling from, the Star Alliance™ network offers you a wide choice of flights to the European Immunogenetics and Histocompatibility Conference (EFI) in Stockholm, Sweden.

And with over 18,000 flights a day to 1,269 destinations across 193 countries, our 26 member airlines extend the same choice to any future conferences you are planning to attend.

You can also save money when you book your flights. Simply quote the Convention Code SK21S14 and you will receive a special discount. Better still, no matter which Star Alliance member airline’s frequent flyer programme you belong to, you can earn and redeem miles across all 26 airlines.

For more information, or to join the airline network that offers you more choice wherever your conferences take you, simply go to www.staralliance.com/conventionsplus
Seek to improve human health.

Discover a new paradigm in HLA typing.

Imagine what you could do with unambiguous, phase-resolved results, high-throughput sample processing, and ultrahigh-resolution sequencing—all in one assay. The TruSight® HLA Sequencing Panel delivers unprecedented accuracy, efficiency, and certainty in HLA typing. We provide the tools: the systems, assays, and analysis software to accelerate genetic research. You provide the drive: the passion, commitment, and inspiration to improve human health.

Together we are transforming possibility into progress.
www.illumina.com/HLA

Visit Illumina at booth #B3 at EFI.
More value for your money – with our new HISTO TYPE Happy Packs

www.bag-healthcare.com

Free validated Happy Taq

HISTO MATCH Software provided free of charge for all our customers

Identify
User friendly HISTO MATCH interpretation software including risk assessment for Coeliac Disease to help you in your daily work

New features of our HISTO TYPE SSP kits that will make you happy:

- Improve Free of charge Happy Taq Polymerase – CE IvD certified and validated for all SSP kits to improve your results
- Save New buffer with cresol red – less DNA required to save your precious samples

© first-art.de

Texas BioGene Inc.
www.texasbiogene.com

DXATM Autopipetting System
Simple HLA Laboratory Automation

HLAssureTM SBT Typing Kit
Locus Specific Primers
Group Specific Primers

MorganTM SSP Typing Kit

ABCDRDQ on 1 Tray
More value for your money –
with our new HISTO TYPE Happy Packs

New features of our HISTO TYPE SSP kits
that will make you happy:

**Improve**  Free of charge Happy Taq Polymerase – CE IvD certified and validated for all SSP kits to improve your results

**Save**  New buffer with cresol red – less DNA required to save your precious samples

**HISTO MATCH Software provided free of charge for all our customers**

**Identify**  User friendly HISTO MATCH interpretation software including risk assessment for Coeliac Disease to help you in your daily work

[www.bag-healthcare.com](http://www.bag-healthcare.com)
Sequencing-Based HLA Typing

GenDx supports your Sequencing-Based HLA Typing.
Sanger and NGS technologies.
Platform independent reagents and software.
Find out more during our Teaching Session or at our booth #B1.

NGS HLA full workflow
- NGSgo® AmpX Amplification primes
- NGSgo® FragX Fragmentase
- NGSgo® LibrX Library prep kit
- NGSgo® IndX Adaptor & Indices
- NGSengine® HLA typing software

www.gendx.com
Author index

A
A, Yohana O35
Aarnink, Alice P71
Abade, Olga P17
Abaza, Hajar P295, P297
Abd-El-Fatah-Khalil, Sedeka O57, P230
Abdrakhmanova, Sanya P67, P252
Abecasis, Manuel P17
Abel, Angela O13, P92, P138
Abels, Wiebke O6
Abisheva, Saule T. P299
Abrahamsen, Greger O73
Abroun, Saed P11, P247, P260
Absi, Lena P198
Adam, Kalliopi P213
Adamek, Martina P96
Adema, Jeroen P152, P156
Adriaanse, Marlou PM. P279
Afanasiev, Boris P28
Agis, Frantz P173
Agostini, Tina P158, P208, P224
Ahmadpoor, Pedram P94
Aires, Paula P69, P74
Akar, Himmet Haluk. P302, P308, P309
Akay, Abdurrahman P309
Akilzhanova, Ainur R. P258
Akinanjuy, Olu P231
Aksoy, Rahime P141
Aktuna, Suleyman P269
Akyigit, Fatma P269
Al Baz, Nabeela P81
Al Meshari, Khalid P122
Al-Daccak, Reem P315
Alaez, Carmen P27, P233
Alakulppi, Noora P21
Albrecht, Mark O25, O28, O56
Albrecht, Viviane P183
Aleksandrova, Krasimira P23
Alessandrino, Emilio Paolo P13
Alessia, Marcolin P300
Algarra, Ignacio P57
Alheim, Mats P123
Al Hussein, Khaled P122, P322
Ali, Redha P278
Alina, Martinescu P229
Alizadeh, Mehdi P184
Aljurf, Mahmoud D. P322
Allat, Rachida P66
Almeida, Renata S. P267
Alonso, Antonio Alonso P126
Alonso-Rubio, Javier O57, P230
Alou, Sabra P270
Alpini, Claudia P159
Alvarez, Cristiam M. O48
Alvarez, Karen D. O48
Alvarez-Lopez, Maria Rocío. O72, P118, P127, P149, P313
Alves, Helena P115, P117, P189
Alyanskiy, Alexandr P28
Alyasin, Zeynab P193
Alzate, Luis P287
Amarelli, Cristiano P106
Ambroz, Natalija P8
Ambruzova, Zuzana P47, P131
Ameur, Adam P196
Amico, Patrizia P83
Amirzargar, Ali akbar P94, P230
Amadio, Giada O34
Amokrane, Kahina P160, P165, P272
Amoroso, Antonio P89, P195
Amroun, Rabba P66, P326
Anak, Sema P282
Anastasopoulou, Eleftheria P311
Anastasova, Velizar P167
Anderson, Matthew P176
Andersson, Sandra O73
Andrade, Raul J. P319
Andreani, Marco
Ayim, Jack O24
Ayo, Christiane M. P323, P325
Ayvaz, Özge P269
Azzarone, Raffaella P205

B
Baba, Hideo A. P77
Babrzadeh, Farbod O55
Bacchetta, Rosa O40, P54
Bacelar, Michelle P152, P156
Bach, Gideon P237
Bachelet, Thomas P121
Bade-Doeding, Christina O6, P263
Badet, Lionel O47
Badulli, Carla O50, P13, P159
Bagheri, Nadia P35, P241
Baier, Daniel M. P174
Baimukasheva, Dana P67, P252
Bajema, Ingeborg M. O36
Bakay, Valentina P32
Bakiri, Maria P304
Balas, Iulia P229
Balen, Sanja P125, P199, P292
Baltaci, Aysun P269
Baltaci, Volkan P269
Bandelier, Cédric O68
Bangol, Barbara P22
Banister, Lauren E. P1
Bannour, Ichrak P270
Baptista, Tiago P216
Bara, Constantin P264, P277
Baranzini, Sergio O27, P226
Barbolla, Luz P230
Barcella, Matteo O2
Bardet, Wilfried O4
Barlassina, Cristina O2
Barlogis, V. P4
Baroudi, Olfa P295
Barsakis, Konstantinos O55
Barsegian, Vahé O29
Barton, K. P242
Bartonova, Iveta P215
Basire, Agnès P164

O40, O50, O52, P7, P54, P231
Andreas, Johanna M. P174
Andric, Zorana P. P250
Andrikovics, Hajnalka P256
Andrés, Amado P129
Angius, Andrea P54
Anholts, Jacqueline D. O36, O44
Anna, Colpo P300
Antoniou, Fotini P275
Antovich, Zachary P98, P316
Apaza, Jacqueline P129
Apostolaki, Maria P133
Apostolou, Theofanis P146
Aptsiauri, Natalia P273
Aragon, Larratz P287
Areces, Cristina O57, P230
Arnaiz-Villena, Antonio O57, P230
Arnaudov, Georgi P3
Arnold, Marie-Luise O43
Arnold, Renate O61
Arntzen, Magnus Ø. P62
Arriga, Roberto O71
Arseniev, Lubomir P23
Asadiasl, Sara P94
Asbe-Vollkopf, Aida P72
Asensio, Esther P24
Ashim, Simbat P67, P252
Ask, Eivind H. O73
Askar, Medhat P259
Assal, Azzedine P18
Atanasova, Valentina P3
Athanassiades, Theofilos
P146, P214, P303, P304
Au, Benoit P121
Augé, Nathalie O42
Aureli, Anna O71, P262, P281
Auriemma, Laura P205
Avila, Yannick O16
Avinens, Odile P2, P41
Avramenko, Inessa P. P239
Avramova, Boryana P3
Ayari, Faiza P295
Aydin, Filiz P49, P55, P56
Battarra, Maria-Rosa O40
Battelino, Tadej P276
Battle, Richard P59, P88, P92, P138
Batu, Duygu P50
Bavetta, Rosalba P130, P305
Baxevanis, Constantin P311
Becker, Jan U. P77, P97
Becker, Petra SA. O67
Bedreli, Sotiria O29
Beelen, Dietrich W. O64, P6, P43
Beheshtiana, Azadeh O27
Behr, Colleen P197, P259
Bello, Francis P18
Belyayeva, Elena P32
Ben Chaaben, Arij P295, P297
Ben El Baghdadi, Imane P240
Beneventi, Fausta P159
Bengtsson, Mats P196
Benhamomouch, Soraya O52
Benkô, Sára P253, P256
Bennabi, Meriem P160, P165
Benzo, Serena P265
Berces, Attila P223
Berg-Hansen, Pal P274
Berghea, Camelia P264
Bergseng, Elin P62
Berkos, Andrey P32
Bernal, Monica P307
Bernardi, Massimo O2, O59
Bernardo, Maria V. P149
Bertani, Giambattista P37
Berthomieu, M. P234
Bertinetto, Francesca E. P195
Bertrand, Gerald P184
Bertrand, Veronique P218
Besik, Sevgi Kalayoglou. P48, P49
Bessmeltsev, Stanislav P310
Bessoles, Stéphanie P318
Best, Jan O29
Bettens, Florence O65
Betz, Christoph P72
Bevilacqua, Elena P202
Bharathi, Vidhya P169
Bialozynski, Carolyn P158, P224
Biancone, Luigi P89
Bicalho, Maria da Graca. P61, P90, P296, P324
Biderman, Bella V. P38
Bielanska, Maria P294
Bielen, Els P75
Billes, Marc-Alain P73
Binder, Thomas M. C. P320, P321
Birkner, Kerstin O12
Bischof, Magdalena P217
Bistrup, Claus P85
Björklund, Andreas T. O70
Blaise, C. P238
Blancher, Antoine P71
Blanco-García, Rosa P313
Blando, Maria P130, P305
Blaszyk, Rainer O6, O14, O37, O41, O60, P23
Blokhuis, Jeroen H. O9
Bockisch, Andreas O29
Bogantes Hernandez, Pablo J. P195
Bogunia-Kubik, Katarzyna P288, P291, P294
Bojic, Svetlana P250
Bojinca, Mihai P277
Bojinca, Violeta P277
Bokhari, Ahmad P81
Bolarin, José M. P127, P313
Bolcková, Hana T. P209, P215
Boldyreva, Margarita O52
Bologov, Andrey P29
Bondarenko, Sergey P28
Bonfim, Carmem Sales. P9
Bonini, Chiara O2, O59
Bontadini, Andrea P201
Bontrop, Ronald E. O9, P166, P179, P317
Boots, Mieke O3
Bordignon, Claudio O59
Bordoni, C. P234, P238
Borg, Cecile O49
Borlado, Luis R. P315
Boros-Major, Anita P253, P256
Bors, András P253, P256
Borst, Eric O62
Bos, Gerard M.J. O66, P75
Bos, Steffan P274
Bossi, Grazia P265
Bost, Doug P152
Bouassida, Jihen P295, P297
Bouatou, Yassine P150
Boudífa, Abdelali P218
Boukouaci, Wahid P160, P165, P272, P315
Boumans, Evelien E. O66
Bouwman, Ilby P206
Bowman, Brett N. O17, P155, P227
Brabcova, Eva P203
Braha, Michelle P187
Brambati, Chiara O59
Brambilla, Caterina P82, P86, P110
Bravo, Elena P175
Braund, Henny O17, P155
Braunsgaard, Helle P104
Bryncińska, Fernanda F C. P296
Brunet, Lydie O65
Brodux, Liesbeth O3
Brown, Colin P175
Buchli, Rico O45
Buffi, Ornella P201
Buhler, Stéphane O23, O38, O52, P8, P253
Buhlin, Kåre O32
Bulfone, Alessandro P54
Bultitude, Will P. O17, P155
Bunnes, Donald O61, O62
Bunse, Carola O37, O41
Buonomo, Oreste O71
Burek Kamenaric, Marija P10, P45, P145
Burgueño, Celestina P24, P99
Burkitbaev, Zhandos P67, P252
Buzmistrova, Alexandra L. P194, P246
Bushara, Mohamed P12
Busurin, Pavel P29
Buttkereit, Ulrike O64
Buturca, Oana P245
Buus, Sören P62
Béziat, Vivien O73
Böhme, Irina O12, P174, P181, P183
Büttner, Stefan P72
Caballero, Abelardo P126
Cabañas-Perianes, Valentín O72
Cabrera, Teresa P307
Cagni, Nicoletta P82, P86, P110
Caillard, Sophie P113, P128, P134
Canfield, Elizabeth T. O4
Canivet, Sabine P218
Campillo, José A. P118, P127, P149, P313
Canossi, Angelica O52, O71
Capit, Denis O42
Capistran, Yasar P56
Cambon-Thomsen, Anne P167, P220
Campbell, Witt S. P154
Campillo, José A. P118, P127, P149, P313
Canfield, Elizabeth T. O4
Canivet, Sabine P218
Canossi, Angelica O52, O71
Capistran, Yasar P56
Cappuzzo, Valentina P130, P305
Cardillo, Massimo P82, P86, P110
Cardoso, Sandra Pinto. P175
Carlini, F. P242
Carlsten, Mattias O70, O73
Carmagnat, Maryvonnick P107, P108
Carrabba, Matteo O59
Carrington, Mary P14
Casamassimi, Amelia P64, P106
Casanova, A M. P26
Caser, Linda P199
Castagnet, Stéphanie P16
Castiella, Augustin P287
Castillo Rama, Marcela P129
Castro Panete, María José P129
Cavalca, Francesco P64
Cavalcanti, Marcela P296
Ceballos, Patrice P41
Cechova, Hana P31
Cely, Wilder L. P163
Cepek, Pavel O26
Cerci Gurbuz, Burcu P140, P147
Cereb, Nezih P169, P171, P222
Cerna, Marie O26
Cervera, Isabel P204
Cesbron, Anne P16
Chabannon, C. P234, P238
Chafai, S. P238
Chalbi, Salma P297
Chambers, Geoffrey K. P259
Chambost, H. P4
Chang, Kathererine P176
Charron, Dominique O5, P5, P19, P107, P108, P160, P165, P187, P272, P315
Chassang, Gauthier P167
Chatzika, Georgia P136
Chatzikyrkou, Christos P97
Chatzistamatiou, Theofanis P210, P257
Cherciu, Marius P277
Cherel, Mathilde P184
Chernova, Maria S. P246
Cherouat, Nicem P164
Chevallier, Elodie P231
Chevallier, Patrice P16

Chiaroni, Jacques O52
Chiesa, Lorenza O59
Chin, Jason O17
Chong, Winnie P175
Chorianopoulou, Kyriaki P275
Chouridi, Maria P136
Chowdhry, Mohit P79, P103
Christiaans, Maarten H.L. P75
Christiansen, Mette O11, P85, P153
Chung, Hwa Ran P169
Ciceri, Fabio O2, O59, P54
Cittaro, Davide O2, O59
Claas, Frans H.J. O7, O9, O36, O44, O45, O46, P14, P102, P112, P237
Clahsen-van Groningen, Marian C. O36
Clark, Brendan P59
Clavel, Carlos O72
Colanardi, Alessia P240
Collado, Antonia P57
Collares, Cristianna P293
Collenberg, Monika O30
Collin, Matthew P44
Collura, Emanuela P130, P305
Colturato, Vergilio Rense. P9
Concha, Angel P307
Congy-Jolivet, Nicolas P71
Conradson, Scott P95, P158, P208, P224
Constantinescu, Ileana P119, P120, P229
Contin-Bordes, Cécile P73
Contreras, Johanna O32
Cooley, Sarah O70
Coppola, Sergio P205
Corbin, Susan P151, P157, P182, P200
Cornacchini, Giorgia P37
Costa, Cynthia H. P61, P324
Coustaud, E. P238
Coutinho, Maria P216
Couture, Félix P5
Couzi, Lionel O49, P121
Crane, Jason P226
Cretzas, George P214
Cree, Bruce P226
Cremaschi, Anna Luisa P13, P159, P265
Crespiatico, Loretta P86, P110, P202
Crníc, Tajana P125, P199, P292
Crucitti, Lara O2
Cruz, Nataly P163
Culina, Slobodan P52
Curkovic, Milena P125, P199, P292
Currat, Mathias P236
Curtillet, C. P4
Czajka, Przemyslaw O58
Cómbita, Alba L. P163

De Santis, Dianne P154
de Souza, Gustavo A. P62
de Vaal, Yvonne J.H. O45
de Vos-Rouweler, Annemiek J. M. P179
Decolasse, Nathalie P19
Dehn, Jason O25
Deiteren, Kathleen P170
Del Beato, Tiziana O71, P240, P262, P281
Del Bello, Arnaud P71
Delaunay, Jacques P16
Delgado, Carmen P307
Dellepiane, Rosa Maria P265
Dempogioto, Fotini P314
Dendrinos, Spyridon P214
Desmartea, Yvonne M. P100
Devys, Anne P16
Di Cristofaro, Julie
O52, P46, P234, P238, P242
Di Iulio, Barbara P205
Di Loreto, Silvia P262, P281
Di Rocco, Marilena P262
Di, Da P236
Dican, Lucia P245
Dick, Andrea O43, P15, P70, P185, P190
Dicristofaro, Julie P164
Digón, Montserrat P101, P109
Dimitrovski, Kocho P142
Dimovski, Karolina P1
Dinauer, David P95, P154, P158, P208, P224
Diniz, George T.N. P267
Dinou, Amalia P210, P257, P314
Dinu, Andrei-Antoniu P119, P120
DiPrima, Stephanie O28, O56
Dobrovolna, Marie P40
Dolff, Sebastian O46
Dolsak, Veronika P8
Domouchtsidou, Aglaia O29
Donadi, Eduardo A. P267, P280, P293
Donskov, Sergey I. P239, P248
Dorak, Mehmet T. O10, P282
Doran, Sandra P154
Doroschak, Kathryn J. P222
Dorra, Ben Ghezala P297

D

da Costa, Laís B. P280
Da Silva Nardi, Fabiola P43, P263
Daburon, Sophie P73
Dada, Ashraf P81
Dalalio, Márcia MO. P323, P325
Dam, Noemie P315
Dametto, Ennia P195
Davevska-Todorovska, Olga P142
Daniarova, Bakhitgul P67, P252
Danielzik, Tina O64
Danelits, Violetta V. P239
Danzer, Martin P217
Darke, Chris O52, P151, P157, P182, P200, P246, P251
Dauber, Eva-Maria P58, P60
David, Lowe P88
Davis, Ronald W. O53
Davydova, Lubov E. P248
De Castro, Paola P220
De Fazio, Nicola P82
De Feo, Tullia P110
de Fijter, Hans W. O36
de Fijter, Johannes W. O44
de Graaff, Anna C. O18
de Groot, Nanine P179
de Groot, Natasja G. O9, O51, P166, P317
De Hoop, Talitha A. O18
De Juan, Maria Dolores P287
De Marco, Renato P105
de Rham, Casimir O16, O68
De Samblanx, Emilie P211
dos Santos Francisco, Rodrigo O38
Douik, Hayet P295, P297
Downing, Jonathan P197
Doxiadis, Gaby G.M. O9, O51, P166, P179
Doxiadis, Ilias I.N. O43, O46, P112
Drabko, Katarzyna O58
Drace, Zahida P89
Drago, Francesca P82
Drakopoulos, Spiros P146
Dressel, Ralf O1
Drews, Birgit P207
Dromer, Claire P73
Drouet, Mireille P198
Dubkin, Igor V. P239, P248
Dubois, Valérie O47, O52, P121, P198
Dubois-Dauphin, Michel O16
Ducreux, Stephanie O47
Dukić, Tatjana P250
Duman, Türker P141, P268, P269
Dunn, Adrian N. P44
Dunn, Paul P. P197, P259
Dutescu, Irina Monica P245, P264, P277
Dutescu, Monica I. P277
Dziallas, Phillip O46
Dzierzak-Mietla, Monika O58
Dziopa, Joanna O58, P306
Dørum, Siri P62
Dührsen, Ulrich P263
Dürrig, Jan P263

E
Edinur, Hisham A. P259
Edwards, Angela P92
Eglite, Jelena P286
Eguia, Jorge P118, P149
Eiermann, Thomas H. P320, P321
Eikmans, Michael O36, O44
Einsele, Hermann O61
Eisenberger, Ute P77
Eiz-Vesper, Britta O14, O37, O41, O60, P23
El Aouad, Rajae P240
El Fergougui, S. P238
El-khobar, Korri Elvanita. O35
Elamin, Nadra O52
Eldali, Abdelmoneim P122, P322
Elfishawi, Sally M. P254
Elhaddad, Alaa P254
Eliaou, Jean Francois. O52, P2, P41, P198
Elkaim, E. P4
Elmay, Mezri P270
Elnahas, Yasser P254
Elong-Bertard, Cecile P41
Elsner, Leslie O1
Emonds, Marie-Paule P170, P211
Emparanza, Jose Ignacio P287
Emporiadou, Maria P271, P285
Ender, Andrea O43
Eng, Kevin O17, O69, P155, P227
Engel, Wolfgang O1
Enqvist, Monika O73
Enríquez-de-Salamanca, Mercedes O57, P230
Ercilla, Guadalupe P101, P109
Eriksson, Jenny M. P30
Erkek, Esra P49
Erlich, Henry A. O54
Erokhina, Ludmila P32
Ertle, Judith O29
Espadinha, Carla P17
Essaid El Feydi, Abdellah P240
Etain, Bruno P160, P165
Evangelista, Adriane Feijó. P293
Evnouchidou, Irini O39

F
Fabbricini, Rossella P106
Fabris, Annalisa P202
Fadhlaoui-Zid, Karima O52
Fadli, Mohammed P270
Farahi, Fatemeh P35
Farid, Eman P278
Farjadian, Shirin P193
Farzanehkhhah, Mohammad P11, P247
Fasano, Maria E. P195
Faê, Ingrid P180, P244
Fegueux, Nathalie P41
Fernandez, Nieves Fernandez P126
Fernandez-Vina, Marcelo A. O22, O53, O55
Fernández-Honrado, Mercedes O57, P230
Ferran, Jennifer P2, P41
Ferrari-Lacraz, Sylvie O68, P150
Ferreira, David P16
Ferreira, Isabelina P17
Ferreira, V. P46, P242
Fettah, O. P238
Feuchtinger, Stefanie P72
Fidler, Samantha J. P80
Fiedler, Melanie O15
Figueiredo, Constanca O14, O37, O37, O41, O60, P23
Figueiredo, Manuel P216
Filion, Alain P5
Fink, Katharina P186
Fiorito, Carmela P64
Fischer, Gottfried F. O22, O43, O52, P180, P244
Fleischhauer, Katharina O2, O59, P6, P7, P54
Fleva, Alexandra P271
Flick, Camille P113
Flores-A, Hilario P27, P233
Floris, Matteo P54
Flåm, Siri T. P161, P289
Fogdell-Hahn, Anna P186
Fons, C. P238
Fonseca, Teresa C. P267
Fonstad, Rachel O25
Forslund, Elin O73
Fortier, Catherine P160, P165, P272, P295, P297
Fortmeier, Valentin O41
Foss, Milton Cesar. P293
Foss-Freitas, Maria Cristina P293
Fowle, Rosemary P84
Franchini, Nicolas O49
Francis-Lyon, Patricia P219
Franciuc, Irina P229
Frassati, Coralie P164
Freitas, Fátima P69, P74, P137, P216
Frijns, Jacqueline J.Y. P75
Frison, Sara P202
Froelich, Nadine P113, P128, P134
Frome, Matthew P98
Fruet, Fiorenza P201
Frémeaux-Bacchi, Véronique P73
Fucak, Marina P125, P199, P292
Fuerst, Daniel O61, O62, P261
Funke, Vaneuza Moreira. P9
Fusco, Caterina P205
Fylaktou, Asimina P136
Gaafar, Ameera P122, P322
Gabriel, Christian P217
Gachet, Christian P113, P128, P134
Gagne, Katia P16
Gai, Elena P245
Galambrun, C. P4
Galian, Jose A. P118, P149
Gallo, Lucia P205
Galvani, Sylvain O42
Gamerre, M. P234
Ganeva, Penka P3
Garbin, Giulia P159
Garcia Alonso, Ana Maria. P127, P313
Garcia, David P27
Garcia, Luis F. O48
Garcia, Renan G. P267
García-Garay, Maria Carmen. O72
García-Lora, Angel P57
Garen, Torhild P289
Garino, Elena P195
Garofalaki, Maria P214
Garrido, Federico P57, P273, P307
Gasova, Zdenka P209
Gauer, Stefan P72
Gautier-Vargas, Gabriela P113, P128
Gauntreaux, Chantal P107, P108
Gaziev, Javid P7
Gebura, Katarzyna P288, P291, P294
<table>
<thead>
<tr>
<th>Name</th>
<th>Affiliation</th>
</tr>
</thead>
<tbody>
<tr>
<td>Geerligs, Job P42</td>
<td>P221</td>
</tr>
<tr>
<td>Geiger, Helmut P72</td>
<td></td>
</tr>
<tr>
<td>Gelder, Michel O66</td>
<td></td>
</tr>
<tr>
<td>Gelle-Hossó, Adrienn P256</td>
<td></td>
</tr>
<tr>
<td>Gelmine, Geórgia F. P324</td>
<td></td>
</tr>
<tr>
<td>Gelmini, Georgia F. P61</td>
<td></td>
</tr>
<tr>
<td>Gendzekhadze, Ketevan P316</td>
<td></td>
</tr>
<tr>
<td>Geneugelijk, Kirsten O8</td>
<td></td>
</tr>
<tr>
<td>George, Michael P222</td>
<td></td>
</tr>
<tr>
<td>Georgescu, Vera P41</td>
<td></td>
</tr>
<tr>
<td>Georgieva, Atanaska P3, P283</td>
<td></td>
</tr>
<tr>
<td>Georgiou, D. P76</td>
<td></td>
</tr>
<tr>
<td>Geraghty, Daniel E. O69</td>
<td></td>
</tr>
<tr>
<td>Gerbase-DeLima, Maria P93, P105</td>
<td></td>
</tr>
<tr>
<td>Gerritsen, Kevin E.H. P168, P173, P178</td>
<td></td>
</tr>
<tr>
<td>Gertow, Jens O63</td>
<td></td>
</tr>
<tr>
<td>Getz, Joselito P9</td>
<td></td>
</tr>
<tr>
<td>Geyeregger, René O37</td>
<td></td>
</tr>
<tr>
<td>Gheorghe, Loredana G. P229</td>
<td></td>
</tr>
<tr>
<td>Gianolini, Monica Emma. O40</td>
<td></td>
</tr>
<tr>
<td>Giffey, Christian P320, P321</td>
<td></td>
</tr>
<tr>
<td>Gifford, Benjamin D. O22, P224</td>
<td></td>
</tr>
<tr>
<td>Gil, Ines P287</td>
<td></td>
</tr>
<tr>
<td>Gil-Vernet, S P101</td>
<td></td>
</tr>
<tr>
<td>Gilbertas, C. P234</td>
<td></td>
</tr>
<tr>
<td>Gimeno, Lourdes O72, P313</td>
<td></td>
</tr>
<tr>
<td>Gimeno, Luisa P118</td>
<td></td>
</tr>
<tr>
<td>Ginovalt, Nathalie Ginovalt O16</td>
<td></td>
</tr>
<tr>
<td>Giordano, Alberto P89</td>
<td></td>
</tr>
<tr>
<td>Gkiokas, Vassiliki P210</td>
<td></td>
</tr>
<tr>
<td>Glass, Bertram O61</td>
<td></td>
</tr>
<tr>
<td>Glavaš-Obrovac, Ljubica P312</td>
<td></td>
</tr>
<tr>
<td>Glidewell-Kenney, Christine P176</td>
<td></td>
</tr>
<tr>
<td>Glotz, Denis O5</td>
<td></td>
</tr>
<tr>
<td>Goerg, Siegfried P135</td>
<td></td>
</tr>
<tr>
<td>Golovkina, Larisa Leonidovna. P34</td>
<td></td>
</tr>
<tr>
<td>Gomes, Renan G. P280</td>
<td></td>
</tr>
<tr>
<td>Gomez, Margarita P24</td>
<td></td>
</tr>
<tr>
<td>Goncalves-Primo, Amador P93</td>
<td></td>
</tr>
<tr>
<td>Gonzalez, Ana F. P319</td>
<td></td>
</tr>
<tr>
<td>Gonzalez, Consuelo O72</td>
<td></td>
</tr>
<tr>
<td>Gonzalez, Maria J. P118, P149</td>
<td></td>
</tr>
<tr>
<td>Goodridge, Damian P154</td>
<td></td>
</tr>
<tr>
<td>Gorea, Ionut P154</td>
<td></td>
</tr>
<tr>
<td>Gorodezky, Clara P25, P27, P233</td>
<td></td>
</tr>
<tr>
<td>Goudeva, Lilia O14, P23</td>
<td></td>
</tr>
<tr>
<td>Goudogianni, Vasiliki D. P51</td>
<td></td>
</tr>
<tr>
<td>Gouix, Anne-Claire P19</td>
<td></td>
</tr>
<tr>
<td>Gourraud, Pierre-Antoine O19, O20, O27, P</td>
<td></td>
</tr>
<tr>
<td>220, P226, P274</td>
<td></td>
</tr>
<tr>
<td>Gozdzik, Jolanta O58</td>
<td></td>
</tr>
<tr>
<td>Gracheva, Liudmila P29</td>
<td></td>
</tr>
<tr>
<td>Graczyk-Pol, Elzbieta O58, P306</td>
<td></td>
</tr>
<tr>
<td>Gragert, Loren O24, O28, O56</td>
<td></td>
</tr>
<tr>
<td>Gramatzki, Martin O61</td>
<td></td>
</tr>
<tr>
<td>Gras, Christiane O60</td>
<td></td>
</tr>
<tr>
<td>Graziosi, Alessandra P262, P281</td>
<td></td>
</tr>
<tr>
<td>Green, Ari P226</td>
<td></td>
</tr>
<tr>
<td>Gregori, Silvia O34, O40, P54</td>
<td></td>
</tr>
<tr>
<td>Grillo, Giovanni P37</td>
<td></td>
</tr>
<tr>
<td>Grimaldi, Vincenzo P106</td>
<td></td>
</tr>
<tr>
<td>Groeneveld, Lisette P279</td>
<td></td>
</tr>
<tr>
<td>Groeneweg, Mathijs</td>
<td></td>
</tr>
<tr>
<td>P168, P228, P232, P235</td>
<td></td>
</tr>
<tr>
<td>Gronkowska, Anna O58</td>
<td></td>
</tr>
<tr>
<td>Grubic, Zorana O52, P10, P45, P145</td>
<td></td>
</tr>
<tr>
<td>Grubovik, Rada P142</td>
<td></td>
</tr>
<tr>
<td>Grumet, F. Carl P98</td>
<td></td>
</tr>
<tr>
<td>Guan, Kaomei O1</td>
<td></td>
</tr>
<tr>
<td>Guarda, Greta P318</td>
<td></td>
</tr>
<tr>
<td>Guarene, Marco O50</td>
<td></td>
</tr>
<tr>
<td>Guberina, Hana O46</td>
<td></td>
</tr>
<tr>
<td>Guemira, Fethi P295, P297</td>
<td></td>
</tr>
<tr>
<td>Guerard, Christine P19</td>
<td></td>
</tr>
<tr>
<td>Guethlein, Lisbeth A. O9, P317</td>
<td></td>
</tr>
<tr>
<td>Guidicelli, Gwendaline O49, P73, P121</td>
<td></td>
</tr>
<tr>
<td>Guillaume, Thierry P16</td>
<td></td>
</tr>
<tr>
<td>Guillemette, Chantal P5</td>
<td></td>
</tr>
<tr>
<td>Guloswens Celius, Elisabeth P274</td>
<td></td>
</tr>
<tr>
<td>Gunnarsson, Ragnar P289</td>
<td></td>
</tr>
<tr>
<td>Gupta, Rahul P171</td>
<td></td>
</tr>
<tr>
<td>Gupta, Subhash P79</td>
<td></td>
</tr>
<tr>
<td>Gustavsen, Marte P274</td>
<td></td>
</tr>
<tr>
<td>Guénette, Suzanne P52</td>
<td></td>
</tr>
<tr>
<td>Gwinner, Wilfried P97</td>
<td></td>
</tr>
<tr>
<td>Gylensten, Ulf P196</td>
<td></td>
</tr>
</tbody>
</table>
Gómez-Fernández, Margarita P99

Haasnoot, Geert W. P112, P237
Haberl, Manuela P22
Habets, Thomas H.P.M. P75
Habhab, Wael P81
Habicht, Antje P97
Hadaya, Karine O68, P150
Hadjianastassiou, V. P76
Hague, Tim O22, P223
Hajilooi, Mehrdad P261
Halaburda, Kazimierz O58
Halkovitch, Aurore P41
Hall, Richard O69
Haller, Hermann P97
Haller, Stefanie O31
Hallersleben, Michael O43
Halliwell, Jason A. P190
Halpin, Anne P139
Hamann, Carina O1
Hamdy, Nayera P254
Hammond, Laura P259
Hammond, Mouna P270
Hansen, Jannie S. P104
Haouala, Faouzi P270
Harahap, Alida Roswita. O35
Harbo, Hanne P274
Harriff, Melanie O4
Harting, John P227
Harzallah, Latifa P295, P297
Hasenfuss, Gerd O1
Hassen, Saada P81
Hauser, Ingeborg Anna P72
Hauser, Stephen O27, P226, P274
Hauzenberger, Dan P30, P123, P290
Havan, Mine P268
Havulinna, Aki S. P225
Haziot, Alain O5
Heder, Carolin O12, P181, P183
Heidt, Sebastiaan O44, O45
Heijmans, Corrine M.C. O9, P317
Heim, Albert O37
Heinemann, Falko M. O15, O43, O46, P6, P77, P90, P97
Heinold, Andreas P6, P77
Held, Werner P318
Hellmann, Andrzej O58
Hellström-Lindberg, Eva O70
Helmberg, Wolfgang O54
Hemmatpour, Shahram P12, P84
Hennecke, Johannes F. O67
Henry, Roland O27, P226
Hepkema, Bouke P143, P206
Hepler, Lance O17, P227
Hermann, Eugenie O64
Hermanrud, Christina P186
Hernandez, Domingo Hernandez P126
Hernandez, Marcela O32
Heroes, Anne-Sophie P170
Herraiz, Miguel Angel P204
Herrmann, R P80
Herry, Patricia P16
Hesami Shahryari, Soroosh P261
Heuer, Michael P222
Heuft, Hans-Gert P23
Heutinck, Kirstin M. O7
Hidajat, Melanny P170
Hildebrand, William O4
Hildebrandt, York P320, P321
Hill, Brian O28
Hillert, Jan P186
Hiraki, Debra D. O55
Hirv, Kaimo P22
Hitzel, Richard P169, P171
Hitzler, W.E. O43
Hoffmeister, Hans O66
Hofmann, Jan O12, P174, P181
Hogan, Hayley P1, P9
Holcomb, Cherie L. O22
Hole, Brian P220
Holgersson, Jan P212
Hollenbach, Jill A.
O19, O20, O22, P219, P222
Holschuh, Lisa P72
Hon, Lawrence O69
Kekik, Cigdem P50, P282
Keles, Deniz P77
Keramitsoglou, Theodora P275, P311, P314
Kere, Juha O33
Kesmir, Can O62
Keven, Kenan P141
Khamaganova, Ekaterina G. P38, P284
Khan, Saiqua P84
KhanKhanian, Pouya O27
Kheav, Vissal David P107, P108
Khromova, Elena B. P246
Kiani, Javad P261
Kilicaslan Ayna, Tulay P140, P147
Kim, DongYong P171
Kim, Jin Kyung P169
Kim, Nancy P176
Kim, Seonghan P222
Kim, Soo-Kyung P188
Kimball, Pamela P316
Kirgizov, Kirill P29
Kitsiou, Vasiliki P146, P214, P303, P304
Kiviniemi, Minna P301
Klein, Tirza P20
Kleppinger, Anja O67
Klug, John O24
Kluiver, Joost O3
Klyuchnikov, Dmitry P235
Kneidinger, Nikolaus P70
Knip, Mikael P301
Knutson, Carina P196
Knuuttila, Matti O32
Kobrle, Jana P207
Kockum, Ingrid P186
Koefoed-Nielsen, Pernille P78, P85, P87
Koehl, Ulrike P23
Kokkinou, Dimitra V. P51
Kolesar, Libor O52, P203
Koller, Michael T. P83
Konstantinov, Dobrin P3
Kontos, Athanasios P213
Kooter, Raul O18, P156, P221
Kor, Aga P320
Kordelas, Lambros P43
Kordossis, Theodoros P213
Korfage, Nelleke P112
Korman, Lucyna P291, P294
Kosari, Soghra P261
Koscinska, Katarzyna O58
Koskela, Satu P21, P162
Kotrbova-Kozak, Anna O26
Koukoulaki, Maria P146
Kouni, Karel P131
Krivchenko, Andrey O46, P77
Krishnakumar, Sujatha O53
Krishnamoorthy, Rajagopal P160, P165, P272
Kris, Don P20
Kroesen, Bart-Jan O3, P143
Krol, Laura P152
Krumina, Angelika P286
Krystufkova, Olga P63
Kröger, Nikolaus P320, P321
Kuball, Jürgen O62
Kunilo Jamnik, Sabina P8, P276
Kuntzel, Richard P206
Kunze-Schumacher, Heike O6
Kuraishy, Ali P176
Kuranov, Alexandr B. P258, P299
Kurtovic, Helena P125, P199, P292
Kurtulmus, Yusuf P140
Kuzmich, Elena P28
Kuzmina, Larisa A. P38
Kuzminova, Elena P. P194, P284
Kwon, Jangyoung P171
Kyrcz-Krzemien, Slawomira O58
Königova, Nikola P47
Kühn, Petra P90
Kündgen, Lukas P39

L
La Nasa, Giorgio P54
Lachmann, Nils O43
Lafarge, Xavier P18, P172, P198
Lahtela, Elisa P225
Laine, Antti-Pekka P301
Lal, Vandana P144
Lalancette, Marc P5
Lang, Kathrin O12, P174, P181, P183
Lange, Andrzej O58
Lange, Janusz O58
Lange, Vinzenz O12, P174, P181, P183
Lanzer, Gerhard P191
Lapierre, Valérie P19
Larsen, Connie P104
Las Heras, Beatriz P127, P313
Latham, Katy O17, P26, P155
Lauden, Laura P315
Lavacca, Antonio P89
Laverdière, Isabelle P5
Lazarevic, Dejan O2, O59
Lazidou, Panagiota P271, P285
Leboyer, Marion P160, P165
Lecoq, P. P238
Lee, Jar-How P121
Leelayuwat, Chanvit P65
Legaz, Isabel O72, P127, P313
Lemin, Andrew J. P251
Leontyevcovca, Monika P31
Leslie, Stephen O19
Levinson, Douglas O53
Lewinsohn, David O4
Lewinsohn, Deborah O4
Li, Tatyana P67, P252
Lie, Benedicte A. P161, P289
Ligeiro, Dario O52, P17
Liles, Lauren M. O4
Lima, Alice P17
Lima, Bruno A. P115, P117, P189
Lima, Izaura P186
Lima, Sara M.S. P280
Lin, Charles P176
Linares, Isabel P57
Lindemann, Monika O15, O29, O31, O64, P6
Lineros, Johana A. P163
Linjama, Tiina P21, P162
Link, Jenny P186
Lion, Julien O5
Lippert, Eric P18
Liu, Lisa O70
Liwski, Robert P83
Lizée, Antoine M. O19, O20, P226
Ljunggren, Hans-Gustaf O70
Ljungman, Per T. O70
Llorente, Santiago P118, P149
Lobashevsky, Andrew L. P53
Lockhart, Symon D. O13, P92, P138, P148
Loga, Luminita P245
Logina, Inara P286
Loginova, Maria P255
Loiseau, Pascale P5, P19, P187
Loizou, P. P76
Lokki, Marja-Liisa O32, O52, P225
Longhi, Elena P82, P86, P110, P202
Lopez, Manuela P118, P149
Lopez, Marcos P24
Lopez-Hernandez, Ruth P118, P149
Lora Pablos, David P129
Loren, Raphaelle P226
Loundou, A. P4
Lucarelli, Guido P7, P231
Lucena, María Isabel P319
Lucena-Silva, Norma P267, P280
Luciano, Michela P281
Ludigs, Kristina P318
Ludwig, Charlotte O15
Lukanov, Tsvetelin P3, P283
Lundkvist Ryner, Malin P186
Luscalov, Dan P245
Ly, Ngoc P98, P316
Lévesque, Éric P5
López, Marta P307
López- Nevot, Miguel Angel P319
López-Hernández, Ruth P313
López-Hoyos, Marcos P99
López-Álvarez, M Rocio O72, P127, P313
Lövlie, Roger P30
Lübke, Simon P185

M
Maat, Henny O3
Maatouk, Mouna P270
Mabile, Laurence P220
Macedo, Claudia P293
Mack, Steven J.
O19, O20, O22, O54, P219, P222
Madrigal, J Alejandro O17, P26, P155
Maecker-Kolhoff, Britta O37, P23
Magalon, J. P234
Magistrini, Paola P195
Maiello, Ciro P64, P106
Maiers, Martin O19, O20, O22, O24, O25, O28, O56, P222
Makarenko, Olga P28
Makarovska-Bojadzieva, Tatjana P142
Makrobasili, Fani P136
Makroo, RN P79, P103
Malamos, Nikolaos P275
Malard, Florent P16
Malheiro, Jorge P137
Malinowska, Agnieszka P306
Mallar, Marko J. K. O36
Malmberg, Karl-Johan O70, O73
Mamoghli, Tasnim P295, P297
Mancebo, Esther P129
Mann, Herman P63, P177
Mannarino, Savina P265
Mansouri, Ahmed O1
Manuel-Caetano, Fernanda P293
Manvailer, Luis Felipe Santos. O30
Manzanares, Felícitas P233
Marangoni, Francesca P110
Marceno, Raimondo P130, P305
Marchesani, Marja O32
Marczi, Saška P312

Marenco, Paola P37
Maria Antonietta, Businaro P300
Maria Paola, Albergoni P300
Mariaselvam, Christina P272
Marimpietri, Anna P262, P281
Marioli, Dimitra I. P51
Markiewicz, Mirosław O58
Markova, Marketa P40
Marks, Patrick O17, P155, P227
Marktel, Sarah P54
Marosz-Rudnicka, Anna O58, P306
Marques, Ester A.V. P267
Marsh, Steven GE. O17, P26, P155
Martin, Pierre-Yves P150
Martinelli, Valéria P280
Martinetti, Miryam O50, P13, P159, P265
Martinez, Lina M. P163
Martinez, Patricia P154
Martinez-Banaclocha, Helios P118, P149
Martinez-Laso, Jorge P204
Martorell, Jaume P101, P109
Martín-Villa, José Manuel P230
Martínez Banaclocha, Helios P313
Martínez-Escribano, Jorge A P313
Marzais, François P160, P165
Masbate, Khara P81
Mascaretti, Luca G. P202
Maskalan, Marija P10, P45, P145
Massij, Franka AM. P168
Masson, Dominique P198
Masson, Emeline P19
Masuya, Anri P249
Matejkova, Eva P40, P209, P215
Matthews, C Jane P44
Matthews, Paul O27
Mattsson, Jonas O63
Maurer, David P98
Mautner, Josef P190
Mauvais, François-Xavier P52
Mayor, Neema P. O17, P155
Mayr, Wolfgang R. P58, P60
Mazzi, Benedetta O59
Mc Gregor, Brigitte O47
McCann, Tiffany P316
McConnell, Sylvia P148
McMurtrey, Curtis O4
McWhinnie, Alasdair JM. O17, P26, P155
Mean, R. P76
Medina, Vilma L. P163
Medina-Pestana, José O. P93
Mehra, Narinder O52
Meller, Jarek O19
Mendek-Czajkowska, Ewa P306
Mendes, Cecília P137, P216
Mendes, Miguel P115, P117
Mendez, Andrijana P8, P276
Mero, Inger-Lise P274
Merville, Pierre O49, P121
Meyer, Diogo O38
Meyer, Ralf G. O61, O62
Michael, N. P76
Michalopoulos, Efstathios P210, P257
Michel, G. P4
Michelazzi, Cristian P202
Michelon, Tatiana F. P61
Middleton, Derek O21, P88
Midwinter, William O17, P155
Mihaljević, Željko P312
Mihaylova, Anastasia P3, P283
Mihidjai, A. P242
Mika-Witkowska, Renata O58, P306
Mikk, Mari-Liis P301
Milius, Robert P. O22, P222
Miller, Jeffery S. O70
Milongo, David P71
Milpied, Noel P18
Mindrinos, Michael N. O53, O55
Minguela, Alfredo P118, P127, P149, P313
Minguela-Puras, Alfredo O72
Miqueles, Gloria P175
Miranda, Nuno P17
Miras, Manuel P127
Mirecescu, Gabriel P119, P120
Miserlis, Grigorios P136
Mishra, Mahendra N. P144
Mishra, Manoj P79, P103
Mistretta, Serena P130, P305
Mitsunaga, Shigeki P249
Mizia, Sylwia O58
Mohty, Mohamad P16
Moise, Ana P119, P120
Moiseeva, Lubov P32
Mölberg, Øyvind P289
Molenbroeck, Stefan J.J. P75, P279
Molinari, Nicolas P41
Moll, Solange P150
Mollet, Isabelle P198
Momynaliev, Kuvat T. P258, P299
Monecke, Sebastian O1
Montanic, Sendi P8
Monteiro, Alessandra L.R. P267
Montes, Natividad de los Reyes. O72
Monti, Maria Cristina P13
Mooney, Nuala A. O5
Moraes, Maria Elisa. P9
Morais, António P189
Moraleda, José María. O72
Morales, José María P129
Morales, Pablo P129
Morath, Christian O48, P96, P114
Moraw, Natali O41
Mordak-Domagala, Monika O58
Mordini, Ryan P158
Moreau, Jean-François P121
Moreau, Philippe P16
Morelon, Emmanuel O47
Moreno-Casares, Antonia P319
Moser, Anna P52
Mossallam, Ghada I. P254
Moulin, Bruno P113, P128, P134
Moussière, Marielle P2, P41
Moya-Quiles, Maria R. P118, P149, P313
Mrazek, Frantisek P47
Mrowiec, Anna P313
Mucher, Elodie O42
Muchlbacher, Annelies O43
Mueller, Carlheinz O22, O61
Mueller, Stefan P. O29
Mugica, Fernando P287
Mujic, Aida P125, P199, P292
Mulder, Arend O9
Mulder, Wietse P42, P152, P156, P221
Muljono, David Handojo. O35
Muller, Clotilde P128
Muncher, Liora P33
Munguia, Andrea P233
Muro, Manuel O72, P118, P149, P313
Murtadha, Mariam P278
Mytilineos, Ioannis O43, O61, O62, P39
Mäntylä, Päivi O32
Møller, Bjarne K. O11, P78, P87, P153
Müller, Claudia A. P258, P299

N
Nadvornikova, Sylvie P31
Nafar, Mohsen P94
Nalcaci, Meliha P49
Nane, Ismet P55, P56
Napoli, Claudio P64, P106
Nardi, Fabiola da Silva. P61, P90, P324
Nasilowska-Adamska, Barbara O58
Nastase, Vasile P119, P120
Naumova, Elisaveta P3, P68, P283
Navarrete, Cristina P175
Neau-Cransac, Martine P73
Nedelcu, Filofteia-Daniela P119, P120
Nedyalkova, Antoaneta P3, P68, P283
Negi, Vir Singh P272
Nesci, Sonia P201
Nestorowicz, Klaudia O58
Neumann, Jorge P61
Neurohr, Claus P70
Newby, Crystal P316
Nguyen, Catherine P293
Nguyen, D.K. P238
Nicoloso, Grazia O52
Niederwieser, Dietger O61, O62
Nielsen, Morten P62
Nieminen, Markku S. O32, P225
Noble, Janelle A. O54
Nocco, Angela P82, P86, P110
Nolte, Jessica O1
Nong, Thoa P121
Norman, Paul J. O22
Novelli, Francesco P89
Novoa, Erika P118, P149
Novota, Peter P63, P177
Nowak, Beata P288, P291
Nowak, Jacek O58, P306
Nunes, José Manuel
O23, O38, O51, O52, P8, P253
Nurkina, Zhannur M. P258
Nytes, James P176
Nègre-Salvayre, Anne O42
Nückel, Holger P263

O
Ogret, Yeliz P48, P49, P49
Oguz, Fatma Savran P48, P49, P50
Oh, Heung-Bum P188
Oikonomopoulou, Georgia A. P51
Ok, Engin P309
Oksenberg, Jorge O27, P226, P274
Okudaira, Yuko P249
Olagne, Jerôme P113, P128
Olieslagers, Timo I. P178, P228
Oliveira, Camila F. P323, P325
Oliveira, Giacomo O59
Oliveira, José P160, P165
Oliveira, José GG. P69, P74
Olson, Beck P226
Oltean, Simona P212
Onderkova, Jana P47
Opelz, Gerhard O48, P96, P114
Oppenheimer, Federico P101, P109
Orebrand, Ulrika P196
Ortega, Sofia P204
Osada, Masako P124
Osmanbasoglu, Emre P49
Osório, Ermelinda P137
Ota, Masao P249, P298
Otero, María P307
Otting, Nel P166, P179
Oudin, C. P4
Oudshoorn, Machteld P14, P237
Piras, Ignazio Stefano. P54
Pirim, Ibrahim P140, P147
Pishkhan Dibazar, Shaghayegh P266
Pizzochero, Cinzia O50
Plestilova, Lenka P63, P177
Podgornaya, Tatyana V. P248
Poli, Francesca O52
Polin, Helene P217
Pollack, Jane P222
Pollack, Marilyn S. P139
Poloni, Estella S. O51
Ponte, Belen P150
Ponzoni, Maurilio O59
Popa, Luis P245, P277
Popa, Olívia P264, P277
Popov, Georgi P283
Posch, Ursula P191
Pospelov, Aleksey P29
Potamiti, Louiza P257
Pourrezagholi, Fateme P94
Pourshahidi, Sara P193
Pourtein, Monique P198
Prerovska, Renata P31
Priesner, Christoph P23
Prikis, M. P76
Promponas, Emmanouil P314
Proust, Barbara P198
Psarra, Katerina P146
Puerto, Cesar O57
Puglisi, Giuseppe P86
Pussinen, Pirkko J. O32
Puthier, Denis P293
Pyo, Chul-woo O69
Pyon, Yoon Soo . O69
Pérez, Fernanda P25, P27

Q
Qidan, Sara P72
Quenzel, Philipp P174
Quintieri, Francesca P202
Quinto, Kai P316

R
Rabenstein, Hannah E. P22
Rabeyrin, Maud O47
Radick, Marie P158, P224
Raida, Ludek P47
Raissov, Sandzhar P252
Rajczy, Katalin P253, P256
Ramalhete, Luis P116, P132
Rambaldi, Alessandro O2
Ramil, Diana P252
Ramilyeva, Indira P67, P252
Ramirez, Paloma Ramirez P126
Ramondetta, Miriam P82, P86
Ramade, Swati O17, O69, P155, P227
Ranghino, Andrea P89
Rassi, Diane Meyre. P293
Ratuszny, Dominica O60
Ray, Bryan P124
Rebel, Claudia P152
Rebmann, Vera O30, O46, P43, P90, P263
Redegeld, Frank A.M. P75
Reibke, Roland P15
Reichardt, Anne O66
Reine, Jessica P107
Reis, Pâmela G. P323, P325
Rekers, Niels V. O36
Remakova, Martina P63, P177
Renac, Virginie P184
Rene, Céline P2, P41
Renner, Véronique P113, P134
Resse, Marianna P64
Revile, P P259
Rey, Diego O57, P230
Rezaei, Hamzeh P261
Riahi, Rachida P295
Rial-Sebbag, Emmanuelle P167
Riba, Michela O2
Ribeiro, Enilze P296
Richard, Carlos P24
Richter, Rudolf O67, P72
Rieb, Anja O30
Riebschläger, Sabine P6
Sbarsi, Ilaria P265
Schaffer, Marie O70, O73
Schaub, Stefan O8, O43, P83
Scheffner, Irina P97
Schemmer, Peter P114
Scherer, Sabine P114
Schiano, Concetta P106
Schiller, Jennifer P176
Schlahsa, Laura O14
Schmidt, Alexander H. O12, P174, P181, P183
Schneider, Joel O24, P222
Schott, Nina P279
Schramm, Alexander O30
Schramm, Sabine P263
Schrezenmeier, Hubert O61, P39
Schuffner, Alessandro P61, P324
Schwarz, Anke P97
Schwarzelt, Carmen O12, P174, P181
Schödel, Anna-Alicia P72
Schöne, Bianca O12, P174, P181, P183
Scoazec, Jean Yves O47
Sconocchia, Giuseppe O71
Sebastiani, Pierluigi P240, P262, P281
Sechi, Enzo P262, P281
Segers, Rudi P211
Seidl, Christian O43, O67, P72
Seissfried, Erhard O67, P72
Sekerkova, Alena P203
Sell, Ana M. P323, P325
Selwyn, Caroline P259
Semana, Gilbert P184
Senden-Gijsbers, Birgit LMG. P173
Senitzer, David P316
Senturk Ciftci, Hayriye P55, P56
Sepanjnia, Adel P94
Seri, Sonia P270
Serrano, Alfonso P126
Serventi Seiwerth, Ranka P10
Seshadri, Vijayaragavan P171
Shahib, Nurhalim P243
Shaiegan, Mojgan P35
Sharbafi Eskandani, Mohammad Hossein P91
Sharma, Sonika P79, P103
Shaut, Carley AE. P139
Sheereen, Atia P122, P322
Shi, Joel P154, P158, P208, P224
Shigenari, Atsuko P249
Shiina, Takashi P227, P249
Shin, Sue P36
Shivarov, Velizar St. P68
Shpakova, Anna Petrovna. P34
Sicard, Antoine O47
Sidkaa, Michael O27
Sidorcika, Tatiana P286
Sienowski, Jérémy P107
Sierich, Heidi P320, P321
Siewiera, Johan P315
Silva, M Isabel P116, P132
Simackova, Jitka P215
Simell, Olli P301
Simon, Sophie P164
Simonetta, Margherita P159
Simonovic, Ruzica P250
Sinelnikov, Evgeni O66
Sinescu, Ioan P119, P120
Singh, Mandhata P79, P103
Singh, Sandeep K. O10, P282
Singleton, Deborah P151, P157, P182, P200
Sinisalo, Juha O32, P225
Sioli, Viviana P82, P86, P110
Siorenta, Alexandra P133
Sirvent, Anne P41
Sizano, Federico P7
Skhiri, Habib P270
Skorobogatova, Elena P29
Slatinska, Janka P111
Slavcev, Antonij O52, P111, P114
Slimani, K. P238
Smigielska-Czepiel, Katarzyna O3
Smigoc-Schweiger, Darja P276
Snataniello, Adam P226
Sobhani, Maryam P35, P241
Socié, Gérard P5
Sofiane, Salah P272
Sokolik, Renata P291, P294
Sokolova, Iulia P32, P310
Solgi, Ghasem P261
Sollid, Ludvig M. P62
Solís, Elizabeth P25
Soyoz, Mustafa P140, P147
Spanagl, Michael P15, P70, P190
Spellman, Stephen O25
Spierings, Eric O8, O18, O62
Spinelli, Orietta O2
Spinillo, Arsenio P159
Spioski, Mirkko O52
Spruyt-Gerrits, Marijke J. O36
Spurkland, Anne O73
Spychalska, Justyna P306
Spyridonidis, Alexandros G. P51, P210
Spyropoulou-Vlachou, Maria
O52, P257, P314
Srivastava, Priyanka P79, P103
Stamou, Panagiota K. P51
Stankova, Martina P31
Stashkevich, Daria S. P246
Stavropoulos-Giokas, Catherine P210, P257
Štefanić, Mario P312
Stein, Sophia P102
Steitzer, Hansjörg P217
Stenström, Magnus P30
Stephens, Camilla P319
Strikvoort, Arwen O63
Stigl Jankovic, Katarina P10, P145
Street, Jane P200
Stricker, Nicola O67
Striz, Ilja P203
Stuhler, Gernot O61
Stupka, Elia O2, O59
Stuurman, M P80
Styleianou, G. P76
Suarez, Natalia P101
Suberbielle, Caroline P107, P108
Sudarikov, Andrey B. P38
Suésal, Caner O48, P114, P114
Sulcebe, Genc O52
Sundaresh, Aparna P272
Sundin, Mikael O63
Suominen, Anna L. O32
Suslova, Tatiana A. O52, P246
Suzuki, Shingo P249
Svetla, Marketa P63
Svilibic, Danijela P45, P145
Svitalkova, Tana P63, P177
Swobodova, Ewa P111
Swaminathan, R P80
Swarbrick, Gwendolyn O4
Swierkot, Jerzy P288, P291, P294
Syme, Lorraine P148
Symeonidi, Dionysia P304
Syukriani, Yoni P243
Szczechowski, Andrzej O58
Szilvási, Anikó P253, P256
Szlenck, Urszula O58
Szypkowski, Dido A. O67
Sánchez Zapardiel, Elena P129
Sánchez, Diego P27, P233

T
Tabbara, Khaled P278
Tabrizi, Reza P18
Tachon, Gaelle P41
Taflin, Cécile O5
Tafuło, Sandra P137, P216
Tagen, Ingrid P232
Taghavi, Simin P260
Takeshita, Louise O21
Tamm, Anu P232
Tamouza, Ryad P5, P160, P165, P272, P29
5, P297
Tanaka, Eiji P298
Tandoi, Francesco P195
Tarassi, Katerina P146, P214, P303, P304
Tarlykov, Pavel V. P258
Taupin, Jean-Luc O49, P73, P121
Tavarozzi, F P26
Taylor, Kent O19
Tedesco-Silva, Hélio P93
Tefik, Tzevat P55, P56
Teixeira, Gilda P17
Temurhan, Sonay P50
Tessitore, Alessandra P240
Testi, Manuela
O40, O50, O52, P7, P54, P231
Thakur, Yogita P79, P103
Thamanichanond, Duangtawan O43
Thaunat, Olivier O47
Theodorou, Ioannis P218
Theofani, Efthymia Ch. P51
Thomsen, Mogens O42, P220
Thuizat, Audrey P2
Thurer, I. P4
Thus, Kirsten A. O62
Tieng Caulet, Vannary O16
Tiercy, Jean-Marie O52, O65, P198
Tilanus, Marcel G.J. O66, P75, P168, P173, P178, P228, P232, P235, P279
Tinelli, Carmine O50, P159, P265
Tischer, Sabine O37, O41, P23
Toader, Maria-Adela P119, P120
Toffalori, Cristina O2, O59
Tokić, Stana P312
Tomaszew ska, Agnieszka O58
Tordai, Attila P253, P256
Torfs, Anneleen P170, P211
Toriello, Mario P205
Torres, Margareth Afonso. P9
Totur, Ismail P147
Toumgouz Nevesignsky, Michel O52
Tournier, Benjamin O16
Tous, A. P46
Traina, Tiziana P130
Tran, Thuong Hien P96, P114
Trayssac, Magali O42
Trindade, Helder P17, P116, P132
Troiano, Maria P7
Trusova, Larisa P235
Tsalimalma, Kalli ro P213
Tsamadou, Chrysanthi P303, P304
Tsinopoulou-Galli, Asimina P271, P285
Tsirogianni, Alexandra P303
Tugmen, Cem P140
Turganbekova, Aida P67, P252
Turkmen, Aydin P55, P56
Turner, David
O13, P59, P88, P92, P138, P148
Turner, Marc O13
Turpeinen, Hannu P122
Turyadi, Turyadi O35
Turk, Hüseyin P141, P268, P269
Tyan, Dolly B. O55
Tyumina, Olga P235
Tzonis, Panagiotis P311
Tüzüner, Acar P141
Uhlin, Michael O63
Ulea, Lorena P245
Ulrich, Silvia P191
Umemura, Takeji P298
Ünsal, Evrim P269
Upsall, Elizabeth P176
Urdapilleta, Gregorio P287
Usta, Sehabat P50
Utzschneider, Daniel P318
Uzuner, Mehmet P30, P290
V
v. Welser, Georg P190
Vaarala, Outi O33
Vago, Luca O2, O59
Valcazar, Luz P24
Valcárcel, María L. P99
Valdes, Ana M. O54
Valdez, Riccardo P100
Valencia, Miriam P27, P233
Valero Hervás, Diana P129
Valhova, Sarka P111, P203
Valkova, Veronika P40
van den Berg, Anke O3
van den Boomgaard, Els P206
van den Heuvel, Heleen O7
van der Lei, Roelof Jan O3
van der Meer-Prins, Ellen M.W. O7
van der Velde, Hans P206
Wozniak, Jolanta P306
Wulf, Gerald O61
Wunsch, Andreas P90
Wysoczanska, Barbara P288, P294

X
Xavier, Danilo Jordão. P293
Xavier, Maria Paula DP. P69, P74
Xhaard, Aliénor P19

Y
Yakiyayeva, Dinara P67, P252
Yakutik, Igor A. P38
Yang, Soo Young P169, P171
Yari, Fatemeh P35, P241, P266
Yavuz, Selim P49
Yonal, Ipek P49, P50
Yoon, Jong Hyun P36
Yordanova, Maya P3
Yoshizawa, Kaname P298
Youngs, Danny P139
Yushkova, Anna A. P284

Z
Zabani, Najla P81
Zadrazil, Josef P131
Zahn, Robert P185
Zajacova, Marta O26
Zalite, Mara P286
Zaman vaziri, Maryam P35, P241
Zamani, Alireza P261
Zandbergen, Malu O36
Zapata, Eva P287
Zapletalova, Jana P131
Zaras, Charalampos P136
Zarrabi, Morteza P11, P247
Zavaran Hosseini, Ahmad P266
Zehn, Dietmar P318
Zeier, Martin O48, P114
Zhang, Haijiao O14, O60
Zhang, Tao P171
Zhao, Bin P95, P224
Zhao, Lue Ping O19
Zhao-Yang, Lu P41
Zheng, Xiwen O19
Zholdybayeva, Elena V. P258
Ziemann, Malte O43, P135
Zikos, Panagiotis M. P51
Zilian, Eva O41, P97
Zisser, Bracha P237
Zito, Laura O2
Zoet, Yvonne M. O46, P112
Zollikofer, Christine O61, P39
Zoudiari, Natassa N. P51
Zubiaurre, Leire P287
Zuckova, Marie P215
Zunec, Renata P10, P45, P145

Ö
Ölmez, Ümit P268
Önfelt, Björn O73
Özartam, Semahat P141
Özer, Leyla P269
Özgüçlü, Selcan P141, P268
Stockholm Waterfront Congress Center
Nils Ericsons Plan 4

The Brewery (Münchenbryggeriet)
Torkel Knutssonsgatan 2

Stockholm City Hall
Hantverkargatan 1

Junibacken
Galärvarsvägen 8

Nobel Museum
Stortorget 2

The Central Station
Centralplan 1

Radisson Blu Waterfront Hotel
Nils Ericsons Plan 4

Clarion Hotel Sign
Östra Järnvägs gatan 35

Freys Hotel
Bryggargatan 12

Hotel Lilla Rådmannen
Rådmansgatan 67

Rica Hotel Kungsgatan
Kungsgatan 47

Rica Hotel Stockholm
Slöjdgatan 7

Scandic Hotel Grand Central
Kungsgatan 70
WELCOME TO THE 29TH EUROPEAN IMMUNOGENETICS AND HISTOCOMPATIBILITY CONFERENCE (EFI)

We are happy to invite you to the next EFI European Federation for Immunogenetics Conference in Geneva Switzerland, 26-29 April 2015. We have prepared a meeting with world class speakers in the field of Genetics, Immunology and Transplantation, with a focus on pluripotent stem cells and a WHO/WMDA special session. Join us in the smallest of the international cities located in the middle of Europe with easy connections. We hope to welcome you soon in Geneva and in the meantime visit our website at www.EFI2015.org

Geneva: Imagine a place that brings the world together... Geneva, this multi-faceted city of humane dimensions, has all a metropolis can offer. Geneva is in the centre of Europe and therefore just a stone’s throw away – by all means of transport. International airport with direct flights to over 130 destinations, low cost carriers & high-speed trains from European cities. First rate hotel infrastructure with over 118 hotels and 9,000 hotel rooms. www.geneve-tourisme.ch

Conference Venue: The International Conference Centre of Geneva is conveniently located near the International Airport, the railway station, the international organizations, Lake Geneva and the historic old town. A vast choice of hotels offers the best hospitality close to the conference center. www.cicg.ch

Conference Secretariat:
Symporg SA | Rue Rousseau, 30 | 1201 Geneva – Switzerland
Phone: +41 22 839 84 84 | Email: info@efi2015.org

Sylvie Ferrari-Lacraz, Jean Marie Tiercy, Jean Villard
Organizing Committee

www.EFI2015.org
Olerup Lunch Symposium, EFI 2014
June 27th, 12.15 - 13.15, Room A2 - Level 6, Stockholm Waterfront Congress Center

Improving Clinical Results in Stem Cell Transplantation
The Impact of Tissue Typing and Donor Characteristics on Outcome after Allogeneic Stem Cell Transplantation
Jonas Mattsson, Medical Director, Centre for Allogeneic Stem Cell Transplantation, Karolinska University Hospital.

Back to the Future: Improving HSCT Outcomes by Matching MHC Genomic Blocks
David Sayer, CEO, Conexio Genomics.